U.S. patent application number 10/817334 was filed with the patent office on 2005-02-03 for inhibitors for the soluble epoxide hydrolase.
This patent application is currently assigned to Regents of the University of California. Invention is credited to Hammock, Bruce D., Kim, In-Hae, Morisseau, Christophe, Newman, John W., Watanabe, Takaho.
Application Number | 20050026844 10/817334 |
Document ID | / |
Family ID | 33159782 |
Filed Date | 2005-02-03 |
United States Patent
Application |
20050026844 |
Kind Code |
A1 |
Hammock, Bruce D. ; et
al. |
February 3, 2005 |
Inhibitors for the soluble epoxide hydrolase
Abstract
Inhibitors of the soluble epoxide hydrolase (sEH) are provided
that incorporate multiple pharmacophores and are useful in the
treatment of diseases.
Inventors: |
Hammock, Bruce D.; (Davis,
CA) ; Kim, In-Hae; (Davis, CA) ; Morisseau,
Christophe; (West Sacramento, CA) ; Watanabe,
Takaho; (Davis, CA) ; Newman, John W.;
(Woodland, CA) |
Correspondence
Address: |
TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO
CA
94111-3834
US
|
Assignee: |
Regents of the University of
California
Oakland
CA
|
Family ID: |
33159782 |
Appl. No.: |
10/817334 |
Filed: |
April 2, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60460559 |
Apr 3, 2003 |
|
|
|
Current U.S.
Class: |
514/1.5 ;
514/15.4; 514/15.7; 514/16.6; 514/21.9; 514/6.9 |
Current CPC
Class: |
C07C 311/04 20130101;
A61P 9/08 20180101; A61P 11/00 20180101; C07D 207/16 20130101; C07C
2603/74 20170501; A61P 19/02 20180101; C07C 311/05 20130101; A61P
9/00 20180101; A61P 13/12 20180101; C07C 323/59 20130101; A61P
43/00 20180101; C07C 275/42 20130101; A61P 29/00 20180101; A61P
11/06 20180101; C07D 233/64 20130101; A61P 3/10 20180101; C07D
233/24 20130101; C07C 275/26 20130101; C07C 2601/14 20170501; C07C
2601/02 20170501; A61P 9/12 20180101; C07C 311/51 20130101; C07C
275/30 20130101 |
Class at
Publication: |
514/018 ;
514/019 |
International
Class: |
A61K 038/04; A61K
038/05 |
Goverment Interests
[0002] The U.S. Government has certain rights to the invention
pursuant to contract ES02710 awarded by the National Institutes of
Health.
Claims
What is claimed is:
1. A method for inhibiting a soluble epoxide hydrolase, comprising
contacting said soluble epoxide hydrolase with an inhibiting amount
of a compound having a formula selected from the group consisting
of: 97and their pharmaceutically acceptable salts, wherein R.sup.1
is a member selected from the group consisting of C.sub.5-C.sub.12
cycloalkyl, aryl, heteroaryl and combinations thereof, wherein said
cycloalkyl portions are monocyclic or polycyclic; P.sup.1 is a
primary pharmacophore selected from the group consisting of
--NHC(O)NH--, --OC(O)NH--, --NHC(O)O--, --CH.sub.2C(O)NH--,
--C(O)NH-- and --NHC(O)--; P.sup.2 is a secondary pharmacophore
selected from the group consisting of --C(O)--, --CH(OH)--,
--C(O)O--, --OC(O)--, --NHC(O)NH--, --OC(O)NH--, --NHC(O)O--,
--C(O)NH-- and --NHC(O)--; P.sup.2a is selected from the group
consisting of --C(O)-- and --NHC(O)--; P.sup.3 is a tertiary
pharmacophore selected from the group consisting of C.sub.2-C.sub.6
alkynyl, C.sub.1-C.sub.6 haloalkyl, aryl, heteroaryl,
--C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.2, --NHS(O).sub.2R.sup.2,
--C(O)OR.sup.1 and carboxylic acid analogs, wherein R.sup.2 is a
member selected from the group consisting of hydrogen, substituted
or unsubstituted C.sub.1-C.sub.4 alkyl, substituted or
unsubstituted C.sub.3-C.sub.8 cycloalkyl, substituted or
unsubstituted aryl and substituted or unsubstituted aryl
C.sub.1-C.sub.4 alkyl; the subscripts n and m are each
independently 0 or 1, and at least one of n or m is 1; L.sup.1 is a
first linker selected from the group consisting of substituted and
unsubstituted C.sub.2-C.sub.6 alkylene, substituted or
unsubstituted arylene and substituted or unsubstituted
heteroarylene; L.sup.2 is a second linker selected from the group
consisting of substituted and unsubstituted C.sub.2-C.sub.12
alkylene, substituted and unsubstituted arylene, and combinations
thereof; and A.sup.1 is a member selected from the group consisting
of an amino acid, a dipeptide and a dipeptide analog.
2. A method for inhibiting a soluble epoxide hydrolase, comprising
contacting said soluble epoxide hydrolase with an inhibiting amount
of a compound having a formula selected from the group consisting
of: 98and their pharmaceutically acceptable salts, wherein R.sup.1
is a member selected from the group consisting of C.sub.5-C.sub.12
cycloalkyl, aryl, heteroaryl and combinations thereof, wherein said
cycloalkyl portions are monocyclic or polycyclic; P.sup.1 is a
primary pharmacophore selected from the group consisting of
--NHC(O)NH--, --OC(O)NH--, --NHC(O)O--, --CH.sub.2C(O)NH--,
--C(O)NH-- and --NHC(O)--; P.sup.2 is a secondary pharmacophore
selected from the group consisting of --C(O)--, --CH(OH)--,
--O(CH.sub.2CH.sub.2O).sub.q--, --C(O)O--, --OC(O)--, --NHC(O)NH--,
--OC(O)NH--, --NHC(O)O--, --C(O)NH-- and --NHC(O)--; P.sup.2a is
selected from the group consisting of --C(O)-- and --NHC(O)--;
P.sup.3 is a tertiary pharmacophore selected from the group
consisting of C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl,
aryl, heteroaryl, --C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.2,
--NHS(O).sub.2R.sup.2, --C(O)OR.sup.2 and carboxylic acid analogs,
wherein R.sup.2 is a member selected from the group consisting of
hydrogen, substituted or unsubstituted C.sub.1-C.sub.4 alkyl,
substituted or unsubstituted C.sub.3-C.sub.8 cycloalkyl,
substituted or unsubstituted aryl and substituted or unsubstituted
aryl C.sub.1-C.sub.4 alkyl; the subscripts n and m are each
independently 0 or 1, and at least one of n or m is 1, and the
subscript q is 0 to 3; L.sup.1 is a first linker selected from the
group consisting of substituted and unsubstituted C.sub.2-C.sub.6
alkylene, substituted and unsubstituted C.sub.3-C.sub.6
cycloalkylene, substituted or unsubstituted arylene and substituted
or unsubstituted heteroarylene; L.sup.2 is a second linker selected
from the group consisting of substituted and unsubstituted
C.sub.2-C.sub.12 alkylene, substituted and unsubstituted arylene,
and combinations thereof; and A.sup.1 is a member selected from the
group consisting of an amino acid, a dipeptide and a dipeptide
analog.
3. The method in accordance with claim 1, wherein R.sup.1 is
selected from the group consisting of C.sub.5-C.sub.12 cycloalkyl,
phenyl and naphthyl.
4. The method in accordance with claim 1, wherein P.sup.1 is
selected from the group consisting of --NHC(O)NH--, --OC(O)NH-- and
--NHC(O)O--.
5. The method in accordance with claim 1, wherein the compound has
formula (I), wherein P.sup.1 is selected from the group consisting
of --NHC(O)NH--, --OC(O)NH-- and --NHC(O)O--; P.sup.2 is selected
from the group consisting of --C(O)O--, --CH(OH)--, --OC(O)--,
--C(O)NH-- and --NHC(O)--; m is 0 and L.sup.1 is selected from the
group consisting of unsubstituted C.sub.2-C.sub.6 alkylene.
6. The method in accordance with claim 1, wherein the compound has
formula (I), wherein P.sup.1 is selected from the group consisting
of --NHC(O)NH--, --OC(O)NH-- and --NHC(O)O--; P.sup.2 is selected
from the group consisting of --C(O)O--, --OC(O)--, --C(O)NH-- and
--NHC(O)--; n and m are each 1; L.sup.1 is selected from the group
consisting of unsubstituted C.sub.2-C.sub.6 alkylene; L.sup.2 is
selected from the group consisting of substituted or unsubstituted
C.sub.2-C.sub.6 alkylene; and P.sup.3 is selected from the group
consisting of --C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.2,
--NHS(O).sub.2R.sup.2, and --C(O)OR.sup.2, wherein R.sup.2 is a
member selected from the group consisting of hydrogen, substituted
or unsubstituted C.sub.1-C.sub.4 alkyl, substituted or
unsubstituted C.sub.3-C.sub.8 cycloalkyl, substituted or
unsubstituted aryl and substituted or unsubstituted aryl
C.sub.1-C.sub.4 alkyl.
7. The method in accordance with claim 1, wherein the compound has
formula (I), wherein P.sup.1 is selected from the group consisting
of --NHC(O)NH--, --OC(O)NH-- and --NHC(O)O--; n is 0; m is 1;
L.sup.1 is selected from the group consisting of unsubstituted
C.sub.2-C.sub.6 alkylene; L.sup.2 is selected from the group
consisting of substituted or unsubstituted C.sub.2-C.sub.6
alkylene; and P.sup.3 is selected from the group consisting of
--C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.2, --NHS(O).sub.2R.sup.2,
and --C(O)OR.sup.2, wherein R.sup.2 is a member selected from the
group consisting of hydrogen, substituted or unsubstituted
C.sub.1-C.sub.4 alkyl, substituted or unsubstituted C.sub.3-C.sub.8
cycloalkyl, substituted or unsubstituted aryl and substituted or
unsubstituted aryl C.sub.1-C.sub.4 alkyl.
8. The method in accordance with claim 1, wherein said compound has
formula (II) wherein A.sup.1 is a dipeptide or dipeptide
analog.
9. The method in accordance with claim 8, wherein A.sup.1 is a
dipeptide having an N-terminal residue selected from the group
consisting of Tyr, His, Lys, Phe and Trp, and a C-terminal residue
selected from the group consisting of Ala, Arg, Asp, Gly, Ile, Leu,
Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr and Val.
10. The method in accordance with claim 1, wherein m is 1 and
P.sup.3 is selected from those groups that reduce metabolism by
esterase dependent inactivation, beta-oxidation, P450-dependent
omega hydroxylation or by inhibiting P450 omega hydroxylase.
11. The method in accordance with claim 2, wherein R.sup.1 is
selected from the group consisting of C.sub.5-C.sub.12 cycloalkyl,
phenyl and naphthyl.
12. The method in accordance with claim 2, wherein P.sup.1 is
selected from the group consisting of --NHC(O)NH--, --OC(O)NH-- and
--NHC(O)O--.
13. The method in accordance with claim 2, wherein the compound has
formula (I), wherein P.sup.1 is selected from the group consisting
of --NHC(O)NH--, --OC(O)NH-- and --NHC(O)O--; P.sup.2 is selected
from the group consisting of --C(O)O--, --CH(OH)--,
--O(CH.sub.2CH.sub.2O).sub.q--- , --OC(O)--, --C(O)NH-- and
--NHC(O)--; m is 0 and L.sup.1 is selected from the group
consisting of unsubstituted C.sub.2-C.sub.6 alkylene, substituted
and unsubstituted C.sub.3-C.sub.6 cycloalkylene, and substituted or
unsubstituted arylene.
14. The method in accordance with claim 2, wherein the compound has
formula (I), wherein P.sup.1 is selected from the group consisting
of --NHC(O)NH--, --OC(O)NH-- and --NHC(O)O--; P.sup.2 is selected
from the group consisting of --C(O)O--,
--O(CH.sub.2CH.sub.2O).sub.q--, --OC(O)--, --C(O)NH-- and
--NHC(O)--; n and m are each 1; L.sup.1 is selected from the group
consisting of unsubstituted C.sub.2-C.sub.6 alkylene, substituted
and unsubstituted C.sub.3-C.sub.6 cycloalkylene, and substituted or
unsubstituted arylene; L.sup.2 is selected from the group
consisting of substituted or unsubstituted C.sub.2-C.sub.6
alkylene; and P.sup.3 is selected from the group consisting of
C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl, aryl,
heteroaryl, --NHS(O).sub.2R.sup.2, --C(O)OR.sup.2 and carboxylic
acid analogs, wherein R.sup.2 is a member selected from the group
consisting of hydrogen, substituted or unsubstituted
C.sub.1-C.sub.4 alkyl, substituted or unsubstituted C.sub.3-C.sub.8
cycloalkyl, substituted or unsubstituted aryl and substituted or
unsubstituted aryl C.sub.1-C.sub.4 alkyl.
15. The method in accordance with claim 2, wherein the compound has
formula (I), wherein P.sup.1 is selected from the group consisting
of --NHC(O)NH--, --OC(O)NH-- and --NHC(O)O--; n is 0; m is 1;
L.sup.1 is selected from the group consisting of unsubstituted
C.sub.2-C.sub.6 alkylene, substituted and unsubstituted
C.sub.3-C.sub.6 cycloalkylene, and substituted or unsubstituted
arylene; L.sup.2 is selected from the group consisting of
substituted or unsubstituted C.sub.2-C.sub.6 alkylene; and P.sup.3
is selected from the group consisting of C.sub.2-C.sub.6 alkynyl,
C.sub.1-C.sub.6 haloalkyl, aryl, heteroaryl, --NHS(O).sub.2R.sup.2,
--C(O)OR.sup.2 and carboxylic acid analogs, wherein R.sup.2 is a
member selected from the group consisting of hydrogen, substituted
or unsubstituted C.sub.1-C.sub.4 alkyl, substituted or
unsubstituted C.sub.3-C.sub.8 cycloalkyl, substituted or
unsubstituted aryl and substituted or unsubstituted aryl
C.sub.1-C.sub.4 alkyl.
16. The method in accordance with claim 2, wherein m is 1 and
P.sup.3 is selected from those groups that reduce metabolism by
esterase dependent inactivation, beta-oxidation, P450-dependent
omega hydroxylation or by inhibiting P450 omega hydroxylase.
17. A method for inhibiting a soluble epoxide hydrolase, comprising
contacting said soluble epoxide hydrolase with an inhibiting amount
of a compound having the formula described in Tables 1-18 and their
pharmaceutically acceptable salts.
18. A method of treating diseases modulated by soluble epoxide
hydrolases, said method comprising administering to a subject in
need of such treatment an effective amount of a compound having a
formula selected from the group consisting of: 99and their
pharmaceutically acceptable salts, wherein R.sup.1 is a member
selected from the group consisting of C.sub.5-C.sub.12 cycloalkyl,
aryl, heteroaryl and combinations thereof, wherein said cycloalkyl
portions are monocyclic or polycyclic; P.sup.1 is a primary
pharmacophore selected from the group consisting of --NHC(O)NH--,
--OC(O)NH--, --NHC(O)O--, --CH.sub.2C(O)NH--, --C(O)NH-- and
--NHC(O)--; P.sup.2 is a secondary pharmacophore selected from the
group consisting of --C(O)--, --CH(OH)--, --C(O)O--, --OC(O)--,
--NHC(O)NH--, --OC(O)NH--, --NHC(O)O--, --C(O)NH-- and --NHC(O)--;
P.sup.2a is selected from the group consisting of --C(O)-- and
--NHC(O)--; P.sup.3 is a tertiary pharmacophore selected from the
group consisting of C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6
haloalkyl, aryl, heteroaryl, --C(O)NHR.sup.2,
--C(O)NHS(O).sub.2R.sup.2, --NHS(O).sub.2R.sup.2, --C(O)OR.sup.2
and carboxylic acid analogs, wherein R.sup.2 is a member selected
from the group consisting of hydrogen, substituted or unsubstituted
C.sub.1-C.sub.4 alkyl, substituted or unsubstituted C.sub.3-C.sub.8
cycloalkyl, substituted or unsubstituted aryl and substituted or
unsubstituted aryl C.sub.1-C.sub.4 alkyl; the subscripts n and m
are each independently 0 or 1, and at least one of n or m is 1;
L.sup.1 is a first linker selected from the group consisting of
substituted and unsubstituted C.sub.2-C.sub.6 alkylene, substituted
or unsubstituted arylene and substituted or unsubstituted
heteroarylene; L.sup.2 is a second linker selected from the group
consisting of substituted and unsubstituted C.sub.2-C.sub.12
alkylene, substituted and unsubstituted arylene, and combinations
thereof; and A.sup.1 is a member selected from the group consisting
of an amino acid, a dipeptide and a dipeptide analog.
19. The method in accordance with claim 18, wherein said disease is
selected from the group consisting of hypertension, inflammation,
adult respiratory distress syndrome; diabetic complications; end
stage renal disease; Raynaud syndrome and arthritis.
20. The method in accordance with claim 19, wherein said
hypertension is selected from the group consisting of renal
hypertension, pulmonary hypertension and hepatic hypertension.
21. The method in accordance with claim 19, wherein said
inflammation is selected from the group consisting of renal
inflammation, vascular inflammation, and lung inflammation.
22. A method of treating diseases modulated by soluble epoxide
hydrolases, said method comprising administering to a subject in
need of such treatment an effective amount of a compound having a
formula selected from the group consisting of: 100and their
pharmaceutically acceptable salts, wherein R.sup.1 is a member
selected from the group consisting of C.sub.5-C.sub.12 cycloalkyl,
aryl, heteroaryl and combinations thereof, wherein said cycloalkyl
portions are monocyclic or polycyclic; P.sup.1 is a primary
pharmacophore selected from the group consisting of --NHC(O)NH--,
--OC(O)NH--, --NHC(O)O--, --CH.sub.2C(O)NH--, --C(O)NH-- and
--NHC(O)--; P.sup.2 is a secondary pharmacophore selected from the
group consisting of --C(O)--, --CH(OH)--,
--O(CH.sub.2CH.sub.2O).sub.q--, --C(O)O--, --OC(O)--, --NHC(O)NH--,
--OC(O)NH--, --NHC(O)O--, --C(O)NH-- and --NHC(O)--; P.sup.2a is
selected from the group consisting of --C(O)-- and --NHC(O)--;
P.sup.3 is a tertiary pharmacophore selected from the group
consisting of C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl,
aryl, heteroaryl, --C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.2,
--NHS(O).sub.2R.sup.2, --C(O)OR.sup.2 and carboxylic acid analogs,
wherein R.sup.2 is a member selected from the group consisting of
hydrogen, substituted or unsubstituted C.sub.1-C.sub.4 alkyl,
substituted or unsubstituted C.sub.3-C.sub.8 cycloalkyl,
substituted or unsubstituted aryl and substituted or unsubstituted
aryl C.sub.1-C.sub.4 alkyl; the subscripts n and m are each
independently 0 or 1, and at least one of n or m is 1, and the
subscript q is 0 to 3; L.sup.1 is a first linker selected from the
group consisting of substituted and unsubstituted C.sub.2-C.sub.6
alkylene, substituted and unsubstituted C.sub.3-C.sub.6
cycloalkylene, substituted or unsubstituted arylene and substituted
or unsubstituted heteroarylene; L.sup.2 is a second linker selected
from the group consisting of substituted and unsubstituted
C.sub.2-C.sub.12 alkylene, substituted and unsubstituted arylene,
and combinations thereof; and A.sup.1 is a member selected from the
group consisting of an amino acid, a dipeptide and a dipeptide
analog.
23. The method in accordance with claim 22, wherein said disease is
selected from the group consisting of hypertension, inflammation,
adult respiratory distress syndrome; diabetic complications; end
stage renal disease; Raynaud syndrome and arthritis.
24. The method in accordance with claim 23, wherein said
hypertension is selected from the group consisting of renal
hypertension, pulmonary hypertension and hepatic hypertension.
25. The method in accordance with claim 23, wherein said
inflammation is selected from the group consisting of renal
inflammation, vascular inflammation, and lung inflammation.
26. A method of treating diseases modulated by soluble epoxide
hydrolases, said method comprising administering to a subject in
need of such treatment an effective amount of a compound having the
formula described in Tables 1-18 and their pharmaceutically
acceptable salts.
27. The method in accordance with claim 26, wherein said disease is
selected from the group consisting of hypertension, inflammation,
adult respiratory distress syndrome; diabetic complications; end
stage renal disease; Raynaud syndrome and arthritis.
28. The method in accordance with claim 27, wherein said
hypertension is selected from the group consisting of renal
hypertension, pulmonary hypertension and hepatic hypertension.
29. The method in accordance with claim 27, wherein said
inflammation is selected from the group consisting of renal
inflammation, vascular inflammation, and lung inflammation.
30. A method for reducing renal deterioration in a subject, said
method comprising administering to said subject an effective amount
of a compound having a formula selected from the group consisting
of: 101and their pharmaceutically acceptable salts, wherein R.sup.1
is a member selected from the group consisting of C.sub.5-C.sub.12
cycloalkyl, aryl, heteroaryl and combinations thereof, wherein said
cycloalkyl portions are monocyclic or polycyclic; P.sup.1 is a
primary pharmacophore selected from the group consisting of
--NHC(O)NH--, --OC(O)NH--, --NHC(O)O--, --CH.sub.2C(O)NH--,
--C(O)NH-- and --NHC(O)--; P.sup.2 is a secondary pharmacophore
selected from the group consisting of --C(O)--, --CH(OH)--,
--C(O)O--, --OC(O)--, --NHC(O)NH--, --OC(O)NH--, --NHC(O)O--,
--C(O)NH-- and --NHC(O)--; P.sup.2a is selected from the group
consisting of --C(O)-- and --NHC(O)--; P.sup.3 is a tertiary
pharmacophore selected from the group consisting of C.sub.2-C.sub.6
alkynyl, C.sub.1-C.sub.6 haloalkyl, aryl, heteroaryl,
--C(O)NHR.sup.22, --C(O)NHS(O).sub.2R.sup.2, --NHS(O).sub.2R.sup.1,
--C(O)OR.sup.2 and carboxylic acid analogs, wherein R.sup.2 is a
member selected from the group consisting of hydrogen, substituted
or unsubstituted C.sub.1-C.sub.4 alkyl, substituted or
unsubstituted C.sub.3-C.sub.8 cycloalkyl, substituted or
unsubstituted aryl and substituted or unsubstituted aryl
C.sub.1-C.sub.4 alkyl; the subscripts n and m are each
independently 0 or 1, and at least one of n or m is 1; L.sup.1 is a
first linker selected from the group consisting of substituted and
unsubstituted C.sub.2-C.sub.6 alkylene, substituted or
unsubstituted arylene and substituted or unsubstituted
heteroarylene; L.sup.2 is a second linker selected from the group
consisting of substituted and unsubstituted C.sub.2-C.sub.12
alkylene, substituted and unsubstituted arylene, and combinations
thereof, and A.sup.1 is a member selected from the group consisting
of an amino acid, a dipeptide and a dipeptide analog.
31. The method in accordance with claim 30, wherein said renal
deterioration is present in said subject afflicted with diabetes,
hypertension or an inflammatory disorder.
32. A method for reducing renal deterioration in a subject, said
method comprising administering to said subject an effective amount
of a compound having a formula selected from the group consisting
of: 102and their pharmaceutically acceptable salts, wherein R.sup.1
is a member selected from the group consisting of C.sub.5-C.sub.12
cycloalkyl, aryl, heteroaryl and combinations thereof, wherein said
cycloalkyl portions are monocyclic or polycyclic; P.sup.1 is a
primary pharmacophore selected from the group consisting of
--NHC(O)NH--, --OC(O)NH--, --NHC(O)O--, --CH.sub.2C(O)NH--,
--C(O)NH-- and --NHC(O)--; P.sup.2 is a secondary pharmacophore
selected from the group consisting of --C(O)--, --CH(OH)--,
--O(CH.sub.2CH.sub.2O).sub.q--, --C(O)O--, --OC(O)--, --NHC(O)NH--,
--OC(O)NH--, --NHC(O)O--, --C(O)NH-- and --NHC(O)--; P.sup.2a is
selected from the group consisting of --C(O)-- and --NHC(O)--;
P.sup.3 is a tertiary pharmacophore selected from the group
consisting of C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl,
aryl, heteroaryl, --C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.2,
--NHS(O).sub.2R.sup.2, --C(O)OR.sup.2 and carboxylic acid analogs,
wherein R.sup.2 is a member selected from the group consisting of
hydrogen, substituted or unsubstituted C.sub.1-C.sub.4 alkyl,
substituted or unsubstituted C.sub.3-C.sub.8 cycloalkyl,
substituted or unsubstituted aryl and substituted or unsubstituted
aryl C.sub.1-C.sub.4 alkyl; the subscripts n and m are each
independently 0 or 1, and at least one of n or m is 1, and the
subscript q is 0 to 3; L.sup.1 is a first linker selected from the
group consisting of substituted and unsubstituted C.sub.2-C.sub.6
alkylene, substituted and unsubstituted C.sub.3-C.sub.6
cycloalkylene, substituted or unsubstituted arylene and substituted
or unsubstituted heteroarylene; L.sup.2 is a second linker selected
from the group consisting of substituted and unsubstituted
C.sub.2-C.sub.12 alkylene, substituted and unsubstituted arylene,
and combinations thereof; and A.sup.1 is a member selected from the
group consisting of an amino acid, a dipeptide and a dipeptide
analog.
33. The method in accordance with claim 32, wherein said renal
deterioration is present in said subject afflicted with diabetes,
hypertension or an inflammatory disorder.
34. A method for reducing renal deterioration in a subject, said
method comprising administering to said subject an effective amount
of a compound having the formula described in Tables 1-18 and their
pharmaceutically acceptable salts.
35. The method in accordance with claim 34, wherein said renal
deterioration is present in said subject afflicted with diabetes,
hypertension or an inflammatory disorder.
36. A method for inhibiting progression of nephropathy in a
subject, said method comprising administering to said subject an
effective amount of a compound having a formula selected from the
group consisting of: 103and their pharmaceutically acceptable
salts, wherein R.sup.1 is a member selected from the group
consisting of C.sub.5-C.sub.12 cycloalkyl, aryl, heteroaryl and
combinations thereof, wherein said cycloalkyl portions are
monocyclic or polycyclic; P.sup.1 is a primary pharmacophore
selected from the group consisting of --NHC(O)NH--, --OC(O)NH--,
--NHC(O)O--, --CH.sub.2C(O)NH--, --C(O)NH-- and --NHC(O)--; P.sup.2
is a secondary pharmacophore selected from the group consisting of
--C(O)--, --CH(OH)--, --O(CH.sub.2CH.sub.2O).sub.q--, --C(O)O--,
--OC(O)--, --NHC(O)NH--, --OC(O)NH--, --NHC(O)O--, --C(O)NH-- and
--NHC(O)--; P.sup.2a is selected from the group consisting
of-C(O)-- and --NHC(O)--; P.sup.3 is a tertiary pharmacophore
selected from the group consisting of C.sub.2-C.sub.6 alkynyl,
C.sub.1-C.sub.6 haloalkyl, aryl, heteroaryl, --C(O)NHR.sup.22,
--C(O)NHS(O).sub.2R.sup.2, --NHS(O).sub.2R.sup.1, --C(O)OR.sup.2
and carboxylic acid analogs, wherein R.sup.2 is a member selected
from the group consisting of hydrogen, substituted or unsubstituted
C.sub.1-C.sub.4 alkyl, substituted or unsubstituted C.sub.3-C.sub.8
cycloalkyl, substituted or unsubstituted aryl and substituted or
unsubstituted aryl C.sub.1-C.sub.4 alkyl; the subscripts n and m
are each independently 0 or 1, and at least one of n or m is 1, and
the subscript q is 0 to 3; L.sup.1 is a first linker selected from
the group consisting of substituted and unsubstituted
C.sub.2-C.sub.6 alkylene, substituted and unsubstituted
C.sub.3-C.sub.6 cycloalkylene, substituted or unsubstituted arylene
and substituted or unsubstituted heteroarylene; L.sup.2 is a second
linker selected from the group consisting of substituted and
unsubstituted C.sub.2-C.sub.12 alkylene, substituted and
unsubstituted arylene, and combinations thereof; and A.sup.1 is a
member selected from the group consisting of an amino acid, a
dipeptide and a dipeptide analog.
37. The method in accordance with claim 36 wherein the subject is
(a) a person with diabetes mellitus whose blood pressure is 130/85
or less, (b) a person with metabolic syndrome whose blood pressure
is 130/85 or less, (c) a person with a triglyceride level over 215
mg/dL, or (d) a person with a cholesterol level over 200 mg/dL.
38. A method for inhibiting progression of nephropathy in a
subject, said method comprising administering to said subject an
effective amount of a compound having the formula described in
Tables 1-18 and their pharmaceutically acceptable salts.
39. The method in accordance with claim 38 wherein the subject is
(a) a person with diabetes mellitus whose blood pressure is 130/85
or less, (b) a person with metabolic syndrome whose blood pressure
is 130/85 or less, (c) a person with a triglyceride level over 215
mg/dL, or (d) a person with a cholesterol level over 200 mg/dL.
40. A method for reducing blood pressure in a subject, said method
comprising administering to said subject an effective amount of a
compound having a formula selected from the group consisting of:
104and their pharmaceutically acceptable salts, wherein R.sup.1 is
a member selected from the group consisting of C.sub.5-C.sub.12
cycloalkyl, aryl, heteroaryl and combinations thereof, wherein said
cycloalkyl portions are monocyclic or polycyclic; P.sup.1 is a
primary pharmacophore selected from the group consisting of
--NHC(O)NH--, --OC(O)NH--, --NHC(O)O--, --CH.sub.2C(O)NH--,
--C(O)NH-- and --NHC(O)--; P.sup.2 is a secondary pharmacophore
selected from the group consisting of --C(O)--, --CH(OH)--,
--O(CH.sub.2CH.sub.2O).sub.q--, --C(O)O--, --OC(O)--, --NHC(O)NH--,
--OC(O)NH--, --NHC(O)O--, --C(O)NH-- and --NHC(O)--; P.sup.2a is
selected from the group consisting of --C(O)-- and --NHC(O)--;
P.sup.3 is a tertiary pharmacophore selected from the group
consisting of C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl,
aryl, heteroaryl, --C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.2,
--NHS(O).sub.2R.sup.2, --C(O)OR.sup.2 and carboxylic acid analogs,
wherein R.sup.2 is a member selected from the group consisting of
hydrogen, substituted or unsubstituted C.sub.1-C.sub.4 alkyl,
substituted or unsubstituted C.sub.3-C.sub.8 cycloalkyl,
substituted or unsubstituted aryl and substituted or unsubstituted
aryl C.sub.1-C.sub.4 alkyl; the subscripts n and m are each
independently 0 or 1, and at least one of n or m is 1, and the
subscript q is 0 to 3; L.sup.1 is a first linker selected from the
group consisting of substituted and unsubstituted C.sub.2-C.sub.6
alkylene, substituted and unsubstituted C.sub.3-C.sub.6
cycloalkylene, substituted or unsubstituted arylene and substituted
or unsubstituted heteroarylene; L.sup.2 is a second linker selected
from the group consisting of substituted and unsubstituted
C.sub.2-C.sub.12 alkylene, substituted and unsubstituted arylene,
and combinations thereof; and A.sup.1 is a member selected from the
group consisting of an amino acid, a dipeptide and a dipeptide
analog.
41. The method in accordance with claim 40, said method further
comprising administering to said subject an effective amount of a
cis-epoxyeicosantrienoic acid.
42. The method in accordance with claim 41, wherein said
cis-epoxyeicosantrienoic acid is administered with said compound
having formula (I) or (II).
43. A method for reducing blood pressure in a subject, said method
comprising administering to said subject an effective amount of a
compound having the formula described in Tables 1-18 and their
pharmaceutically acceptable salts.
44. The method in accordance with claim 43, said method further
comprising administering to said subject an effective amount of a
cis-epoxyeicosantrienoic acid.
45. The method in accordance with claim 44, wherein said
cis-epoxyeicosantrienoic acid is administered with said compound
having formula (I) or (II).
46. A method of inhibiting the proliferation of vascular smooth
muscle cells in a subject, said method comprising administering to
said subject an effective amount of a compound having a formula
selected from the group consisting of: 105and their
pharmaceutically acceptable salts, wherein R.sup.1 is a member
selected from the group consisting of C.sub.5-C.sub.12 cycloalkyl,
aryl, heteroaryl and combinations thereof, wherein said cycloalkyl
portions are monocyclic or polycyclic; P.sup.1 is a primary
pharmacophore selected from the group consisting of --NHC(O)NH--,
--OC(O)NH--, --NHC(O)O--, --CH.sub.2C(O)NH--, --C(O)NH-- and
--NHC(O)--; P.sup.2 is a secondary pharmacophore selected from the
group consisting of --C(O)--, --CH(OH)--,
--O(CH.sub.2CH.sub.2O).sub.q--, --C(O)O--, --OC(O)--, --NHC(O)NH--,
--OC(O)NH--, --NHC(O)O--, --C(O)NH-- and --NHC(O)--; P.sup.2a is
selected from the group consisting of --C(O)-- and --NHC(O)--;
P.sup.3 is a tertiary pharmacophore selected from the group
consisting of C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl,
aryl, heteroaryl, --C(O)NHR.sup.22, --C(O)NHS(O).sub.2R.sup.2,
--NHS(O).sub.2R.sup.2, --C(O)OR.sup.2 and carboxylic acid analogs,
wherein R.sup.2 is a member selected from the group consisting of
hydrogen, substituted or unsubstituted C.sub.1-C.sub.4 alkyl,
substituted or unsubstituted C.sub.3-C.sub.8 cycloalkyl,
substituted or unsubstituted aryl and substituted or unsubstituted
aryl C.sub.1-C.sub.4 alkyl; the subscripts n and m are each
independently 0 or 1, and at least one of n or m is 1, and the
subscript q is 0 to 3; L.sup.1 is a first linker selected from the
group consisting of substituted and unsubstituted C.sub.2-C.sub.6
alkylene, substituted and unsubstituted C.sub.3-C.sub.6
cycloalkylene, substituted or unsubstituted arylene and substituted
or unsubstituted heteroarylene; L.sup.2 is a second linker selected
from the group consisting of substituted and unsubstituted
C.sub.2-C.sub.12 alkylene, substituted and unsubstituted arylene,
and combinations thereof; and A.sup.1 is a member selected from the
group consisting of an amino acid, a dipeptide and a dipeptide
analog.
47. A method of inhibiting the proliferation of vascular smooth
muscle cells in a subject, said method comprising administering to
said subject an effective amount of a compound having the formula
described in Tables 1-18 and their pharmaceutically acceptable
salts.
48. A method of inhibiting the progression of obstructive pulmonary
disease, an interstitial lung disease, or asthma in a subject, said
method comprising administering to said subject an effective amount
of a compound having a formula selected from the group consisting
of: 106and their pharmaceutically acceptable salts, wherein R.sup.1
is a member selected from the group consisting of C.sub.5-C.sub.12
cycloalkyl, aryl, heteroaryl and combinations thereof, wherein said
cycloalkyl portions are monocyclic or polycyclic; P.sup.1 is a
primary pharmacophore selected from the group consisting of
--NHC(O)NH--, --OC(O)NH--, --NHC(O)O--, --CH.sub.2C(O)NH--,
--C(O)NH-- and --NHC(O)--; P.sup.2 is a secondary pharmacophore
selected from the group consisting of --C(O)--, --CH(OH)--,
--O(CH.sub.2CH.sub.2O).sub.q--, --C(O)O--, --OC(O)--, --NHC(O)NH--,
--OC(O)NH--, --NHC(O)O--, --C(O)NH-- and --NHC(O)--; P.sup.2a is
selected from the group consisting of --C(O)-- and --NHC(O)--;
P.sup.3 is a tertiary pharmacophore selected from the group
consisting of C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl,
aryl, heteroaryl, --C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.2,
--NHS(O).sub.2R.sup.2, --C(O)OR.sup.2 and carboxylic acid analogs,
wherein R.sup.2 is a member selected from the group consisting of
hydrogen, substituted or unsubstituted C.sub.1-C.sub.4 alkyl,
substituted or unsubstituted C.sub.3-C.sub.8 cycloalkyl,
substituted or unsubstituted aryl and substituted or unsubstituted
aryl C.sub.1-C.sub.4 alkyl; the subscripts n and m are each
independently 0 or 1, and at least one of n or m is 1, and the
subscript q is 0 to 3; L.sup.1 is a first linker selected from the
group consisting of substituted and unsubstituted C.sub.2-C.sub.6
alkylene, substituted and unsubstituted C.sub.3-C.sub.6
cycloalkylene, substituted or unsubstituted arylene and substituted
or unsubstituted heteroarylene; L.sup.2 is a second linker selected
from the group consisting of substituted and unsubstituted
C.sub.2-C.sub.12 alkylene, substituted and unsubstituted arylene,
and combinations thereof; and A.sup.1 is a member selected from the
group consisting of an amino acid, a dipeptide and a dipeptide
analog.
49. The method in accordance with claim 48, wherein said
obstructive pulmonary disease is selected from the group consisting
of chronic obstructive pulmonary disease, emphysema, and chronic
bronchitis.
50. The method in accordance with claim 48, wherein said
interstitial lung disease is idiopathic pulmonary fibrosis or is
one associated with exposure to dust.
51. The method in accordance with claim 48, said method further
comprising administering to said subject an effective amount of a
cis-epoxyeicosantrienoic acid.
52. The method in accordance with claim 51, wherein said
cis-epoxyeicosantrienoic acid is administered with said compound
having formula (I) or (II).
53. A method of inhibiting the progression of obstructive pulmonary
disease, an interstitial lung disease, or asthma in a subject, said
method comprising administering to said subject an effective amount
of a compound having the formula described in Tables 1-18 and their
pharmaceutically acceptable salts.
54. The method in accordance with claim 53, wherein said
obstructive pulmonary disease is selected from the group consisting
of chronic obstructive pulmonary disease, emphysema, and chronic
bronchitis.
55. The method in accordance with claim 53, wherein said
interstitial lung disease is idiopathic pulmonary fibrosis or is
one associated with exposure to dust.
56. The method in accordance with claim 53, said method further
comprising administering to said subject an effective amount of a
cis-epoxyeicosantrienoic acid.
57. The method in accordance with claim 56, wherein said
cis-epoxyeicosantrienoic acid is administered with said compound
having formula (I) or (II).
58. A compound having a formula selected from the group consisting
of: 107and their pharmaceutically acceptable salts, wherein R.sup.1
is a member selected from the group consisting of C.sub.5-C.sub.12
cycloalkyl, aryl, heteroaryl and combinations thereof, wherein said
cycloalkyl portions are monocyclic or polycyclic; P.sup.1 is a
primary pharmacophore selected from the group consisting of
--NHC(O)NH--, --OC(O)NH--, --NHC(O)O--, --CH.sub.2C(O)NH--,
--C(O)NH-- and --NHC(O)--; P.sup.2 is a secondary pharmacophore
selected from the group consisting of --C(O)--, --CH(OH)--,
--C(O)O--, --OC(O)--, --NHC(O)NH--, --OC(O)NH--, --NHC(O)O--,
--C(O)NH-- and --NHC(O)--; P.sup.2a is selected from the group
consisting of --C(O)-- and --NHC(O)--; P.sup.3 is a tertiary
pharmacophore selected from the group consisting of C.sub.2-C.sub.6
alkynyl, C.sub.1-C.sub.6 haloalkyl, aryl, heteroaryl,
--C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.2, --NHS(O).sub.2R.sup.2,
--C(O)OR.sup.2 and carboxylic acid analogs, wherein R.sup.2 is a
member selected from the group consisting of hydrogen, substituted
or unsubstituted C.sub.1-C.sub.4 alkyl, substituted or
unsubstituted C.sub.3-C.sub.8 cycloalkyl, substituted or
unsubstituted aryl and substituted or unsubstituted aryl
C.sub.1-C.sub.4 alkyl; the subscripts n and m are each
independently 0 or 1, and at least one of n or m is 1; L.sup.1 is a
first linker selected from the group consisting of substituted and
unsubstituted C.sub.2-C.sub.6 alkylene, substituted or
unsubstituted arylene and substituted or unsubstituted
heteroarylene; L.sup.2 is a second linker selected from the group
consisting of substituted and unsubstituted C.sub.2-C.sub.12
alkylene, substituted and unsubstituted arylene, and combinations
thereof; and A.sup.1 is a member selected from the group consisting
of an amino acid, a dipeptide and a dipeptide analog.
59. A compound having a formula selected from the group consisting
of: 108and their pharmaceutically acceptable salts, wherein R.sup.1
is a member selected from the group consisting of C.sub.5-C.sub.12
cycloalkyl, aryl, heteroaryl and combinations thereof, wherein said
cycloalkyl portions are monocyclic or polycyclic; P.sup.1 is a
primary pharmacophore selected from the group consisting of
--NHC(O)NH--, --OC(O)NH--, --NHC(O)O--, --CH.sub.2C(O)NH--,
--C(O)NH-- and --NHC(O)--; P.sup.2 is a secondary pharmacophore
selected from the group consisting of --C(O)--, --CH(OH)--,
--O(CH.sub.2CH.sub.2O).sub.q--, --C(O)O--, --OC(O)--, --NHC(O)NH--,
--OC(O)NH--, --NHC(O)O--, --C(O)NH-- and --NHC(O)--; P.sup.2a is
selected from the group consisting of --C(O)-- and --NHC(O)--;
P.sup.3 is a tertiary pharmacophore selected from the group
consisting of C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl,
aryl, heteroaryl, --C(O)NHR.sup.1, --C(O)NHS(O).sub.2R.sup.1,
--NHS(O).sub.2R.sup.2, --C(O)OR.sup.2 and carboxylic acid analogs,
wherein R.sup.2 is a member selected from the group consisting of
hydrogen, substituted or unsubstituted C.sub.1-C.sub.4 alkyl,
substituted or unsubstituted C.sub.3-C.sub.8 cycloalkyl,
substituted or unsubstituted aryl and substituted or unsubstituted
aryl C.sub.1-C.sub.4 alkyl; the subscripts n and m are each
independently 0 or 1, and at least one of n or m is 1, and the
subscript q is 0 to 3; L.sup.1 is a first linker selected from the
group consisting of substituted and unsubstituted C.sub.2-C.sub.6
alkylene, substituted and unsubstituted C.sub.3-C.sub.6
cycloalkylene, substituted or unsubstituted arylene and substituted
or unsubstituted heteroarylene; L.sup.2 is a second linker selected
from the group consisting of substituted and unsubstituted
C.sub.2-C.sub.12 alkylene, substituted and unsubstituted arylene,
and combinations thereof; and A.sup.1 is a member selected from the
group consisting of an amino acid, a dipeptide and a dipeptide
analog.
60. The compound in accordance with claim 58, wherein R.sup.1 is
selected from the group consisting of C.sub.5-C.sub.12 cycloalkyl,
phenyl and naphthyl.
61. The compound in accordance with claim 58, wherein the compound
has formula (I), wherein P.sup.1 is selected from the group
consisting of --NHC(O)NH--, --OC(O)NH-- and --NHC(O)O--; P.sup.2 is
selected from the group consisting of --C(O)O--, --CH(OH)--,
--OC(O)--, --C(O)NH-- and --NHC(O)--; n and m are each 1; L.sup.1
is selected from the group consisting of unsubstituted
C.sub.2-C.sub.6 alkylene; L.sup.2 is selected from the group
consisting of substituted or unsubstituted C.sub.2-C.sub.6
alkylene; and P.sup.3 is selected from the group consisting of
--C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.2, --NHS(O).sub.2R.sup.2,
and --C(O)OR.sup.2, wherein R.sup.1 is a member selected from the
group consisting of hydrogen, substituted or unsubstituted
C.sub.1-C.sub.4 alkyl, substituted or unsubstituted C.sub.3-C.sub.8
cycloalkyl, substituted or unsubstituted aryl and substituted or
unsubstituted aryl C.sub.1-C.sub.4 alkyl.
62. The compound in accordance with claim 58, wherein the compound
has formula (I), wherein P.sup.1 is selected from the group
consisting of --NHC(O)NH--, --OC(O)NH-- and --NHC(O)O--; n is 0; m
is 1; L.sup.1 is selected from the group consisting of
unsubstituted C.sub.2-C.sub.6 alkylene; L.sup.2 is selected from
the group consisting of substituted or unsubstituted
C.sub.2-C.sub.6 alkylene; and P.sup.3 is selected from the group
consisting of --C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.2,
--NHS(O).sub.2R.sup.2, and --C(O)OR.sup.2, wherein R.sup.2 is a
member selected from the group consisting of hydrogen, substituted
or unsubstituted C.sub.1-C.sub.4 alkyl, substituted or
unsubstituted C.sub.3-C.sub.8 cycloalkyl, substituted or
unsubstituted aryl and substituted or unsubstituted aryl
C.sub.1-C.sub.4 alkyl.
63. The compound in accordance with claim 58, wherein said compound
has formula (II) wherein A.sup.1 is a dipeptide or dipeptide
analog.
64. The compound in accordance with claim 58, wherein said compound
has formula (II) wherein A.sup.1 is a dipeptide having an
N-terminal residue selected from the group consisting of Tyr, His,
Lys, Phe and Trp, and a C-terminal residue selected from the group
consisting of Ala, Arg, Asp, Gly, Ile, Leu, Lys, Met, Phe, Pro,
Ser, Thr, Trp, Tyr and Val.
65. The compound in accordance with claim 59, wherein R.sup.1 is
selected from the group consisting of C.sub.5-C.sub.12 cycloalkyl,
phenyl and naphthyl.
66. The compound in accordance with claim 59, wherein the compound
has formula (I), wherein P.sup.1 is selected from the group
consisting of --NHC(O)NH--, --OC(O)NH-- and --NHC(O)O--; P.sup.2 is
selected from the group consisting of --C(O)O--, --CH(OH)--,
--O(CH.sub.2CH.sub.2O).sub.q--- , --OC(O)--, --C(O)NH-- and
--NHC(O)--; n and m are each 1; L.sup.1 is selected from the group
consisting of unsubstituted C.sub.2-C.sub.6 alkylene, substituted
or unsubstituted C.sub.3-C.sub.6cycloalkylene, and substituted or
unsubstituted arylene; L.sup.2 is selected from the group
consisting of substituted or unsubstituted C.sub.2-C.sub.6
alkylene; and P.sup.3 is selected from the group consisting of
--C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.2, --NHS(O).sub.2R.sup.2,
and --C(O)OR.sup.2, wherein R.sup.2 is a member selected from the
group consisting of hydrogen, substituted or unsubstituted
C.sub.1-C.sub.4 alkyl, substituted or unsubstituted C.sub.3-C.sub.8
cycloalkyl, substituted or unsubstituted aryl and substituted or
unsubstituted aryl C.sub.1-C.sub.4 alkyl.
67. The compound in accordance with claim 59, wherein the compound
has formula (I), wherein P.sup.1 is selected from the group
consisting of --NHC(O)NH--, --OC(O)NH-- and --NHC(O)O--; n is 0; m
is 1; L.sup.1 is selected from the group consisting of
unsubstituted C.sub.2-C.sub.6 alkylene, substituted or
unsubstituted C.sub.3-C.sub.6cycloalkylene, and substituted or
unsubstituted arylene; L2 is selected from the group consisting of
substituted or unsubstituted C.sub.2-C.sub.6 alkylene; and P.sup.3
is selected from the group consisting of C.sub.2-C.sub.6 alkynyl,
C.sub.1-C.sub.6 haloalkyl, aryl, heteroaryl, --C(O)NHR.sup.2,
--C(O)NHS(O).sub.2R.sup.2, --NHS(O).sub.2R.sup.2, --C(O)OR.sup.2
and carboxylic acid analogs, wherein R.sup.2 is a member selected
from the group consisting of hydrogen, substituted or unsubstituted
C.sub.1-C.sub.4 alkyl, substituted or unsubstituted C.sub.3-C.sub.8
cycloalkyl, substituted or unsubstituted aryl and substituted or
unsubstituted aryl C.sub.1-C.sub.4 alkyl.
68. The compound in accordance with claim 59, wherein-the compound
has formula (I) wherein R.sup.1 is a member selected from the group
consisting of C.sub.5-C.sub.12 cycloalkyl, wherein said cycloalkyl
portions are monocyclic or polycyclic; P.sup.1 is selected from the
group consisting of --NHC(O)NH--; P.sup.2 is selected from the
group consisting of --O(CH.sub.2CH.sub.2O).sub.q-- and --C(O)O--;
P.sup.3 is selected from the group consisting of C.sub.2-C.sub.6
alkynyl, C.sub.1-C.sub.6 haloalkyl, aryl, heteroaryl,
--NHS(O).sub.2R.sup.2, --C(O)OR.sup.2 and carboxylic acid analogs,
wherein R.sup.2 is a member selected from the group consisting of
hydrogen, substituted or unsubstituted C.sub.1-C.sub.4 alkyl,
substituted or unsubstituted C.sub.3-C.sub.8 cycloalkyl,
substituted or unsubstituted aryl and substituted or unsubstituted
aryl C.sub.1-C.sub.4 alkyl; m is 1 and q is 0 to 3; L.sup.1 is
selected from the group consisting of substituted and unsubstituted
C.sub.2-C.sub.6 alkylene, substituted and unsubstituted
C.sub.3-C.sub.6 cycloalkylene, and substituted or unsubstituted
arylene; and L.sup.2 is selected from the group consisting of
substituted and unsubstituted C.sub.2-C.sub.12 alkylene.
69. A compound having the formula described in Tables 1-18 and
their pharmaceutically acceptable salts.
70. A pharmaceutical composition comprising a pharmaceutically
acceptable excipient and a compound of claim 58.
71. A pharmaceutical composition comprising a pharmaceutically
acceptable excipient and a compound of claim 59.
72. A pharmaceutical composition comprising a pharmaceutically
acceptable excipient and a compound of claim 69.
73. A method for stabilizing biologically active epoxides in the
presence of a soluble epoxide hydrolase, said method comprising
contacting said soluble epoxide hydrolase with an amount of a
compound of claim 58, sufficient to inhibit the activity of said
soluble epoxide hydrolase and stabilize said biologically active
epoxide.
74. A method for stabilizing biologically active epoxides in the
presence of a soluble epoxide hydrolase, said method comprising
contacting said soluble epoxide hydrolase with an amount of a
compound of claim 59, sufficient to inhibit the activity of said
soluble epoxide hydrolase and stabilize said biologically active
epoxide.
75. A method for stabilizing biologically active epoxides in the
presence of a soluble epoxide hydrolase, said method comprising
contacting said soluble epoxide hydrolase with an amount of a
compound having the formula described in Tables 1-18 and their
pharmaceutically acceptable salts.
76. The method in accordance with claim 73, wherein said contacting
is conducted in an in vitro assay.
77. The method in accordance with claim 73, wherein said contacting
is conducted in vivo.
78. The method in accordance with claim 74, wherein said contacting
is conducted in an in vitro assay.
79. The method in accordance with claim 74, wherein said contacting
is conducted in vivo.
80. The method in accordance with claim 75, wherein said contacting
is conducted in an in vitro assay.
81. The method in accordance with claim 75, wherein said contacting
is conducted in vivo.
82. The method for reducing the formation of a biologically active
diol produced by the action of a soluble epoxide hydrolase, said
method comprising contacting said soluble epoxide hydrolase with an
amount of a compound of claim 58, sufficient to inhibit the
activity of said soluble epoxide hydrolase and reduce the formation
of said biologically active diol.
83. The method for reducing the formation of a biologically active
diol produced by the action of a soluble epoxide hydrolase, said
method comprising contacting said soluble epoxide hydrolase with an
amount of a compound of claim 59, sufficient to inhibit the
activity of said soluble epoxide hydrolase and reduce the formation
of said biologically active diol.
84. A method for reducing the formation of a biologically active
diol produced by the action of a soluble epoxide hydrolase, said
method comprising contacting said soluble epoxide hydrolase with an
amount of a compound having the formula described in Tables 1-18
and their pharmaceutically acceptable salts.
85. The method in accordance with claim 82, wherein said contacting
is conducted in an in vitro assay.
86. The method in accordance with claim 82, wherein said contacting
is conducted in vivo.
87. The method in accordance with claim 83, wherein said contacting
is conducted in an in vitro assay.
88. The method in accordance with claim 83, wherein said contacting
is conducted in vivo.
89. The method in accordance with claim 84, wherein said contacting
is conducted in an in vitro assay.
90. The method in accordance with claim 84, wherein said contacting
is conducted in vivo.
91. A method for monitoring the activity of a soluble epoxide
hydrolase, said method comprising contacting said soluble epoxide
hydrolase with an amount of a compound of claim 58 sufficient to
produce a detectable change in fluorescence of said soluble epoxide
hydrolase by interacting with one or more tryptophan residues
present in the catalytic site of said sEH.
92. A method for monitoring the activity of a soluble epoxide
hydrolase, said method comprising contacting said soluble epoxide
hydrolase with an amount of a compound of claim 59 sufficient to
produce a detectable change in fluorescence of said soluble epoxide
hydrolase by interacting with one or more tryptophan residues
present in the catalytic site of said sEH.
93. A method for monitoring the activity of a soluble epoxide
hydrolase, said method comprising contacting said soluble epoxide
hydrolase with an amount of a compound having the formula described
in Tables 1-18 and their pharmaceutically acceptable salts.
94. The method in accordance with claim 92, wherein said compound
has an aryl group present one or more components selected from the
group consisting of R.sup.1, L.sup.2, P.sup.3 and A.sup.1.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of U.S. Provisional
Patent Application No. 60/460,559, filed Apr. 3, 2003, the content
of which is incorporated herein by reference.
REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER PROGRAM
LISTING APPENDIX SUBMITTED ON A COMPACT DISK.
[0003] NOT APPLICABLE
BACKGROUND OF THE INVENTION
[0004] Epoxide hydrolases (EHs, EC 3.3.2.3) catalyze the hydrolysis
of epoxides or arene oxides to their corresponding diols by the
addition of water (see, Oesch, F., et al., Xenobiotica 1973, 3,
305-340). EHs play an important role in the metabolism of a variety
of compounds including hormones, chemotherapeutic drugs,
carcinogens, environmental pollutants, mycotoxins, and other
harmful foreign compounds.
[0005] There are two well-studied EHs, microsomal epoxide hydrolase
(mEH) and soluble epoxide hydrolase (sEH). These enzymes are very
distantly related, have different subcellular localization, and
have different but partially overlapping substrate selectivities.
The soluble and microsomal EH forms are known to complement each
other in detoxifying a wide array of mutagenic, toxic, and
carcinogenic xenobiotic epoxides (see, Hammock, B. D., et al.,
COMPREHENSIVE TOXICOLOGY. Oxford: Pergamon Press 1977, 283-305 and
Fretland, A. J., et al., Chem. Biol. Intereract 2000, 129,
41-59).
[0006] The sEH is also involved in the metabolism of arachidonic
acid (see, Zeldin, D. C., et al., J. Biol. Chem. 1993, 268,
6402-6407), linoleic (see, Moghaddam, M. F., et al., Nat. Med.
1997, 3, 562-567) acid, and other lipid epoxides, some of which are
endogenous chemical mediators (see, Carroll, M. A., et al., Thorax
2000, 55, S13-16). Epoxides of arachidonic acid
(epoxyeicosatrienoic acids or EETs) are known effectors of blood
pressure (see, Capdevila, J. H., et al., J. Lipid. Res. 2000, 41,
163-181), and modulators of vascular permeability (see, Oltman, C.
L., et al., Circ Res. 1998, 83, 932-939). The vasodilatory
properties of EETs are associated with an increased open-state
probability of calcium-activated potassium channels leading to
hyperpolarization of the vascular smooth muscle (see Fisslthaler,
B., et al., Nature 1999, 401, 493-497). Hydrolysis of the epoxides
by sEH diminishes this activity (see, Capdevila, J. H., et al., J.
Lipid. Res. 2000, 41, 163-181). sEH hydrolysis of EETs also
regulates their incorporation into coronary endothelial
phospholipids, suggesting a regulation of endothelial function by
sEH (see, Weintraub, N. L., et al., Am. J. Physiol. 1992, 277,
H2098-2108). It has recently been shown that treatment of
spontaneous hypertensive rats (SHRs) with selective sEH inhibitors
significantly reduces their blood pressure (see, Yu, Z., et al.,
Circ. Res. 2000, 87, 992-998). In addition, male knockout sEH mice
have significantly lower blood pressure than wild-type mice (see
Sinal, C. J., et al., J. Biol. Chem. 2000, 275, 40504-405010),
further supporting the role of sEH in blood pressure
regulation.
[0007] The EETs have also demonstrated anti-inflammatory properties
in endothelial cells (see, Node, K., et al., Science 1999, 285,
1276-1279 and Campbell, W. B. Trends Pharmacol. Sci. 2000, 21,
125-127). In contrast, diols derived from epoxy-linoleate
(leukotoxin) perturb membrane permeability and calcium homeostasis
(see, Moghaddam, M. F., et al.; Nat. Med. 1997, 3, 562-567), which
results in inflammation that is modulated by nitric oxide synthase
and endothelin-1 (see, Ishizaki, T., et al., Am. J. Physiol. 1995,
269, L65-70 and Ishizaki, T., et al., J. Appl. Physiol. 1995, 79,
1106-1611). Micromolar concentrations of leukotoxin reported in
association with inflammation and hypoxia (see, Dudda, A., et al.,
Chem. Phys. Lipids 1996, 82, 39-51), depress mitochondrial
respiration in vitro (see, Sakai, T., et al., Am. J. Physiol. 1995,
269, L326-331), and cause mammalian cardiopulmonary toxicity in
vivo (see, Ishizaki, T., et al., Am. J. Physiol. 1995, 269, L65-70;
Fukushima, A., et al., Cardiovasc. Res. 1988, 22, 213-218; and
Ishizaki, T., et al., Am. J. Physiol. 1995, 268, L123-128).
Leukotoxin toxicity presents symptoms suggestive of multiple organ
failure and acute respiratory distress syndrome (ARDS) (see, Ozawa,
T. et al., Am. Rev. Respir. Dis. 1988, 137, 535-540). In both
cellular and organismal models, leukotoxin-mediated toxicity is
dependent upon epoxide hydrolysis (see, Moghaddam, M. F., et al.,
Nat. Med. 1997, 3, 562-567; Morisseau, C., et al., Proc. Natl.
Acad. Sci. USA 1999, 96, 8849-8854; and Zheng, J., et al., Am. J.
Respir. Cell Mol. Biol. 2001, 25, 434-438), suggesting a role for
sEH in the regulation of inflammation. The bioactivity of these
epoxy-fatty acids suggests that inhibition of
vicinal-dihydroxy-lipid biosynthesis may have therapeutic value,
making sEH a promising pharmacological target.
[0008] Recently, 1,3-disubstituted ureas, carbamates, and amides
have been reported as new potent and stable inhibitors of sEH (FIG.
1). See, U.S. Pat. No. 6,150,415. Compounds 192 and 686 are
representative structures for this type of inhibitors (FIG. 1).
These compounds are competitive tight-binding inhibitors with
nanomolar K, values that interact stoichiometrically with purified
recombinant sEH (see, Morisseau, C., et al., Proc. Natl. Acad. Sci.
USA 1999, 96, 8849-8854). Based on the X-ray crystal structure, the
urea inhibitors were shown to establish hydrogen bonds and to form
salt bridges between the urea function of the inhibitor and
residues of the sEH active site, mimicking features encountered in
the reaction coordinate of epoxide ring opening by this enzyme
(see, Argiriadi, M. A., et al., Proc. Natl. Acad. Sci. USA 1999,
96, 10637-10642 and Argiriadi, M. A., et al., J. Biol. Chem. 2000,
275, 15265-15270). These inhibitors efficiently reduced epoxide
hydrolysis in several in vitro and in vivo models (see, Yu, Z., et
al., Circ. Res. 2000, 87, 992-998; Morisseau, C., et al., Proc.
Natl. Acad. Sci. USA 1999, 96, 8849-8854; and Newman, J. W., et
al., Environ. Health Perspect. 2001, 109, 61-66). Despite the
activity associated with these inhibitors, there exists a need for
compounds possessing similar or increased activities, with improved
solubility to facilitate formulation and delivery.
[0009] Surprisingly, the present invention provides such compounds
along with methods for their use and compositions that contain
them.
BRIEF SUMMARY OF THE INVENTION
[0010] In one aspect, the present invention provides a method for
inhibiting a soluble epoxide hydrolase, comprising contacting the
soluble epoxide hydrolase with an inhibiting amount of a compound
having a formula selected from the group consisting of: 1
[0011] and their pharmaceutically acceptable salts, wherein the
symbol R.sup.1 represents C.sub.5-C.sub.12 cycloalkyl, aryl,
heteroaryl or combinations thereof, wherein the cycloalkyl portions
are monocyclic or polycyclic; the symbol P.sup.1 represents a
primary pharmacophore selected from --NHC(O)NH--, --OC(O)NH--,
--NHC(O)O--, --CH.sub.2C(O)NH--, --C(O)NH-- and --NHC(O)--; the
symbol P.sup.2 represents a secondary pharmacophore selected from
--C(O)--, --CH(OH)--, --O(CH.sub.2CH.sub.2O).- sub.q--, --C(O)O--,
--OC(O)--, --NHC(O)NH--, --OC(O)NH--, --NHC(O)O--, --C(O)NH-- and
--NHC(O)--; the symbol P.sup.2a represents --C(O)-- or --NHC(O)--;
the symbol P.sup.3 represents a tertiary pharmacophore selected
from C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 haloalkyl, aryl,
heteroaryl, --C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.2,
--NHS(O).sub.2R.sup.2, --C(O)OR.sup.2 and carboxylic acid analogs,
wherein R.sup.2 is hydrogen, substituted or unsubstituted
C.sub.1-C.sub.4 alkyl, substituted or unsubstituted C.sub.3-C.sub.8
cycloalkyl, substituted or unsubstituted aryl or substituted or
unsubstituted aryl C.sub.1-C.sub.4 alkyl. In the above formulae,
the subscripts n and m are each independently 0 or 1, and at least
one of n or m is 1, and the subscript q is 0 to 3.
[0012] Turning next to the linking groups, the symbol L.sup.1
represents a first linker that is a substituted and unsubstituted
C.sub.2-C.sub.6 alkylene or C.sub.3-C.sub.6-cycloalkylene, or an
arylene or heteroarylene group; the symbol L2 represents a second
linker selected from substituted and unsubstituted C.sub.2-C.sub.12
alkylene, substituted and unsubstituted arylene, and combinations
thereof. The symbol A.sup.1 represents an amino acid, a dipeptide
or a dipeptide analog.
[0013] In a related aspect, the present invention provides methods
of treating diseases modulated by soluble epoxide hydrolases, the
method comprising administering to a subject in need of such
treatment an effective amount of a compound having a formula
selected from formulae (I) and (II), above.
[0014] In other aspects, the present invention provides methods of
reducing renal deterioration in a subject, the method comprising
administering to the subject an effective amount of a compound of
formulae (I) or (II), above.
[0015] In a related aspect, the present invention provides methods
method for inhibiting progression of nephropathy in a subject, the
method comprising administering to the subject an effective amount
of a compound of formulae (I) or (II), above.
[0016] In another aspect, the present invention provides for
reducing blood pressure in a subject, the method comprising
administering to the subject an effective amount of a compound of
formulae (I) or (II), above.
[0017] In a related aspect, the present invention provides methods
of inhibiting the proliferation of vascular smooth muscle cells in
a subject, the method comprising administering to the subject an
effective amount of a compound of formulae (I) or (II), above.
[0018] In another aspect, the present invention provides methods of
inhibiting the progression of an obstructive pulmonary disease, an
interstitial lung disease, or asthma in a subject, the method
comprising administering to the subject an effective amount of a
compound of formulae (I) or (II), above. The obstructive pulmonary
disease can be, for example, chronic obstructive pulmonary disease
("COPD"), emphysema, or chronic bronchitis. The interstitial lung
disease can be, for example, idiopathic pulmonary fibrosis, or one
associated with occupational exposure to a dust.
[0019] In yet another aspect, the present invention provides
compounds having a formulae selected from (I) and (II) above, as
well as pharmaceutical compositions containing one or more of the
subject compounds.
BRIEF DESCRIPTION OF THE DRAWINGS
[0020] FIG. 1 provides structures of known sEH inhibitors having
only a primary pharmacophore: 1-adamantyl-3-cyclohexylurea (192),
1-adamantyl-3-dodecylurea (686).
[0021] FIG. 2 provides a structural diagram defining the sEH
inhibitors primary, secondary, and tertiary pharmacophores. The
nomenclature used refers to the three pharmacophores and two
substituents (R and R' groups). The secondary and tertiary
pharmacophores located in the R' area are illustrated linearly from
the primary pharmacophore. The secondary pharmacophore generally
consists of a polar carbonyl group or a polar ether group. When the
secondary pharmacophore is a carbonyl group, it is located about
7.5.+-.1 .ANG. from the carbonyl of the primary pharmacophore, with
either side of the carbonyl (X and Y) being a CH.sub.2, O or NH.
When the secondary pharmacophore is a ether group it is preferably
located about 1 carbon unit further from the carbonyl of the
primary pharmacophore. The tertiary pharmacophore is also a polar
group located approximately 11 carbon units (17.+-.1 .ANG.) from
the carbonyl of the primary pharmacophore with the Z group as an
OH, or a substituted amine or alcohol or a heterocyclic or acyclic
structure mimicing the terminal ester or acid.
[0022] FIG. 3 provides a hydrophobicity map of the mouse sEH
substrate binding pocket co-crystalyzed with the inhibitor
1-cyclohexyl-3-dodecyl urea. A shading gradient indicates degrees
of hydrophobicity. A series of hydrophilic residues were observed
on the "top" side of the channel, while the "bottom" of the channel
was very hydrophobic, with the exception of the catalytic aspartate
(Asp.sup.333). This structural analysis indicated that a number of
potential hydrogen bonding sites are observed in the substrate
binding pocket of the soluble epoxide hydrolase, primarily located
on the surface opposite Asp.sup.333 (the catalytic nucleophile
which reacts with the substrate or binds to the primary
pharmacophores).
[0023] FIG. 4 provides mammalian soluble epoxide hydrolase protein
sequence alignments (residue 1-340).
[0024] FIG. 5 provides mammalian soluble epoxide hydrolase protein
sequence alignments (residue 341-554).
[0025] FIG. 6 is a graph illustrating the metabolic stabilities of
1-adamantyl-3-dodecyl urea (686) and 1-cyclohexyl-3-dodecyl urea
(297) in rat hepatic microsomes. Microsomes were incubated with 1
.mu.M 686 or 297 in the presence of an NADPH generating system.
Data are expressed as mean .+-.SD of triplicate experiments.
[0026] FIG. 7 is a graph illustrating the metabolic stabilities of
686 and 687 in rat hepatic microsomes as described above.
[0027] FIG. 8 is a series of graphs illustrating the metabolic
conversion of 1-adamantyl-3-dodecyl urea (686) in microsomal
preparations from rat, mouse, and human hepatic tissues. The
metabolites identified are the omega hydroxyl (686-M1), the omega
aldehyde (686-M2), the omega acid (687), and a mixture of
monohydroxy adamantyl omega hydroxylated compounds (686-M3). These
structures are shown in Table 11.
[0028] FIG. 9 provides a mass spectrum showing collision induced
dissociation of a dominant urinary metabolite of
1-adamantyl-3-dodecyl urea (686) and the 3-dodecanoic acid analog
(687) suggesting that these compounds can ultimately enter
beta-oxidation to produce chain shortened inhibitors.
[0029] FIG. 10 is a graph illustrating the blood concentration vs.
time profiles of 687 after oral administration of 5 mg/kg of either
687 or 800 to mice. The ester compound delays the time to achieve
the maximum circulating dose, and increases the maximum circulating
concentration of 687 observed. This translates into a longer
half-life for the inhibitor.
[0030] FIG. 11 is a graph showing the blood concentration vs. time
profiles of 687 after single oral administration of either 687 or
800 to a human subject. While the time of maximum concentration
appears similar in mice and humans (compare with FIG. 10), the
maximum circulating concentration achieved was much higher in
humans.
[0031] FIG. 12 provides a structural evaluation of conserved
hydrogen bond donors in the sEH substrate binding pocket with
linear distances to the primary pharmacophore noted and further
illustrating the effect of functional group distances on
interactions with the mammalian soluble epoxide hydrolases.
[0032] FIG. 13 is a graph illustrating the relative substrate
turnover/relative inhibitor potency as a function of terminal
carboxyl distance to either substrate epoxide of inhibitor
3-position nitrogen.
[0033] FIG. 14 is a bar graph showing the levels of urinary
octadecanoids (A) and urinary eicosanoids (B) in rats treated with
angiotensin II in the presence of absence of 687.
DETAILED DESCRIPTION OF THE INVENTION
[0034] Abbreviations and Definitions:
[0035] "cis-Epoxyeicosatrienoic acids" ("EETs") are biomediators
synthesized by cytochrome P450 epoxygenases.
[0036] "Epoxide hydrolases" ("EH;" EC 3.3.2.3) are enzymes in the
alpha beta hydrolase fold family that add water to 3 membered
cyclic ethers termed epoxides.
[0037] "Soluble epoxide hydrolase" ("sEH") is an enzyme which in
endothelial and smooth muscle cells converts EETs to dihydroxy
derivatives called dihydroxyeicosatrienoic acids ("DHETs"). The
cloning and sequence of the murine sEH is set forth in Grant et
al., J. Biol. Chem. 268(23):17628-17633 (1993). The cloning,
sequence, and accession numbers of the human sEH sequence are set
forth in Beetham et al., Arch. Biochem. Biophys. 305(1):197-201
(1993). The amino acid sequence of human sEH is also set forth as
SEQ ID NO:2 of U.S. Pat. No. 5,445,956; the nucleic acid sequence
encoding the human sEH is set forth as nucleotides 42-1703 of SEQ
ID NO:1 of that patent. The evolution and nomenclature of the gene
is discussed in Beetham et al., DNA Cell Biol. 14(1):61-71 (1995).
Soluble epoxide hydrolase represents a single highly conserved gene
product with over 90% homology between rodent and human (Arand et
al., FEBS Lett., 338:251-256 (1994)).
[0038] The terms "treat", "treating" and "treatment" refer to any
method of alleviating or abrogating a disease or its attendant
symptoms.
[0039] The term "therapeutically effective amount" refers to that
amount of the compound being administered sufficient to prevent or
decrease the development of one or more of the symptoms of the
disease, condition or disorder being treated.
[0040] The term "modulate" refers to the ability of a compound to
increase or decrease the function, or activity, of the associated
activity (e.g., soluble epoxide hydrolase). "Modulation", as used
herein in its various forms, is meant to include antagonism and
partial antagonism of the activity associated with sEH. Inhibitors
of sEH are compounds that, e.g., bind to, partially or totally
block the enzyme's activity.
[0041] The term "composition" as used herein is intended to
encompass a product comprising the specified ingredients in the
specified amounts, as well as any product which results, directly
or indirectly, from combination of the specified ingredients in the
specified amounts. By "pharmaceutically acceptable" it is meant the
carrier, diluent or excipient must be compatible with the other
ingredients of the formulation and not deleterious to the recipient
thereof.
[0042] The "subject" is defined herein to include animals such as
mammals, including, but not limited to, primates (e.g., humans),
cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the
like. In preferred embodiments, the subject is a human.
[0043] As used herein, the term "sEH-mediated disease or condition"
and the like refers to a disease or condition characterized by less
than or greater than normal, sEH activity. A sEH-mediated disease
or condition is one in which modulation of sEH results in some
effect on the underlying condition or disease (e.g., a sEH
inhibitor or antagonist results in some improvement in patient
well-being in at least some patients).
[0044] "Parenchyma" refers to the tissue characteristic of an
organ, as distinguished from associated connective or supporting
tissues.
[0045] "Chronic Obstructive Pulmonary Disease" or "COPD" is also
sometimes known as "chronic obstructive airway disease", "chronic
obstructive lung disease", and "chronic airways disease." COPD is
generally defined as a disorder characterized by reduced maximal
expiratory flow and slow forced emptying of the lungs. COPD is
considered to encompass two related conditions, emphysema and
chronic bronchitis. COPD can be diagnosed by the general
practitioner using art recognized techniques, such as the patient's
forced vital capacity ("FVC"), the maximum volume of air that can
be forceably expelled after a maximal inhalation. In the offices of
general practitioners, the FVC is typically approximated by a 6
second maximal exhalation through a spirometer. The definition,
diagnosis and treatment of COPD, emphysema, and chronic bronchitis
are well known in the art and discussed in detail by, for example,
Honig and Ingram, in Harrison's Principles of Internal Medicine,
(Fauci et al., Eds.), 14th Ed., 1998, McGraw-Hill, New York, pp.
1451-1460 (hereafter, "Harrison's Principles of Internal
Medicine").
[0046] "Emphysema" is a disease of the lungs characterized by
permanent destructive enlargement of the airspaces distal to the
terminal bronchioles without obvious fibrosis.
[0047] "Chronic bronchitis" is a disease of the lungs characterized
by chronic bronchial secretions which last for most days of a
month, for three months a year, for two years.
[0048] As the names imply, "obstructive pulmonary disease" and
"obstructive lung disease" refer to obstructive diseases, as
opposed to restrictive diseases. These diseases particularly
include COPD, bronchial asthma and small airway disease.
[0049] "Small airway disease." There is a distinct minority of
patients whose airflow obstruction is due, solely or predominantly
to involvement of the small airways. These are defined as airways
less than 2 mm in diameter and correspond to small cartilaginous
bronchi, terminal bronchioles and respiratory bronchioles. Small
airway disease (SAD) represents luminal obstruction by inflammatory
and fibrotic changes that increase airway resistance. The
obstruction may be transient or permanent.
[0050] The "interstitial lung diseases (ILDs)" are a group of
conditions involving the alveolar walls, perialveolar tissues, and
contiguous supporting structures. As discussed on the website of
the American Lung Association, the tissue between the air sacs of
the lung is the interstitium, and this is the tissue affected by
fibrosis in the disease. Persons with the disease have difficulty
breathing in because of the stiffness of the lung tissue but, in
contrast to persons with obstructive lung disease, have no
difficulty breathing out. The definition, diagnosis and treatment
of interstitial lung diseases are well known in the art and
discussed in detail by, for example, Reynolds, H. Y., in Harrison's
Principles of Internal Medicine, supra, at pp. 1460-1466. Reynolds
notes that, while ILDs have various initiating events, the
immunopathological responses of lung tissue are limited and the
ILDs therefore have common features.
[0051] "Idiopathic pulmonary fibrosis," or "IPF," is considered the
prototype ILD. Although it is idiopathic in that the cause is not
known, Reynolds, supra, notes that the term refers to a well
defined clinical entity.
[0052] "Bronchoalveolar lavage," or "BAL," is a test which permits
removal and examination of cells from the lower respiratory tract
and is used in humans as a diagnostic procedure for pulmonary
disorders such as IPF. In human patients, it is usually performed
during bronchoscopy.
[0053] As used herein, the term "alkyl" refers to a saturated
hydrocarbon radical which may be straight-chain or branched-chain
(for example, ethyl, isopropyl, t-amyl, or 2,5-dimethylhexyl). This
definition applies both when the term is used alone and when it is
used as part of a compound term, such as "aralkyl," "alkylamino"
and similar terms. Preferred alkyl groups are those containing 1 to
10 carbon atoms. All numerical ranges in this specification and
claims are intended to be inclusive of their upper and lower
limits. Lower alkyl refers to those alkyl groups having 1 to 4
carbon atoms.
[0054] The terms "cycloalkyl" and "cycloalkenyl" refer to a
saturated hydrocarbon ring and includes bicyclic and polycyclic
rings. Preferred cycloalkyl and cycloalkenyl moities are those
having 3 to 12 carbon atoms in the ring (e.g., cyclohexyl,
cyclooctyl, norbornyl, adamantyl, and the like). Additionally, the
term "(cycloalkyl)alkyl" refers to a group having a cycloalkyl
moiety attached to an alkyl moiety. Examples are cyclohexylmethyl,
cyclohexylethyl and cyclopentylpropyl.
[0055] The term "alkenyl" as used herein refers to an alkyl group
as described above which contains one or more sites of unsaturation
that is a double bond. Similarly, the term "alkynyl" as used herein
refers to an alkyl group as described above which contains one or
more sites of unsaturation that is a triple bond.
[0056] The term "alkoxy" refers to an alkyl radical as described
above which also bears an oxygen substituent which is capable of
covalent attachment to another hydrocarbon radical (such as, for
example, methoxy, ethoxy, phenoxy and t-butoxy).
[0057] The term "aryl" refers to an aromatic carbocyclic
substituent which may be a single ring or multiple rings which are
fused together, linked covalently or linked to a common group such
as an ethylene or methylene moiety. Similarly, aryl groups having a
heteroatom (e.g. N, O or S) in place of a carbon ring atom are
referred to as "heteroaryl". Examples of aryl and heteroaryl groups
are, for example, phenyl, naphthyl, biphenyl, diphenylmethyl,
2,2-diphenyl-1-ethyl, thienyl, pyridyl and quinoxalyl. The aryl and
heteroaryl moieties may also be optionally substituted with halogen
atoms, or other groups such as nitro, alkyl, alkylamino, carboxyl,
alkoxy, phenoxy and the like. Additionally, the aryl and heteroaryl
groups may be attached to other moieties at any position on the
aryl or heteroaryl radical which would otherwise be occupied by a
hydrogen atom (such as, for example, 2-pyridyl, 3-pyridyl and
4-pyridyl). Divalent aryl groups are "arylene", and divalent
heteroaryl groups are referred to as "heteroarylene" such as those
groups used as linkers in the present invention.
[0058] The terms "arylalkyl", "arylalkenyl" and "aryloxyalkyl"
refer to an aryl radical attached directly to an alkyl group, an
alkenyl group, or an oxygen which is attached to an alkyl group,
respectively. For brevity, aryl as part of a combined term as
above, is meant to include heteroaryl as well.
[0059] The terms "halo" or "halogen," by themselves or as part of
another substituent, mean, unless otherwise stated, a fluorine,
chlorine, bromine, or iodine atom. Additionally, terms such as
"haloalkyl," are meant to include monohaloalkyl and polyhaloalkyl.
For example, the term "C.sub.1-C.sub.6 haloalkyl" is mean to
include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl,
3-bromopropyl, and the like.
[0060] The term "hydrophobic radical" or "hydrophobic group" refers
to a group which lowers the water solubility of a molecule.
Preferred hydrophobic radicals are groups containing at least 3
carbon atoms.
[0061] The term "carboxylic acid analog" refers to a variety of
groups having an acidic moiety that are capable of mimicking a
carboxylic acid residue. Examples of such groups are sulfonic
acids, sulfinic acids, phosphoric acids, phosphonic acids,
phosphinic acids, sulfonamides, and heterocyclic moieties such as,
for example, imidazoles, triazoles and tetrazoles.
[0062] General:
[0063] The present invention derives from the discovery that
1,3-disubstituted ureas (or the corresponding amides or carbamates,
also referred to as the primary pharmacophore) can be further
functionalized to provide more potent sEH inhibitors with improved
physical properties. As described herein, the introduction of
secondary and/or tertiary pharmacophores can increase water
solubility and oral availability of sEH inhibitors (see FIG. 2).
The combination of the three pharmacophores (see the compounds of
Table 15) provides a variety of compounds of increased water
solubility.
[0064] The discovery of the secondary and tertiary pharmacophores
has also led to the employment of combinatorial chemistry
approaches for establishing a wide spectrum of compounds having sEH
inhibitory activity. The polar pharmacophores divide the molecule
into domains each of which can be easily manipulated by common
chemical approaches in a combinatorial manner, leading to the
design and confirmation of novel orally available therapeutic
agents for the treatment of diseases such as hypertension and
vascular inflammation. As shown below (see Example 27 and FIG. 14),
alterations in solubility, bioavailability and pharmacological
properties leads to compounds that can alter the regulatory lipids
of experimental animals increasing the relative amounts of epoxy
arachidonate derivatives when compared either to their diol
products or to the proinflammatory and hypertensive
hydroxyeicosatetraenoic acids (HETEs). Since epoxy arachidonates
are anti-hypertensive and anti-inflammatory, altering the lipid
ratios can lead to reduced blood pressure and reduced vascular and
renal inflammation. This approach has been validated in a patient
approaching end stage renal disease (ESRD) where even a brief oral
treatment with low doses compound 800 altered the serum profile of
regulatory lipids in a positive manner. This resulted in reduced
systolic and diastolic blood pressure, a dramatic reduction in
blood urea nitrogen (an indicator of renal inflammation) and
dramatically reduced serum levels of C reactive protein (a common
indicator of vascular inflammation).
[0065] Without intending to be bound by theory, and with reference
to FIGS. 2, 3, 4 and 5, it is believed that the left side of the
primary pharmacophore or R (in FIG. 2) can be varied to obtain
optimal properties as can the primary pharmacophore, which contains
groups able to hydrogen bond to the catalytic aspartic acid on one
side and the catalytic tyrosines on the other (see FIG. 3). The
right side of the primary pharmacophore is effectively divided into
4 segments: a spacer separating the primary and secondary
pharmacophore (termed L.sup.1 in the present invention), the
secondary pharmacophore (termed P.sup.2 in the present invention)
and a tertiary pharmacophore (P.sup.3) flanked by a spacer (L2) and
finally a terminating group Z (collectively provided with the
tertiary pharmacophore as P.sup.3). The spacer between the primary
and secondary pharmacophores, is optimally 3 atom units in length,
while the secondary pharmacophore can be, for example, a ketone,
carbonate, amide, carbamate, urea, ether/polyether, ester or other
functionality able to form a hydrogen bond with the enzyme
approximately 7.5 angstroms from the carbonyl of the primary
pharmacophore. The identified tertiary pharmacophore consists of a
polar group located approximately six to eleven carbon units from
the primary pharmacophore (see FIG. 2). A conserved asparagine
residue (Asn.sup.471, see FIGS. 4 and 5) is thought to provide the
site of interaction between the protein and the polar functionality
located at this tertiary site. While, in the rodent a threonine
(Thr.sup.468) is also in an appropriate position for hydrogen
bonding, residue 468 is a methionine in the human enzyme (FIG. 5).
As with the secondary pharmacophore, this group improves water
solubility of sEH inhibitors as well as the specificity for the
sEH, and a wide diversity of functionalities such as an ester,
amide, carbamate, or similar functionalities capable of donating or
accepting a hydrogen bond similarly can contribute to this polar
group. For example, in pharmaceutical chemistry heterocyclic groups
are commonly used to mimic carbonyls as hydrogen bond donors and
acceptors. Of course the primary, secondary and tertiary
pharmacophore groups can be combined in a single molecule with
suitable spacers to improve activity or present the inhibitor as a
prodrug.
[0066] FIG. 12 illustrates the binding interaction for structural
evaluation of conserved hydrogen bond donors in the sEH substrate
binding pocket with linear distances to the primary pharmacophore
noted. The table below provides specific distances to residues
provided in FIGS. 4 and 5.
1TABLE Linear distances of hydrophylic residues to the carbonyl
carbon of the bound urea Distance Residue from Urea Carbon
Conserved Asp.sup.333 4.7 .ANG. + Tyr.sup.465 O 4.5 .ANG. +
Tyr.sup.381 O 4.6 .ANG. + Trp.sup.334 N.sub.Ring 7.1 .ANG. +
Gln.sup.382 N 8.2 .ANG. + Tyr.sup.465 N.sub.Back Bone 10.5 .ANG. +
Thr.sup.468 14.9 .ANG. Met in Human Asn.sup.471 N 15.2 .ANG. +
Asn.sup.471 O 16.7 .ANG. + *Note FIG. 12 distances are measured
linearly from the carbonyl oxygen to the alternate pharmacophores.
This Table measures 3 dimensional distances from carbonyl carbon of
the primary pharmacophore to amino acids which could hydrogen bond
with the inhibitor.
[0067] Methods of Inhibiting Soluble Epoxide Hydrolases:
[0068] In view of the above, the present invention provides, in one
aspect, a method for inhibiting a soluble epoxide hydrolase,
comprising contacting the soluble epoxide hydrolase with an
inhibiting amount of a compound having a formula selected from the
group consisting of: 2
[0069] and their pharmaceutically acceptable salts, wherein the
symbol R.sup.1 represents C.sub.5-C.sub.12 cycloalkyl, aryl,
heteroaryl or combinations thereof, wherein the cycloalkyl portions
are monocyclic or polycyclic; the symbol P.sup.1 represents a
primary pharmacophore selected from --NHC(O)NH--, --OC(O)NH--,
--NHC(O)O--, --CH.sub.2C(O)NH--, --C(O)NH-- and --NHC(O)--; the
symbol P.sup.2 represents a secondary pharmacophore selected from
--C(O)--, --CH(OH)--, --O(CH.sub.2CH.sub.2O).- sub.q--, --C(O)O--,
--OC(O)--, --OC(O)O--, --NHC(O)NH--, --OC(O)NH--, --NHC(O)O--,
--C(O)NH-- and --NHC(O)--; the symbol P.sup.2a represents --C(O)--
or --NHC(O)--; the symbol P.sup.3 represents a tertiary
pharmacophore selected from C.sub.2-C.sub.6 alkynyl,
C.sub.1-C.sub.6 haloalkyl, aryl, heteroaryl, --C(O)NHR.sup.2,
--C(O)NHS(O).sub.2R.sup.2, --NHS(O).sub.2R.sup.1, --C(O)OR.sup.2
and carboxylic acid analogs, wherein R.sup.2 is hydrogen,
substituted or unsubstituted C.sub.1-C.sub.4 alkyl, substituted or
unsubstituted C.sub.3-C.sub.8 cycloalkyl, substituted or
unsubstituted aryl or substituted or unsubstituted aryl
C.sub.1-C.sub.4 alkyl. In the above formulae, the subscripts n and
m are each independently 0 or 1, and at least one of n or m is 1,
and the subscript q is 0 to 3.
[0070] Turning next to the linking groups, the symbol L.sup.1
represents a first linker that is a substituted and unsubstituted
C.sub.2-C.sub.6 alkylene, a substituted and unsubstituted
C.sub.3-C.sub.6-cycloalkylene, a substituted or unsubstituted
arylene or a substituted or unsubstituted heteroarylene; the symbol
L.sup.2 represents a second linker selected from substituted and
unsubstituted C.sub.2-C.sub.12 alkylene, substituted and
unsubstituted arylene, substituted or unsubstituted heteroarylene
and combinations thereof. The symbol A.sup.1 represents an amino
acid, a dipeptide or a dipeptide analog. Preferably, the compounds
are other than 11-(3-cyclohexylureido)-undecanoic acid,
11-(3-cyclohexylureido)-undecano- ic acid methyl ester,
11-(3-cyclohexylureido)-undecanoic acid amide,
12-(3-cyclohexylureido)-dodecanoic acid and
12-(3-adamantan-1-yl-ureido)-- dodecanoic acid.
[0071] A number of embodiments are preferred within the above
general description. In a first group of preferred embodiments, the
compounds used are those of formula (I). Within this group of
embodiments, R.sup.1 is selected from C.sub.5-C.sub.12 cycloalkyl,
phenyl and naphthyl. More preferably, R.sup.1 is selected from
C.sub.6-C.sub.10 cycloalkyl and phenyl. Most preferred are those
embodiments in which R.sup.1 is cyclohexyl, cycloheptyl,
cyclooctyl, norbornyl, adamantyl, noradamantyl, and phenyl, wherein
the phenyl group is either unsubstituted or substituted with from
one to three substituents selected from halogen, lower alkyl, lower
halo alkyl, lower alkoxy, C.sub.3-C.sub.5 cycloalkyl and cyano.
[0072] Returning to formula (I), P.sup.1 is preferably selected
from --NHC(O)NH--, --OC(O)NH-- and --NHC(O)O--. Most preferably,
P.sup.1 is --NHC(O)NH--.
[0073] Turning next to the first linking group, L.sup.1 is
preferably selected from substituted and unsubstituted
C.sub.2-C.sub.6 alkylene, wherein the substituents are selected to
impart desired properties to the overall composition. For example,
in some embodiments in which R.sup.1 is a particularly hydrophobic
residue, L.sup.1 may preferably have substituents that are
hydrophilic to offset to some degree the lack of aqueous solubility
normally associated with very hydrophobic compounds. As a result,
in some embodiments, L.sup.1 will have one or two hydroxy moieties
as substituents, preferably only one hydroxy moiety substituents.
In other embodiments, L.sup.1 will be an alkylene or cycloalkylene
linker having the length indicated above, wherein one or more of
the hydrogen atoms are replaced with fluorine atoms to impart other
attractive properties, such as facilitating the compound's use in
stents so that it is slowly released from the stent to then inhibit
the soluble epoxide hydrolase. Further preferred are those
embodiments in which L.sup.1 is C.sub.2-C.sub.5 alkylene, more
preferably C.sub.2-C.sub.4 alkylene, still more preferably
C.sub.2-C.sub.3 alkylene, and most preferably an ethylene linkage.
Where L.sup.1 is C.sub.3-C.sub.6 cycloalkylene, it is more
preferably cyclohexyl that can be linked in a 1,3 or 1,4 manner. In
certain particularly preferred embodiments, L.sup.1 is selected to
provide spacing between the first pharmacophore carbonyl moiety (in
P.sup.1) and the second pharmacophore carbonyl moiety (in P.sup.2)
of about 7.5.+-.2 angstroms and more preferably, about 7.5.+-.1
angstroms.
[0074] The secondary pharmacophore, P.sup.2, when present (n is 1)
is selected from --C(O)--, --O(CH.sub.2CH.sub.2O).sub.q--,
--C(O)O--, --OC(O)--, --OC(O)O--, --NHC(O)NH--, --OC(O)NH--,
--NHC(O)O--, --C(O)NH-- and --NHC(O)--. More preferably, P.sup.2 is
selected from --C(O)--, --O(CH.sub.2CH.sub.2O).sub.q--, --C(O)O--,
--OC(O)--, --OC(O)O--, --OC(O)NH-- and --C(O)NH--. Most preferably,
P.sup.2 is selected from --C(O)--, --O(CH.sub.2CH.sub.2O).sub.q--,
and --C(O)O--.
[0075] The second linking group, L.sup.2 is selected from
substituted and unsubstituted C.sub.2-C.sub.12 alkylene,
substituted and unsubstituted arylene, and combinations thereof.
For those embodiments in which a secondary pharmacophore (P.sup.2)
is not present, the linking group L.sup.2 will be combined with
L.sup.1 to provide spacing between the primary pharmacophore and
the tertiary pharmacophore of about >6, and <12 carbon atoms.
Accordingly, when L.sup.1 is an alkylene or part of a cycloalkylene
linkage of from 2 to 4 carbon atoms, and P.sup.2 is not present,
L.sup.2 will preferably be an alkylene linkage of from 2 to 8
carbon atoms, more preferably, 4 to 8 carbon atoms, and most
preferably 5, 6, 7 or 8 carbon atoms. In some embodiments, L.sup.2
will comprise an arylene group, preferably a phenylene group that
can be linked in a 1,2 or 1,3 or 1,4 manner, preferably in a 1,3 or
1,4 manner. As with L.sup.1, the alkylene portions of L.sup.2 can
be substituted or unsubstituted. The substituents are selected as
described for L.sup.1 above.
[0076] The tertiary pharmacophore, P.sup.3, is C.sub.2-C.sub.6
alkynyl, C.sub.1-C.sub.6 haloalkyl, aryl, heteroaryl,
--C(O)NHR.sup.1, --C(O)NHS(O).sub.2R.sup.2, --NHS(O).sub.2R.sup.2,
--C(O)OR.sup.2 and carboxylic acid analogs, wherein R.sup.2 is a
member selected from the group consisting of hydrogen, substituted
or unsubstituted C.sub.1-C.sub.4 alkyl, substituted or
unsubstituted C.sub.2-C.sub.4 alkenyl, substituted or unsubstituted
C.sub.2-C.sub.4 alkynyl, substituted or unsubstituted
C.sub.3-C.sub.8 cycloalkyl, substituted or unsubstituted
C.sub.3-C.sub.10 cycloalkyl-alkyl, substituted or unsubstituted
aryl and substituted or unsubstituted aryl C.sub.1-C.sub.4 alkyl.
In certain preferred embodiments, R.sup.2 is H, methyl, ethyl,
propyl, allyl, 3-propynyl, butyl, 2-propyl, 1,1-dimethylethyl,
2-butyl, 2-methyl-1-propyl, adamantyl-methyl, benzyl,
2-chlorobenzyl and naphthylmethyl. In one group of preferred
embodiments, P.sup.3 is --C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.2,
--NHS(O).sub.2R.sup.2, --C(O)OR.sup.2 and carboxylic acid analogs,
wherein R.sup.2 is selected from hydrogen, unsubstituted
C.sub.1-C.sub.4 alkyl, and unsubstituted C.sub.3-C.sub.8
cycloalkyl. Still more preferably, R.sup.1 is H, Me or Et. In
particularly preferred embodiments, P.sup.3 is --C(O)OR.sup.2 and
carboxylic acid analogs, wherein R.sup.2 is selected from hydrogen,
Me or Et.
[0077] With the preferred groups provided above, certain
combinations of preferred embodiments represent particularly
preferred embodiments. While all combinations of the preferred
groups represent additional embodiments of the invention,
particularly preferred embodiments include those wherein P.sup.1 is
selected from --NHC(O)NH--, --OC(O)NH-- and --NHC(O)O--; P.sup.2 is
selected from --C(O)O--, --OC(O)--, --O(CH.sub.2CH.sub.2O).sub.q--,
--C(O)NH-- and --NHC(O)--; m is 0 and L.sup.1 is selected from
unsubstituted C.sub.2-C.sub.6 alkylene. In another group of
particularly preferred embodiments, P.sup.1 is selected from
--NHC(O)NH--, --OC(O)NH-- and --NHC(O)O--; P.sup.2 is selected from
--C(O)O--, --OC(O)--, --O(CH.sub.2CH.sub.2O).sub.q--, --C(O)NH--
and --NHC(O)--; n and m are each 1; L.sup.1 is selected from
unsubstituted C.sub.2-C.sub.6 alkylene; L.sup.2 is selected from
substituted or unsubstituted C.sub.2-C.sub.6 alkylene; and P.sup.3
is selected from --C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.1,
--NHS(O).sub.2R.sup.2, and --C(O)OR.sup.1, wherein R.sup.2 is
hydrogen, substituted or unsubstituted C.sub.1-C.sub.4 alkyl,
substituted or unsubstituted C.sub.3-C.sub.8 cycloalkyl,
substituted or unsubstituted aryl or substituted or unsubstituted
aryl C.sub.1-C.sub.4 alkyl. Still other particularly preferred
embodiments are those in which the compound has formula (I),
wherein P.sup.1 is selected from --NHC(O)NH--, --OC(O)NH-- and
--NHC(O)O--; n is 0; m is 1; L.sup.1 is selected from unsubstituted
C.sub.2-C.sub.6 alkylene; L is selected from substituted or
unsubstituted C.sub.2-C.sub.6 alkylene; and P.sup.3 is selected
from --C(O)NHR.sup.2, --C(O)NHS(O).sub.2R.sup.2,
--NHS(O).sub.2R.sup.2, and --C(O)OR.sup.1, wherein R.sup.1 is
hydrogen, substituted or unsubstituted C.sub.1-C.sub.4 alkyl,
substituted or unsubstituted C.sub.3-C.sub.8 cycloalkyl,
substituted or unsubstituted aryl and substituted or unsubstituted
aryl C.sub.1-C.sub.4 alkyl.
[0078] The most preferred compounds for use in this aspect of the
invention are those compounds provided in the Tables below.
[0079] In another group of embodiments, the compounds used are
those of formula (II). In this formula, R.sup.1, P.sup.1 and
L.sup.1 have the meanings provided above with respect to formula
(I). The symbol P.sup.2a represents a carbonyl moiety (--C(O)--) or
an amide (--NHC(O)--) and the symbol A.sup.1 represents an amino
acid, a dipeptide or a dipeptide analog, generally attached to
P.sup.2a to form an amide linkage.
[0080] The compounds of formula (II), as noted above, contain an
amino acid or dipeptide component which can be a dipeptide analog.
The amino acid residues, by themselves or as part of a dipeptide,
are denoted by single-letter or three-letter designations following
conventional practices. The designations for gene-encoded amino
acids are as follows (amino acid, one letter symbol, three letter
symbol): Alanine, A, Ala; Arginine, R, Arg; Asparagine, N, Asn;
Aspartic acid, D, Asp; Cysteine, C, Cys; Glutamine, Q, Gln;
Glutamic acid, E, Glu; Glycine, G, Gly; Histidine, H, His;
Isoleucine, I, Ile; Leucine, L, Leu; Lysine, K, Lys; Methionine, M,
Met; Phenylalanine, F, Phe; Proline, P, Pro; Serine, S, Ser;
Threonine, T, Thr; Tryptophan, W, Trp; Tyrosine, Y, Tyr; and
Valine, V, Val. Commonly encountered amino acids which are not
gene-encoded may also be used in the present invention. These amino
acids and their abbreviations include omithine (Orn);
t-butylglycine (t-BuG); phenylglycine (PhG); cyclohexylalanine
(Cha); norleucine (Nle); 2-naphthylalanine (2-Nal);
1-naphthylalanine (1-Nal); 2-thienylaniline (2-Thi);
N-methylisoleucine (N-Melle), homoarginine (Har),
N.alpha.-methylarginine (N-MeArg) and sarcosine (Sar). All of the
amino acids used in the present invention may be either the D- or
L-isomer. The L-isomers are preferred.
[0081] Preferred compounds of the invention are those in which
A.sup.1 is an amino acid or a dipeptide. Preferably, the dipeptide
has a Tyr, His, Lys, Phe or Trp residue directly attached to
P.sup.2a.
[0082] Other preferred compounds for use in the present invention
are those in which R.sup.1, P.sup.1 and L.sup.1 are selected from
the preferred groupings as described above for formula (I).
Particularly preferred compounds of formula (II) are those in which
R.sup.1 is selected from C.sub.5-C.sub.12 cycloalkyl and phenyl.
More preferably, R.sup.1 is selected from C.sub.6-C.sub.10
cycloalkyl and phenyl. Most preferred are those embodiments in
which R.sup.1 is cyclohexyl, cycloheptyl, cyclooctyl, norbornyl,
adamantly or noradamantyl. P.sup.1 is preferably a urea
(--NHC(O)NH--) or carbamate (--OC(O)NH--), more preferably a urea.
L.sup.1 is preferably a substituted or unsubstituted
C.sub.2-C.sub.5 alkylene, more preferably C.sub.2-C.sub.4 alkylene,
still more preferably an ethylene or propylene linkage.
[0083] For those embodiments in which A.sup.1 is a single amino
acid, A.sup.1 is preferably selected from Ala, Arg, Asp, Cys, Glu,
Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr and Val.
More preferably, A.sup.1 is selected from His, Ile, Lys, Phe, Trp
and Tyr in which the amino acid is linked to P.sup.2a in a manner
to afford an amide linkage and terminal carboxylic acid group. Of
course, one of skill in the art will appreciate that these amino
acids are meant to refer to their corresponding methyl or ethyl
esters, as well as their carboxamide derivatives (e.g., terminal
--C(O)NH.sub.2). Most preferably, the compounds are those provided
in Table 9.
[0084] For those embodiments in which A.sup.1 is a dipeptide,
P.sup.2a is preferably attached to a Tyr, His, Lys, Phe or Trp
residue, with the remaining amino acid being selected from the
gene-encoded amino acids, their D-isomers or analogs thereof (e.g.,
hydroxy acids such as lactic acid and the like). Still more
prefereably, A.sup.1 is selected from TyrAla, TyrArg, TyrAsp,
TyrGly, TyrIle, TyrLeu, TyrLys, TyrMet, TyrPhe, TyrPro, TyrSer,
TyrThr, TyrTrp, TyrTyr and TyrVal. More preferably, A.sup.1 is
selected from TyrArg, TyrAsp, TyrMet, TyrPhe, TyrSer, TyrTrp,
TyrTyr and TyrVal, in which the Tyr amino acid is linked to
P.sup.2a in a manner to afford an amide linkage. As above, these
dipeptides are also meant to refer to their corresponding methyl or
ethyl esters, as well as their carboxamide derivatives (e.g.,
terminal --C(O)NH.sub.2). Most preferably, the compounds are those
provided in Table 10.
[0085] Assays to Monitor Soluble Epoxide Hydrolase Activity:
[0086] Additionally, the present invention provides a variety of
assays and associated methods for monitoring soluble epoxide
hydrolase activity, particularly the activity that has been
modulated by the administration of one or more of the compounds
provided above.
[0087] In one group of embodiments, the invention provides methods
for reducing the formation of a biologically active diol produced
by the action of a soluble epoxide hydrolase, the method comprising
contacting the soluble epoxide hydrolase with an amount of a
compound of formula (I) or (II) above, sufficient to inhibit the
activity of the soluble epoxide hydrolase and reduce the formation
of the biologically active diol.
[0088] In another group of embodiments, the invention provides
methods for stabilizing biologically active epoxides in the
presence of a soluble epoxide hydrolase, the method comprising
contacting the soluble epoxide hydrolase with an amount of a
compound of formula (I) or (II), sufficient to inhibit the activity
of the soluble epoxide hydrolase and stabilize the biologically
active epoxide.
[0089] In each of these groups of embodiments, the methods can be
carried out as part of an in vitro assay or the methods can be
carried out in vivo by monitoring blood titers of the respective
biologically active epoxide or diol.
[0090] Epoxides and diols of some fatty acids are biologically
important chemical mediators and are involved in several biological
processes. The strongest biological data support the action of
oxylipins as chemical mediators between the vascular endothelium
and vascular smooth muscle. Accordingly, the epoxy lipids are
anti-inflammatory and anti-hypertensive. Additionally, the lipids
are thought to be metabolized by beta-oxidation, as well as by
epoxide hydration. The soluble epoxide hydrolase is considered to
be the major enzyme involved in the hydrolytic metabolism of these
oxylipins. The compounds of formula (I) and (II) can inhibit the
epoxide hydrolase and stabilize the epoxy lipids both in vitro and
in vivo. This activity results in a reduction of hypertension in
four separate rodent models. Moreover, the inhibitors show a
reduction in renal inflammation associated with the hypertensive
models.
[0091] More particularly, the present invention provides methods
for monitoring a variety of lipids in both the arachidonate and
linoleate cascade simultaneously in order to address the biology of
the system. A GLC-MS system or a LC-MS method can be used to
monitor over 40 analytes in a highly quantitative fashion in a
single injection. The analytes include the regioisomers of the
arachidonate epoxides (EETs), the diols (DHETs), as well as other
P450 products including HETEs. Characteristic products of the
cyclooxygenase, lipoxygenase, and peroxidase pathways in both the
arachidonate and linoleate series can also be monitored. Such
methods are particularly useful as being predictive of certain
disease states. The oxylipins can be monitored in mammals following
the administration of inhibitors of epoxide hydrolase. Generally,
EH inhibitors increase epoxy lipid concentrations at the expense of
diol concentrations in body fluids and tissues.
[0092] Preferred compounds for use in this aspect of the invention
are those inhibitors of formula (I) in which the primary
pharmacophore is separated from a tertiary pharmacophore by a
distance that approximates the distance between the terminal
carboxylic acid and an epoxide functional group in the natural
substrate.
[0093] Methods of Treating Diseases Modulated by Soluble Epoxide
Hydrolases:
[0094] In another aspect, the present invention provides methods of
treating diseases, especially those modulated by soluble epoxide
hydrolases (sEH). The methods generally involve administering to a
subject in need of such treatment an effective amount of a compound
having a formula selected from (I) and (II) above. The dose,
frequency and timing of such administering will depend in large
part on the selected therapeutic agent, the nature of the condition
being treated, the condition of the subject including age, weight
and presence of other conditions or disorders, the formulation
being administered and the discretion of the attending physician.
Preferably, the compositions and compounds of the invention and the
pharmaceutically acceptable salts thereof are administered via
oral, parenteral or topical routes. Generally, the compounds are
administered in dosages ranging from about 2 mg up to about 2,000
mg per day, although variations will necessarily occur depending,
as noted above, on the disease target, the patient, and the route
of administration. Preferred dosages are administered orally in the
range of about 0.05 mg/kg to about 20 mg/kg, more preferably in the
range of about 0.05 mg/kg to about 2 mg/kg, most preferably in the
range of about 0.05 mg/kg to about 0.2 mg per kg of body weight per
day. The dosage employed for the topical administration will, of
course, depend on the size of the area being treated.
[0095] It has previously been shown that inhibitors of soluble
epoxide hydrolase ("sEH") can reduce hypertension. See, e.g., U.S.
Pat. No. 6,351,506. Such inhibitors can be useful in controlling
the blood pressure of persons with undesirably high blood pressure,
including those who suffer from diabetes.
[0096] In preferred embodiments, compounds of formula (I) or (II)
are administered to a subject in need of treatment for
hypertension, specifically renal, hepatic, or pulmonary
hypertension; inflammation, specifically renal inflammation,
vascular inflammation, and lung inflammation; adult respiratory
distress syndrome; diabetic complications; end stage renal disease;
Raynaud syndrome and arthritis.
[0097] Methods for Inhibiting Progression of Kidney Deterioration
(Nephropathy) and Reducing Blood Pressure:
[0098] In another aspect of the invention, the compounds of the
invention can reduce damage to the kidney, and especially damage to
kidneys from diabetes, as measured by albuminuria. The compounds of
the invention can reduce kidney deterioration (nephropathy) from
diabetes even in individuals who do not have high blood pressure.
The conditions of therapeautic administration are as described
above.
[0099] Cis-epoxyeicosantrienoic acids ("EETs") can be used in
conjunction with the compounds of the invention to further reduce
kidney damage. EETs, which are epoxides of arachidonic acid, are
known to be effectors of blood pressure, regulators of
inflammation, and modulators of vascular permeability. Hydrolysis
of the epoxides by sEH diminishes this activity. Inhibition of sEH
raises the level of EETs since the rate at which the EETs are
hydrolyzed into DHETs is reduced. Without wishing to be bound by
theory, it is believed that raising the level of EETs interferes
with damage to kidney cells by the microvasculature changes and
other pathologic effects of diabetic hyperglycemia. Therefore,
raising the EET level in the kidney is believed to protect the
kidney from progression from microalbuminuria to end stage renal
disease.
[0100] EETs are well known in the art. EETs useful in the methods
of the present invention include 14,15-EET, 8,9-EET and 11,12-EET,
and 5,6 EETs, in that order of preference. Preferably, the EETs are
administered as the methyl ester, which is more stable. Persons of
skill will recognize that the EETs are regioisomers, such as 8S,9R-
and 14R,15S-EET. 8,9-EET, 11,12-EET, and 14R,15S-EET, are
commercially available from, for example, Sigma-Aldrich (catalog
nos. E5516, E5641, and E5766, respectively, Sigma-Aldrich Corp.,
St. Louis, Mo.).
[0101] EETs produced by the endothelium have anti-hypertensive
properties and the EETs 11,12-EET and 14,15-EET may be
endothelium-derived hyperpolarizing factors (EDHFs). Additionally,
EETs such as 11,12-EET have profibrinolytic effects,
anti-inflammatory actions and inhibit smooth muscle cell
proliferation and migration. In the context of the present
invention, these favorable properties are believed to protect the
vasculature and organs during renal and cardiovascular disease
states.
[0102] It is now believed that sEH activity can be inhibited
sufficiently to increase the levels of EETs and thus augment the
effects of administering sEH inhibitors by themselves. This permits
EETs to be used in conjunction with one or more sEH inhibitors to
reduce nephropathy in the methods of the invention. It further
permits EETs to be used in conjunction with one or more sEH
inhibitors to reduce hypertension, or inflammation, or both. Thus,
medicaments of EETs can be made which can be administered in
conjunction with one or more sEH inhibitors, or a medicament
containing one or more sEH inhibitors can optionally contain one or
more EETs.
[0103] The EETs can be administered concurrently with the sEH
inhibitor, or following administration of the sEH inhibitor. It is
understood that, like all drugs, inhibitors have half lives defined
by the rate at which they are metabolized by or excreted from the
body, and that the inhibitor will have a period following
administration during which it will be present in amounts
sufficient to be effective. If EETs are administered after the
inhibitor is administered, therefore, it is desirable that the EETs
be administered during the period during which the inhibitor will
be present in amounts to be effective to delay hydrolysis of the
EETs. Typically, the EET or EETs will be administered within 48
hours of administering an sEH inhibitor. Preferably, the EET or
EETs are administered within 24 hours of the inhibitor, and even
more preferably within 12 hours. In increasing order of
desirability, the EET or EETs are administered within 10, 8, 6, 4,
2, hours, 1 hour, or one half hour after administration of the
inhibitor. Most preferably, the EET or EETs are administered
concurrently with the inhibitor.
[0104] In preferred embodiments, the EETs, the compound of the
invention, or both, are provided in a material that permits them to
be released over time to provide a longer duration of action. Slow
release coatings are well known in the pharmaceutical art; the
choice of the particular slow release coating is not critical to
the practice of the present invention.
[0105] EETs are subject to degradation under acidic conditions.
Thus, if the EETs are to be administered orally, it is desirable
that they are protected from degradation in the stomach.
Conveniently, EETs for oral administration may be coated to permit
them to passage the acidic environment of the stomach into the
basic environment of the intestines. Such coatings are well known
in the art. For example, aspirin coated with so-called "enteric
coatings" is widely available commercially. Such enteric coatings
may be used to protect EETs during passage through the stomach. A
exemplar coating is set forth in the Examples.
[0106] While the anti-hypertensive effects of EETs have been
recognized, EETs have not been administered to treat hypertension
because it was thought endogenous sEH would hydrolyse the EETs too
quickly for them to have any useful effect. Surprisingly, it was
found during the course of the studies underlying the present
invention that exogenously administered inhibitors of sEH succeeded
in inhibiting sEH sufficiently that levels of EETs could be further
raised by the administration of exogenous EETs. These findings
underlie the co-administration of sEH inhibitors and of EETs
described above with respect to inhibiting the development and
progression of nephropathy. This is an important improvement in
augmenting treatment. While levels of endogenous EETs are expected
to rise with the inhibition of sEH activity caused by the action of
the sEH inhibitor, and therefore to result in at least some
improvement in symptoms or pathology, it may not be sufficient in
all cases to inhibit progression of kidney damage fully or to the
extent intended. This is particularly true where the diseases or
other factors has reduced the endogenous concentrations of EETs
below those normally present in healthy individuals. Administration
of exogenous EETs in conjunction with an sEH inhibitor is therefore
expected to be beneficial and to augment the effects of the sEH
inhibitor in reducing the progression of diabetic nephropathy.
[0107] The present invention can be used with regard to any and all
forms of diabetes to the extent that they are associated with
progressive damage to the kidney or kidney function. The-chronic
hyperglycemia of diabetes is associated with long-term damage,
dysfunction, and failure of various organs, especially the eyes,
kidneys, nerves, heart, and blood vessels. The long-term
complications of diabetes include retinopathy with potential loss
of vision; nephropathy leading to renal failure; peripheral
neuropathy with risk of foot ulcers, amputation, and Charcot
joints.
[0108] In addition, persons with metabolic syndrome are at high
risk of progression to type 2 diabetes, and therefore at higher
risk than average for diabetic nephropathy. It is therefore
desirable to monitor such individuals for microalbuminuria, and to
administer an sEH inhibitor and, optionally, one or more EETs, as
an intervention to reduce the development of nephropathy. The
practitioner may wait until microalbuminuria is seen before
beginning the intervention. As noted above, a person can be
diagnosed with metabolic syndrome without having a blood pressure
of 130/85 or higher. Both persons with blood pressure of 130/85 or
higher and persons with blood pressure below 130/85 can benefit
from the administration of sEH inhibitors and, optionally, of one
or more EETs, to slow the progression of damage to their kidneys.
In some preferred embodiments, the person has metabolic syndrome
and blood pressure below 130/85.
[0109] Dyslipidemia or disorders of lipid metabolism is another
risk factor for heart disease. Such disorders include an increased
level of LDL cholesterol, a reduced level of HDL cholesterol, and
an increased level of triglycerides. An increased level of serum
cholesterol, and especially of LDL cholesterol, is associated with
an increased risk of heart disease. The kidneys are also damaged by
such high levels. It is believed that high levels of triglycerides
are associated with kidney damage. In particular, levels of
cholesterol over 200 mg/dL, and especially levels over 225 mg/dL,
would suggest that sEH inhibitors and, optionally, EETs, should be
administered. Similarly, triglyceride levels of more than 215
mg/dL, and especially of 250 mg/dL or higher, would indicate that
administration of sEH inhibitors and, optionally, of EETs, would be
desirable. The administration of compounds of the present invention
with or without the EETs, can reduce the need to administer statin
drugs (HMG-CoA reductase inhibitors) to the patients, or reduce the
amount of the statins needed. In some embodiments, candidates for
the methods, uses and compositions of the invention have
triglyceride levels over 215 mg/dL and blood pressure below 130/85.
In some embodiments, the candidates have triglyceride levels over
250 mg/dL and blood pressure below 130/85. In some embodiments,
candidates for the methods, uses and compositions of the invention
have cholesterol levels over 200 mg/dL and blood pressure below
130/85. In some embodiments, the candidates have cholesterol levels
over 225 mg/dL and blood pressure below 130/85.
[0110] Methods of Inhibiting the Proliferation of Vascular Smooth
Muscle Cells:
[0111] In other embodiments, compounds of formula (I) or (II)
inhibit proliferation of vascular smooth muscle (VSM) cells without
significant cell toxicity, (e.g. specific to VSM cells). Because
VSM cell proliferation is an integral process in the
pathophysiology of atherosclerosis, these compounds are suitable
for slowing or inhibition atherosclerosis. These compounds are
useful to subjects at risk for atherosclerosis, such as individuals
who have had a heart attack or a test result showing decreased
blood circulation to the heart. The conditions of therapeautic
administration are as described above.
[0112] The methods of the invention are particularly useful for
patients who have had percutaneous intervention, such as
angioplasty to reopen a narrowed artery, to reduce or to slow the
narrowing of the reopened passage by restenosis. In some preferred
embodiments, the artery is a coronary artery. The compounds of the
invention can be placed on stents in polymeric coatings to provide
a controlled localized release to reduce restenosis. Polymer
compositions for implantable medical devices, such as stents, and
methods for embedding agents in the polymer for controlled release,
are known in the art and taught, for example, in U.S. Pat. Nos.
6,335,029; 6,322,847; 6,299,604; 6,290,722; 6,287,285; and
5,637,113. In preferred embodiments, the coating releases the
inhibitor over a period of time, preferably over a period of days,
weeks, or months. The particular polymer or other coating chosen is
not a critical part of the present invention.
[0113] The methods of the invention are useful for slowing or
inhibiting the stenosis or restenosis of natural and synthetic
vascular grafts. As noted above in connection with stents,
desirably, the synthetic vascular graft comprises a material which
releases a compound of the invention over time to slow or inhibit
VSM proliferation and the consequent stenosis of the graft.
Hemodialysis grafts are a particularly preferred embodiment.
[0114] In addition to these uses, the methods of the invention can
be used to slow or to inhibit stenosis or restenosis of blood
vessels of persons who have had a heart attack, or whose test
results indicate that they are at risk of a heart attack.
[0115] In one group of preferred embodiments, compounds of the
invention are administered to reduce proliferation of VSM cells in
persons who do not have hypertension. In another group of
embodiments, compounds of the invention are used to reduce
proliferation of VSM cells in persons who are being treated for
hypertension, but with an agent that is not an sEH inhibitor.
[0116] The compounds of the invention can be used to interfere with
the proliferation of cells which exhibit inappropriate cell cycle
regulation. In one important set of embodiments, the cells are
cells of a cancer. The proliferation of such cells can be slowed or
inhibited by contacting the cells with a compound of the invention.
The determination of whether a particular compound of the invention
can slow or inhibit the proliferation of cells of any particular
type of cancer can be determined using assays routine in the
art.
[0117] In addition to the use of the compounds of the invention,
the levels of EETs can be raised by adding EETs. VSM cells
contacted with both an EET and a compound of the invention
exhibited slower proliferation than cells exposed to either the EET
alone or to the a compound of the invention alone. Accordingly, if
desired, the slowing or inhibition of VSM cells of a compound of
the invention can be enhanced by adding an EET along with a
compound of the invention. In the case of stents or vascular
grafts, for example, this can conveniently be accomplished by
embedding the EET in a coating along with a compound of the
invention so that both are released once the stent or graft is in
position.
[0118] Methods of Inhibiting the Progression of Obstructive
Pulmonary Disease, Interstitial Lung Disease, or Asthma:
[0119] Chronic obstructive pulmonary disease, or COPD, encompasses
two conditions, emphysema and chronic bronchitis, which relate to
damage caused to the lung by air pollution, chronic exposure to
chemicals, and tobacco smoke. Emphysema as a disease relates to
damage to the alveoli of the lung, which results in loss of the
separation between alveoli and a consequent reduction in the
overall surface area available for gas exchange. Chronic bronchitis
relates to irritation of the bronchioles, resulting in excess
production of mucin, and the consequent blocking by mucin of the
airways leading to the alveoli. While persons with emphysema do not
necessarily have chronic bronchitis or vice versa, it is common for
persons with one of the conditions to also have the other, as well
as other lung disorders.
[0120] Some of the damage to the lungs due to COPD, emphysema,
chronic bronchitis, and other obstructive lung disorders can be
inhibited or reversed by administering inhibitors of the enzyme
known as soluble epoxide hydrolase, or "sEH". The effects of sEH
inhibitors can be increased by also administering EETs. The effect
is at least additive over administering the two agents separately,
and may indeed be synergistic.
[0121] The studies reported herein show that EETs can be used in
conjunction with sEH inhibitors to reduce damage to the lungs by
tobacco smoke or, by extension, by occupational or environmental
irritants. These findings indicate that the co-administration of
sEH inhibitors and of EETs can be used to inhibit or slow the
development or progression of COPD, emphysema, chronic bronchitis,
or other chronic obstructive lung diseases which cause irritation
to the lungs.
[0122] Animal models of COPD and humans with COPD have elevated
levels of immunomodulatory lymphocytes and neutrophils. Neutrophils
release agents that cause tissue damage and, if not regulated, will
over time have a destructive effect. Without wishing to be bound by
theory, it is believed that reducing levels of neutrophils reduces
tissue damage contributing to obstructive lung diseases such as
COPD, emphysema, and chronic bronchitis. Administration of sEH
inhibitors to rats in an animal model of COPD resulted in a
reduction in the number of neutrophils found in the lungs.
Administration of EETs in addition to the sEH inhibitors also
reduced neutrophil levels. The reduction in neutrophil levels in
the presence of sEH inhibitor and EETs was greater than in the
presence of the sEH inhibitor alone.
[0123] While levels of endogenous EETs are expected to rise with
the inhibition of sEH activity caused by the action of the sEH
inhibitor, and therefore to result in at least some improvement in
symptoms or pathology, it may not be sufficient in all cases to
inhibit progression of COPD or other pulmonary diseases. This is
particularly true where the diseases or other factors have reduced
the endogenous concentrations of EETs below those normally present
in healthy individuals. Administration of exogenous EETs in
conjunction with an sEH inhibitor is therefore expected to augment
the effects of the sEH inhibitor in inhibiting or reducing the
progression of COPD or other pulmonary diseases.
[0124] In addition to inhibiting or reducing the progression of
chronic obstructive airway conditions, the invention also provides
new ways of reducing the severity or progression of chronic
restrictive airway diseases. While obstructive airway diseases tend
to result from the destruction of the lung parenchyma, and
especially of the alveoli, restrictive diseases tend to arise from
the deposition of excess collagen in the parenchyma. These
restrictive diseases are commonly referred to as "interstitial lung
diseases", or "ILDs", and include conditions such as idiopathic
pulmonary fibrosis. The methods, compositions and uses of the
invention are useful for reducing the severity or progression of
ILDs, such as idiopathic pulmonary fibrosis. Macrophages play a
significant role in stimulating interstitial cells, particularly
fibroblasts, to lay down collagen. Without wishing to be bound by
theory, it is believed that neutrophils are involved in activating
macrophages, and that the reduction of neutrophil levels found in
the studies reported herein demonstrate that the methods and uses
of the invention will also be applicable to reducing the severity
and progression of ILDs.
[0125] In some preferred embodiments, the ILD is idiopathic
pulmonary fibrosis. In other preferred embodiments, the ILD is one
associated with an occupational or environmental exposure.
Exemplars of such ILDs, are asbestosis, silicosis, coal worker's
pneumoconiosis, and berylliosis. Further, occupational exposure to
any of a number of inorganic dusts and organic dusts is believed to
be associated with mucus hypersecretion and respiratory disease,
including cement dust, coke oven emissions, mica, rock dusts,
cotton dust, and grain dust (for a more complete list of
occupational dusts associated with these conditions, see Table
254-1 of Speizer, "Environmental Lung Diseases," Harrison's
Principles of Internal Medicine, infra, at pp. 1429-1436). In other
embodiments, the ILD is sarcoidosis of the lungs. ILDs can also
result from radiation in medical treatment, particularly for breast
cancer, and from connective tissue or collagen diseases such as
rheumatoid arthritis and systemic sclerosis. It is believed that
the methods, uses and compositions of the invention can be useful
in each of these interstitial lung diseases.
[0126] In another set of embodiments, the invention is used to
reduce the severity or progression of asthma. Asthma typically
results in mucin hypersecretion, resulting in partial airway
obstruction. Additionally, irritation of the airway results in the
release of mediators which result in airway obstruction. While the
lymphocytes and other immunomodulatory cells recruited to the lungs
in asthma may differ from those recruited as a result of COPD or an
ILD, it is expected that the invention will reduce the influx of
immunomodulatory cells, such as neutrophils and eosinophils, and
ameliorate the extent of obstruction. Thus, it is expected that the
administration of sEH inhibitors, and the administration of sEH
inhibitors in combination with EETs, will be useful in reducing
airway obstruction due to asthma.
[0127] In each of these diseases and conditions, it is believed
that at least some of the damage to the lungs is due to agents
released by neutrophils which infiltrate into the lungs. The
presence of neutrophils in the airways is thus indicative of
continuing damage from the disease or condition, while a reduction
in the number of neutrophils is indicative of reduced damage or
disease progression. Thus, a reduction in the number of neutrophils
in the airways in the presence of an agent is a marker that the
agent is reducing damage due to the disease or condition, and is
slowing the further development of the disease or condition. The
number of neutrophils present in the lungs can be determined by,
for example, bronchoalveolar lavage.
[0128] The conditions of therapeautic administration for all of
these indications are as described above.
[0129] Compounds for Inhibiting Soluble Epoxide Hydrolases:
[0130] In addition to the methods provided above, the present
invention provides in another aspect, compounds that can inhibit
the activity of soluble epoxide hydrolases. In particular, the
present invention provides compounds having a formula selected from
formulae (I) and (II) above. Preferably, the compounds are other
than 11-(3-cyclohexylureido)-undecano- ic acid,
11-(3-cyclohexylureido)-undecanoic acid methyl ester,
11-(3-cyclohexylureido)-undecanoic acid amide,
12-(3-cyclohexylureido)-do- decanoic acid and
12-(3-adamantan-1-yl-ureido)-dodecanoic acid.
[0131] Preferred compounds are those compounds described above as
preferred for the recited uses.
[0132] Methods of Preparation
[0133] The compounds of the present invention can be prepared by a
variety of methods as outlined generally in the schemes below.
[0134] Scheme 1--Introduction of a Secondary Pharmacophore
(Ketone)
[0135] Scheme 1 illustrates general methods that can be used for
preparation of compounds of the invention having a secondary
pharmacophore that is a ketone functional group. While the scheme
is provided for the synthesis of
1-(3-chlorophenyl)-3-(4-oxodecyl)urea, one of skill in the art will
understand that a number of commercially available isocyanates
could be used in place of 3-chlorophenyl isocyanate, and that
shorter or longer analogs of ethyl 4-aminobutyric acid or
hexylbromide could also be employed. 3
[0136] Scheme 1: Synthesis of 1-(3-chlorophenyl)-3-(4-oxodecyl)urea
(794): (a) Benzophenone imine, CH.sub.2Cl.sub.2, rt; (b) DIBAL,
THF, -78.degree. C.; (c) Mg/I.sub.2, hexylbromide, THF, rt; (d)
acetic anhydride, DMSO, rt; (e) 1N HCl/dioxane, rt; (f)
3-chlorophenyl isocyanate, TEA, DMF, rt.
[0137] As shown in Scheme 1, ethyl 4-aminobutyrate hydrochloride
(available from Aldrich Chemical Co., Milwaukee, Wis., USA) is
combined with benzophenone imine at room temperature to provide
intermediate (i). DIBAL reduction of the ester group provides an
unisolated aldehyde moiety that is then reacted with a suitable
Grignard reagent (prepared in situ) to provide intermediate alcohol
(ii). Oxidation of the alcohol moiety to a ketone provides (iii)
which can then be deprotected to form the amino-ketone (iv).
Reaction of (iv) with a suitable isocyanate provides the target
compound (794). Substitution of 3-chlorophenyl isocyanate with, for
example, adamantyl isocyanate or cyclohexyl isocyanate (also
available from Aldrich Chemical Co.) provides other preferred
compounds of the invention. 4
[0138] Scheme 2: Syntheses of 1-(aryl or alkyl)-3-(3-alkylated
proply)ureas: (a) aryl or alkyl isocyanate, DMF, rt; (b)
bromopentane, K.sub.2CO.sub.3, NaI, acetonitrile, reflux; (c)
di-t-butyl dicarbonate, dioxane, 50.degree. C.; (d) pentylamine,
isobutyl chloroformate, NMM, DMF, rt; (e) 4M hydrochloric acid,
dioxane; (f) 3-chlorophenyl isocyanate, TEA, DMF, rt.
[0139] As shown in Scheme 2, a variety of compounds having a
secondary pharmacophore that is either an ester or amide functional
group can be prepared. Beginning with 4-aminobutyric acid,
treatment with a suitable cycloalkyl or aryl isocyanate provides
the urea intermediates shown as (v), wherein R is 3-chlorophenyl,
cyclohexyl or 1-adamantyl. Of course other suitable isocyanates can
also be employed to provide desired urea intermediates.
Esterification via alkylation of the carboxylic acid present in (v)
with, for example, pentyl bromide provides the target compounds
767, 772 and 789. A variety of suitable alkyl halides can be used
to prepare other compounds of the invention. The second path
illustrated in Scheme 2 can be used to prepare compounds such as
768, as well as those compounds having a primary pharmacophore that
is a carbamate. Accordingly, treatment of 4-aminobutyric acid with
di-t-butyl dicarbonate provides the t-butyl carbamate acid (vi)
that is converted to a desired amide (vii) using pentylamine, for
example, in a mild procedure employing isobutyl chloroformate, and
N-methyl morpholine (Removal of the carbamate protecting group (as
it is used in this instance) followed by formation of a urea with a
suitable isocyanate (shown here as 3-chlorophenyl isocyanate)
provides the target compounds (e.g., 768). 5
[0140] Scheme 3: Syntheses of 1-(3-chlorophenyl)-3-(2-alkylated
ethyl)ureas: (a) 3-chlorophenyl isocyanate, DMF, rt; (b) heptanoic
anhydride (761), chloroformic acid pentyl ester (760), or pentyl
isocyanate (762), TEA, DMF, rt; (c) di-t-butyl dicarbonate,
dioxane, rt; (d) heptanoic anhydride (765), chloroformic acid
pentyl ester (777), or pentyl isocyanate (766), DMF, rt; (e) 4M
HCl, dioxane; (f) 3-chlorophenyl isocyanate, TEA, DMF, rt.
[0141] Scheme 3 illustrates a variety of methods for introducing
secondary pharmacophores that are esters, amide, ureas, carbonates
and carbamates, from readily accessible starting materials. In A,
ethanolamine is treated with a suitable isocyanate to introduce a
primary pharmacophore that is a urea and form intermediate (viii).
Treatment of (viii) with an anhydride, a chloro formic acid ester
or an isocyanate provides compounds such as 761, 760 and 762,
respectively. Similar methodology in employed in B, with the
addition of protection/deprotection steps. Accordingly,
ethylenediamine is monoprotected as a t-butyl carbamate. The free
amine is then converted to a secondary pharmacophore that is an
amide, carbamate or urea using reactants and conditions similar to
those employed in "A" to provide intermediates (x). Deprotection of
(x) and reaction with a suitable isocyanate provides the target
compounds 765, 777 and 766. Again, use of isocyanates other than
3-chlorophenyl isocyanate leads to other compounds of the
invention, while substitution of certain reactants used, for
example, in the conversion of (ix) to (x) can provide still other
compounds of the invention. 6
[0142] Scheme 4: Syntheses of 1-(1-adamantyl)-3-(11-alkylated
undecyl)ureas: (a) adamantyl isocyanate, chloroform, reflux; (b)
alkyl or aryl halide, K.sub.2CO.sub.3, NaI, acetonitrile, reflux;
(c) alcohol or amine, isobutyl chloroformate, TEA, DMF, rt; (d)
t-butanol, EDCI, DMAP, methylene chloride, rt.
[0143] Scheme 4 illustrates pathways for the introduction of a
tertiary pharmacophore that is an ester or an amide functional
group. In each case, a carboxylic acid group is converted to the
desired ester or amide. As shown in Scheme 4,12-aminododecanoic
acid (Aldrich Chemical Co.) is converted to urea (687) upon
treatment with adamantyl isocyanate. One of skill in the art will
appreciate that a variety of alkyl, aryl and cycloalkyl isocyanates
can be similarly employed to form other ureas as the primary
pharmacophore. Similarly, 11-aminoundecanoic acid or another long
chain amino fatty acid could be used in place of 12-aminododecanoic
acid. The carboxylic acid moiety can then be esterified or
converted to an amide moiety following standard procedures to
provide, for example, 780-785, 788 and 800-804 (as esters) and 786,
787, 792 and 793 (as esters and amides).
[0144] The following examples are provided to illustrate the
invention and are not intended to limit any aspect of the invention
as set forth above or in the claims below.
EXAMPLES
[0145] All melting points were determined with a Thomas-Hoover
apparatus (A. H. Thomas Co.) and are uncorrected. Mass spectra were
measured by LC-MS (Waters 2790). .sup.1H-NMR spectra were recorded
on QE-300 spectrometer, using tetramethylsilane as an internal
standard. Signal multiplicities are represented as signlet (s),
doublet (d), double doublet (dd), triplet (t), quartet (q), quintet
(quint), multiplet (m), broad (br) and braod singlet (brs).
Synthetic methods are described for representative compounds.
[0146] Lower case bolded Roman numerals in the examples below refer
to the corresponding intermediates in Schemes 1-4 above. Compounds
numbers are also used as provided in the Schemes as well as in the
Tables below.
Example 1
[0147] Synthesis of 1-(3-chlorophenyl)-3-(4-oxodecyl)urea (794)
[0148] 1.00 g (5.52 mmol) of benzophenone imine, 0.94 g (5.52 mmol)
of ethyl 4-aminobutyrate hydrochloride, and 20 mL of methylene
chloride were stirred at room temperature for 24 hr. The reaction
mixture was filtered to remove NH.sub.4Cl and evaporated to
dryness. The benzophenone Schiff base of ethyl 4-aminobutyrate (i)
was extracted with ether (20 mL), and the ether solution was washed
with water (20 mL), dried over sodium sulfate (Na.sub.2SO.sub.4),
and concentrated. The residue was purified by column chromatography
on silica gel eluting with hexane and ethyl acetate (5:1) to give i
(1.00 g, 61%) as an oil. To the solution of the benzophenone Schiff
base (i) in 20 mL of tetrahydrofuran (THF) was added 3.7 mL of 1M
diisobutylaluminium hydride (DIBAL) solution in pentane (3.73 mmol)
at -78.degree. C. under nitrogen, and the reaction was stirred for
2 hr at the temperature. To 0.10 g of magnesium turning (4.07 mmol)
and 12 (catalytic amount) in THF (10 mL) was added 0.48 mL of
hexylbromide (3.39 mmol) at room temperature under nitrogen. After
stirring for 1 hr, this reaction solution was added dropwise to the
above reaction mixture at -78.degree. C., and the solution was
allowed to warm to room temperature with stirring. After stirring
for 5 hr at room temperature, 10 mL of NaHCO.sub.3 aqueous solution
was added to the reaction, then the alkylated alcohol (ii) was
extracted with ether (20 mL), and the ether solution was washed
with water (20 mL), dried over Na.sub.2SO.sub.4, and concentrated
to give 0.26 g (60%) of the alcohol product (ii).
[0149] Acetic anhydride (2 mL) was added to a solution of ii (0.77
mmol) in 5 mL of dimethyl sulfoxide (DMSO). The mixture was allowed
to stand at room temperature for 12 hr and concentrated. The
residue was extracted with ether (20 mL), and the ether was washed
with water (20 mL), dried over Na.sub.2SO.sub.4, and evaporated to
provide 0.26 g (100%) of the ketone compound (iii). To a solution
of iii in dioxane (5 mL) was added 1 mL of 1N HCl in dioxane at
room temperature. The reaction mixture was stirred for 2 hr and
concentrated to give keto amine hydrochloride (iv). Then iv was
dissolved in 5 mL of dimethylformamide (DMF) and treated with
triethylamine (TEA, 0.27 mL, 1.95 mmol) and a solution of
3-chlorophenyl isocyanate (0.10 mL, 0.78 mmol) in DMF (3 mL) at
room temperature. After stirring for 5 hr, the product was
extracted with ether (30 mL), and the ether was washed with water
(30 mL), dried over Na.sub.2SO.sub.4, and evaporated to dryness.
The residue was purified by column chromatography on silica gel
eluting hexane and ethyl acetate (3:1) to afford 75 mg (30%) of
794. .delta.(CDCl.sub.3): 0.88 (3H, t, J=6.9 Hz), 1.21-1.29 (6H,
m), 1.53-1.58 (2H, m), 1.81 (2H, quint, J=6.9 Hz), 2.43 (2H, t,
J=6.9 Hz), 2.49 (2H, t, J=6.9 Hz), 3.23 (2H, t, J=6.9 Hz), 5.10
(1H, s), 6.93 (1H, s), 6.98-7.02 (1H, m), 7.10-7.23 (2H, m), 7.49
(1H, s), [M+H].sup.+325.21
Example 2
[0150] Synthesis of
1-(3-chlorophenyl)-3-(3-pentoxycarbonylpropyl)urea (767)
[0151] To a suspension of 4-aminobutyric acid (1.41 g, 13.7 mol) in
DMF (25 mL) was added 3-chlorophenyl isocyanate (0.70 g, 4.56 mmol;
cyclohexyl isocyanate for 772 and 1-adamantyl isocyanate for 789)
at room temperature. The reaction mixture was stirred for 24 hr.
Then ethyl acetate (30 mL) and 1N HCl aqueous solution (30 mL) were
added into the reaction, and the ethyl acetate layer dissolving the
acid product was collected. The product was extracted with ethyl
acetate (20 mL) two more times from the aqueous layer. The combined
organic solution was dried over Na.sub.2SO.sub.4, and evaporated.
The residue was purified using column chromatography on silica gel
eluting hexane and ethyl acetate (1:1) to give 0.88 g (75%) of urea
acid (v). A mixture of v (0.50 g, 1.95 mmol), potassium carbonate
(K.sub.2CO.sub.3, 0.54 g, 3.90 mmol), bromopentane (0.37 mL, 2.92
mmol), and sodium iodide (60 mg, 0.39 mmol) in DMF (20 mL) was
stirred at room temperature for 20 hr. Then the product was
extracted with ether (20 mL), and the ether was washed with 1N NaOH
aqueous solution (20 mL) and brine (20 mL), dried over
Na.sub.2SO.sub.4, and evaporated to afford 0.59 g (92%) of 767.
.delta.(CDCl.sub.3): 0.90 (3H, t, J=6.9 Hz), 1.26-1.34 (4H, m),
1.62-1.65 (2H, m), 1.88 (2H, quint, J=6.9 Hz), 2.41 (2H, t, J=6.9
Hz), 3.30 (2H, t, J=6.9 Hz), 4.08 (2H, t, J=6.9 Hz), 4.96 (1H, s),
6.62 (1H, s), 7.01-7.04 (1H, m), 7.18-7.22 (2H, m), 7.47 (1H, s),
[M+H].sup.+ 326.90
[0152] The following compounds were prepared in a similar
manner:
[0153] 1-Cyclohexyl-3-(3-pentoxycarbonylpropyl)urea (772)
[0154] .delta.(CDCl.sub.3): 0.89 (3H, t, J=6.9 Hz), 1.04-1.21 (2H,
m), 1.29-1.43 (4H, m), 1.58-1.74 (6H, m), 1.82 (2H, quint, J=6.9
Hz), 2.37 (2H, t, J=6.9 Hz), 3.17-3.24 (2H, m), 3.46-3.48 (1H, m),
4.07 (2H, t, J=6.9 Hz), 4.29 (1H, s), 4.47 (1H, s), [M+H].sup.+
299.24
[0155] 1-(1-Adamantyl)-3-(3-pentoxycarbonylpropyl)urea (789)
[0156] .delta.(CDCl.sub.3): 0.92 (3H, t, J=6.9 Hz), 1.29-1.43 (4H,
m), 1.64-1.69 (m, 10H), 1.83 (2H, quint, J=6.9 Hz), 1.94-1.98 (6H,
m), 2.06-2.09 (3H, m), 2.37 (2H, t, J=6.9 Hz), 3.20 (2H, t, J=6.9
Hz), 4.06-4.14 (3H, m), 4.30 (1H, s), [M+H].sup.+ 251.26
Example 3
[0157] Synthesis of
1-(3-chlorophenyl)-3-(3-pentylaminocarbonylpropyl)urea (768)
[0158] To a suspension of 4-aminobutyric acid (2.84 g, 27.5 mmol)
in DMF (30 mL) was added TEA (3.86 mL, 27.5 mmol). To this mixture,
di-t-butyl dicarbonate (2.00 g, 9.17 mmol) was added with stirring.
The reaction mixture was heated to 50.degree. C. for 12 hr, and
then stirred with ice-cold dilute hydrochloric acid (15 mL) for 10
min. The t-butoxycarbonylated amino acid (vi) was immediately
extracted with ether (2.times.30 mL). The organic extract was dried
over Na.sub.2SO.sub.4 and evaporated to give 1.00 g (54%) of vi as
an oil.
[0159] A solution of vi and 4-methyl morpholine (NMM, 0.54 mL, 4.92
mmol) in DMF (10 mL) was treated at room temperature with isobutyl
chloroformate (0.64 mL, 4.92 mmol). After 30 min, pentylamine (0.57
mL, 4.92 mmol) was added. The reaction mixture was stirred for 12
hr. The solvent was evaporated, and the residue was partitioned
between ethyl acetate (25 mL) and water (25 mL). The ethyl acetate
layer was washed with 5% NaHCO.sub.3 (10 mL) and brine (20 mL) and
dried over Na.sub.2SO.sub.4, and evaporated. The residue was
chromatographed on silica gel eluting hexane and ethyl acetate
(2:1) to give 0.33 g (33%) of t-butoxycarbonylated amino amide
(vii). To a solution of vii in dioxane (10 mL) was treated with 4M
hydrochloric acid (2 mL) in dioxane, and the mixture was stirred
for 1 hr at room temperature. Then the solvent was evaporated to
dryness, and the residual solid was dissolved in DMF (10 mL) and
treated with TEA (0.51 mL, 3.63 mmol) and 3-chlorophenyl isocyanate
(0.15 mL, 1.21 mmol) at room temperature. After stirring for 5 hr,
the product was extracted with ether (30 mL), and the ether was
washed with water (30 mL), dried over Na.sub.2SO.sub.4, and
evaporated to dryness. The residue was purified by column
chromatography on silica gel eluting hexane and ethyl acetate (3:1)
to afford 0.39 g (100%) of 768. .delta.(CDCl.sub.3): 0.89 (t, 3H,
J=6.9 Hz), 1.26-1.28 (4H, m), 1.46-1.50 (2H, m), 1.86 (2H, quint,
J=6.9 Hz), 2.30 (t, 2H, J=6.9 Hz), 3.23 (t, 2H, J=6.9 Hz), 3.30 (t,
2H, J=6.9 Hz), 5.87 (1H, s), 6.06 (1H, s), 6.93-6.97 (1H, m),
7.12-7.23 (2H, m), 7.49 (1H, m), 7.73 (1H, s), [M+H].sup.+
326.16
Example 4
[0160] Synthesis of
1-(3-chlorophenyl)-3-(2-hexylcarbonyloxyethyl)urea (761)
[0161] To a solution of 2-aminoethanol (2.98 g, 48.8 mmol) in DMF
(30 mL) was added 3-chlorophenol isocyanate (2.50 g, 16.3 mmol) at
0.degree. C. The reaction mixture was stirred for 5 hr at room
temperature. The solvent was evaporated, and the residue was
partitioned between ether (30 mL) and 1N hydrochloric acid (20 mL),
and the ether layer was washed with brine, dried over
Na.sub.2SO.sub.4, and evaporated. The residue was purified by
column chromatography on silica gel eluting hexane and ethyl
acetate (1:1) to provide 1.49 g (40%) of urea alcohol (viii) as a
white solid.
[0162] To a solution of viii (1.00 g, 4.60 mmol) and TEA (0.97 mL,
6.90 mmol) in DMF (15 mL) was added a solution of heptanoic
anhydride (2.23 g, 9.20 mmol) in DMF (5 mL) at room temperature.
The reaction was stirred for 12 hr, and the solvent was evaporated.
The residue was partitioned between ether (30 mL) and cold 1N
hydrochloric acid (20 mL). The ether layer was washed with brine,
dried over Na.sub.2SO.sub.4, and evaporated. The residual solid was
purified using silica gel column chromatography (hexane:ethyl
acetate=3:1) to afford 1.05 g (70%) of 761. .delta.(CDCl.sub.3):
0.87 (t, 3H, J=6.9 Hz), 1.20-1.29 (6H, m), 1.60-1.62 (2H, m),
2.22-2.29 (2H, m), 3.50-3.55 (2H, m), 4.09-4.20 (2H, m), 5.32 (1H,
s), 7.01-7.06 (2H, m), 7.16-7.22 (2H, m), 7.40 (1H, s), [M+H].sup.+
327.15
[0163] Compounds 760 and 762 were prepared in the same manner as
that used for compound 761 from chloroformic acid pentyl ester and
pentyl isocyanate in place of heptanoic anhydride,
respectively.
[0164] 1-(3-chlorophenyl)-3-(2-pentoxycarbonyloxyethyl)urea
(760)
[0165] .delta.(CDCl.sub.3): 0.91 (t,3H, J=6.9 Hz), 1.25-1.36 (4H,
m), 1.63-1.67 (2H, m), 3.55-3.60 (2H, m), 4.14 (3H, t, J=6.9 Hz),
4.25-4.28 (2H, m), 5.11 (1H, s), 6.50 (1H, s), 7.02-7.05 (1H, m),
7.19-7.23 (2H, m), 7.42 (1H, s), [M+H].sup.+ 329.09
[0166] 1-(3-chlorophenyl)-3-(2-pentylaminocarbonyloxyethyl)urea
(762)
[0167] 1.delta.(CDCl.sub.3): 0.87 (3H, t, J=6.9 Hz), 1.30-1.33 (4H,
m), 1.46-1.50 (2H, m), 3.12-3.19 (2H, m), 3.50-3.52 (2H, m),
4.17-4.20 (2H, m), 4.83 (1H, s), 5.47 (1H, s), 6.96 (1H, s),
6.98-7.02 (1H, m), 7.18-7.21 (2H, m), 7.44 (1H, s), [M+H].sup.+
328.20
Example 5
[0168] Synthesis of
1-(3-chlorophenyl)-3-(2-hexylcarbonylaminoethyl)urea (765)
[0169] A solution of di-t-butyl dicarbonate (0.50 g, 2.29 mmol) in
dioxane (20 mL) was added over a period of 1 hr to a solution of
1,2-diaminoethane (1.10 g, 18.3 mmol) in dioxane (20 mL). The
mixture was allowed to stir for 22 hr and the solvent was
evaporated to dryness. Water (30 mL) was added to the residue and
the insoluble bis-substituted product was removed by filtration.
The filtrate was extracted with methylene chloride (3.times.30 mL)
and the methylene chloride evaporated to yield ix as an oil (0.35
g, 95%).
[0170] A solution of heptanoic anhydride (0.91 g, 3.75 mmol;
chloroformic acid pentyl ester for 777 and pentyl isocyanate for
766) and ix (0.50 g, 3.13 mmol) in DMF (20 mL) was stirred for 2 hr
at room temperature. Then the solvent was evaporated. The residue
was partitioned between ether (30 mL) and water (30 mL). The ether
layer was dried over Na.sub.2SO.sub.4 and evaporated. The residue
was purified by using column chromatography on silica gel eluting
hexane and ethyl acetate (1:1) to get 0.57 g (67%) of alkylated
N-t-butoxycarbonyl amine (x).
[0171] To a solution of x in dioxane (10 mL) was treated with 4M
hydrochloric acid (2 mL) in dioxane, and the mixture was stirred
for 1 hr at room temperature. Then the solvent was evaporated to
dryness, and the residual solid was dissolved in DMF (10 mL) and
treated with TEA (0.58 mL, 4.19 mmol) and 3-chlorophenyl isocyanate
(0.32 g, 2.10 mmol) at room temperature. After stirring for 5 hr,
the product was extracted with ether (30 mL), and the ether was
washed with water (30 mL), dried over Na.sub.2SO.sub.4, and
evaporated to dryness. The residue was purified by column
chromatography on silica gel eluting hexane and ethyl acetate (1:1)
to afford 0.68 g (100%) of 765. .delta.(CDCl.sub.3): 0.84 (t, 3H,
J=6.9 Hz), 1.16-1.25 (6H, m), 1.55-5.61 (2H, m), 2.21-2.24 (2H, m),
3.31-3.40 (4H, m), 6.27 (1H, s), 6.90-6.95 (2H, m), 7.18-7.20 (2H,
m), 7.56 (1H, s), 8.07 (1H, s), [M+H].sup.+ 326.25
[0172] The following compounds were prepared in a similar
manner:
[0173] 1-(3-chlorophenyl)-3-(2-pentoxycarbonylaminoethyl)urea
(777)
[0174] .delta.(CDCl.sub.3): 0.88 (3H, t, J=6.9 Hz), 1.28-1.32 (4H,
m), 1.44-1.49 (2H, m), 3.23-3.33 (4H, m), 3.95-3.97 (2H, m), 6.01
(1H, s), 6.34 (1H, s), 6.87-6.91 (1H, m), 7.18-7.26 (2H, m), 7.78
(1H, s), 8.21 (1H, s), [M+H].sup.+ 328.22
[0175] 1-(3-chlorophenyl)-3-(2-pentylaminocarbonylaminoethyl)urea
(766)
[0176] .delta.(Acetone): 0.87 (3H, t, J=6.9 Hz), 1.27-1.30 (4H, m),
2.04-2.06 (2H, m), 3.02-3.05 (2H, m), 3.20-3.22 (2H, m), 5.74 (2H,
s), 6.22 (1H, s), 7.23-7.29 (2H, m), 7.82-7.87 (2H, m), 8.67 (1H,
s), [M+H].sup.+ 327.10
Example 6
[0177] Synthesis of 1-(1-adamantyl)-3-(12-dodecanoic acid)urea
(687)
[0178] A mixture of 1-adamantyl isocyanate (1.30 g, 7.34 mmol) and
12-aminododecanoic acid (1.46 g, 6.77 mmol) in chloroform (30 mL)
was refluxed for 10 hr. The solvent was removed by evaporation, and
the residue was washed with ethyl acetate (20 mL) to provide 2.66 g
(100%) of urea acid product as a white solid. .delta.(CDCl.sub.3):
1.20-1.36 (16H, m), 1.42-1.48 (2H, m), 1.57-1.65 (6H, m), 1.82-1.90
(6H, m), 1.94-1.98 (3H, m), 2.18 (2H, t, J=6.9 Hz), 2.86-2.92 (2H,
m), 3.45 (1H, bs), 5.43 (1H, s), 5.587 (1H, t, J=5.4 Hz),
[M+H].sup.+ 393.28, mp 140.degree. C.
Example 7
[0179] Synthesis of
1-(1-adamantyl)-3-(11-methoxycarbonylundecyl)urea (780)
[0180] To a mixture of compound 687 (0.15 g, 0.38 mmol),
K.sub.2CO.sub.3 (64 mg, 0.46 mmol), and iodomethane (54 mg, 0.38
mmol) in acetonitrile (20 mL) was refluxed for 10 hr. Then the
reaction mixture was filtered, and the filtrate was washed with
brine (20 mL), dried over Na.sub.2SO.sub.4, and evaporated. The
residue was purified using column chromatography on silica gel
eluting hexane and ethyl acetate (3:1) to afford 0.14 g (92%) of
780 as a white solid. .delta.(CDCl.sub.3): 1.19-1.34 (12H, m),
1.41-1.48 (2H, m), 1.58-1.62 (4H, m), 1.63-1.75 (6H, m), 1.93-2.00
(6H, m), 2.04-2.07 (3H, m), 2.30 (2H, t, J=6.9 Hz), 3.06-3.12 (2H,
m), 3.67 (3H, s), 4.00 (1H, s), 4.06 (1H, s), [M+H].sup.+ 407.22,
mp 75.degree. C.
[0181] Compounds 784, 783, 781, 788, 800, 785, 802, 803, 804, and
782 were prepared in the same manner using corresponding halides in
a range of 30-95% yield.
[0182] 1-(1-Adamantyl)-3-(11-ethoxycarbonylundecyl)urea (784)
[0183] .delta.(CDCl.sub.3): 1.21-1.38 (12H, m), 1.42-1.68 (15H, m),
1.96 (6H, bs), 2.06 (3H, m), 2.30 (2H, t, J=6.9 Hz), 3.06-3.12 (2H,
m), 3.97-4.01 (2H, bs), 4.12 (2H, q), [M+H].sup.+ 421.46, mp
82.degree. C.
[0184] 1-(1-Adamantyl)-3-(11-propoxycarbonylundecyl)urea (783)
[0185] .delta.(CDCl.sub.3): 0.94(3H,t,J=6.9 Hz), 1.19-1.34(12H,m),
1.41-1.48(2H,m), 1.58-1.62 (4H, m), 1.63-1.75 (8H, m), 1.93-2.00
(6H, m), 2.04-2.07 (3H, m), 2.30 (2H, t, J=6.9 Hz), 3.06-3.12 (2H,
m), 3.95-4.05 (4H, m), [M+H].sup.+ 435.52, mp 86.degree. C.
[0186] 1-(1-Adamantyl)-3-(11-allyloxycarbonylundecyl)urea (781)
[0187] .delta.(CDCl.sub.3): 1.19-1.34(12H,m), 1.41-1.48(2H,m),
1.58-1.73(13H,m), 1.93-2.00 (6H, m), 2.04-2.07 (3H, m), 2.33 (2H,
t, J=6.9 Hz), 3.06-3.12 (2H, m), 3.99 (1H, s), 4.04 (1H, s),
4.57-4.59 (2H, m), [M+H].sup.+ 433.43, mp 81.degree. C.
[0188] 1-(1-Adamantyl)-3-(11-propagyloxycarbonylundecyl)urea
(788)
[0189] .delta.(CDCl.sub.3): 1.24-1.31(12H,m), 1.44-1.46(2H,m),
1.58-1.67(11H,m), 1.94-1.98 (6H, m). 2.05-2.07 (3H, m), 2.35 (2H,
t, J=6.9 Hz), 3.05-3.12 (2H, m), 3.99 (1H, s), 4.04 (1H, s), 4.67
(2H, s), [M+H].sup.+ 431.67, mp 79.degree. C.
[0190] 1-(1-Adamantyl)-3-(11-butoxycarbonylundecyl)urea (800)
[0191] .delta.(CDCl.sub.3): 0.95(3H,t,J=6.9 Hz), 1.23-1.35(12H,m),
1.44-1.52(4H,m), 1.57-1.61 (4H, m), 1.66-1.69 (6H, m), 1.96-2.00
(8H, m), 2.07-2.09 (3H, m), 2.30 (2H, t, J=6.9 Hz), 3.09-3.13 (2H,
m), 4.02-4.10 (4H, m), [M+H].sup.+ 449.34
[0192] 1-(1-Adamantyl)-3-(11-iso-propoxycarbonylundecyl)urea
(785)
[0193] .delta.(CDCl.sub.3): 1.19-1.26(18H,m), 1.41-1.48(2H,m),
1.58-1.62(4H,m), 1.63-1.75 (6H, m), 1.94-2.00 (6H, m), 2.03-2.07
(3H, m), 2.30 (2H, t, J=6.9 Hz), 3.06-3.12 (2H, m), 3.67 (3H, s),
4.00 (1H, s), 4.06 (1H, s), 4.94-5.04 (1H, m), [M+H].sup.+ 435.33,
mp 90.degree. C.
[0194] 1-(1-Adamantyl)-3-(11-sec-butoxycarbonylundecyl)urea
(802)
[0195] .delta.(CDCl.sub.3): 0.89(3H,t,J=6.9 Hz), 1.19(3H,d,J=6.9
Hz), 1.23-1.35(12H,m), 1.44-1.50 (2H, m), 1.57-1.61 (4H, m),
1.66-1.72 (8H, m), 1.96-2.00 (6H, m), 2.07-2.09 (3H, m), 2.27 (2H,
t, J=6.9 Hz), 3.09-3.13 (2H, m), 4.00 (1H, s), 4.05 (1H, s),
4.91-4.96 (1H, m); and [M+H].sup.+ 449.29, mp 65.degree. C.
[0196] 1-(1-Adamantyl)-3-(11-isobutoxycarbonylundecyl)urea
(803)
[0197] .delta.(CDCl.sub.3): 0.93(6H,d,J=6.9 Hz), 1.23-1.35(12H,m),
1.45-1.47(2H,m), 1.56-1.58 (4H, m), 1.65-1.68 (6H, m), 1.94-1.97
(7H, m), 2.06-2.08 (3H, m), 2.31 (2H, t, J=6.9 Hz), 3.07-3.11 (2H,
m), 3.85 (2H, d, J=6.9 Hz), 3.99 (1H, s), 4.03 (1H, s), [M+H].sup.+
449.32, mp 91.degree. C.
[0198] 1-(1-Adamantyl)-3-(11-benzyloxycarbonylundecyl)urea
(804)
[0199] .delta.(CDCl.sub.3): 1.24-1.28 (12H, m), 1.44-1.48 (2H, m),
1.63-1.68 (10H, m), 1.94-1.97 (6H, m), 2.05-2.07 (3H, m), 2.34 (2H,
t, J=6.9 Hz), 3.05-3.13 (2H, m), 4.04 (1H, s), 4.09 (1H, s), 5.12
(2H, s), 7.33-7.37 (5H, m), [M+H].sup.+ 483.33, mp 49.degree.
C.
[0200]
1-(1-Adamantyl)-3-(11-(2-chlorobenzyl)oxycarbonylundecyl)urea
(782)
[0201] .delta.(CDCl.sub.3): 1.24-1.28 (12H, m), 1.44-1.48 (2H, m),
1.63-1.68 (10H, m), 1.94-1.97 (6H, m), 2.05-2.07 (3H, m), 2.39 (2H,
t, J=6.9 Hz), 3.07-3.13 (2H, m), 4.00 (1H, s), 4.06 (1H, s), 5.23
(2H, s), 7.27-7.30 (3H, m), 7.39-7.42 (1H, m), [M+H].sup.+ 517.05,
mp 48.degree. C.
Example 8
[0202] Synthesis of
1-(1-adamantyl)-3-(11-(1-adamantyl)methyloxycarbonylun- decyl)urea
(786)
[0203] A solution of 687 (0.15, 0.38 mmol) and TEA (96 mg, 0.96
mmol) in DMF (10 mL) was treated at room temperature with isobutyl
chloroformate (52 mg, 0.38 mmol). After 30 min, a solution of
adamantanemethanol (64 mg, 0.38 mmol) in DMF (2 mL) was added. The
reaction mixture was stirred for 12 hr. The solvent was evaporated,
and the residue was partitioned between ethyl acetate (25 mL) and
water (25 mL). The ethyl acetate layer was washed with 5%
NaHCO.sub.3 (10 mL) and brine (20 mL) and dried over
Na.sub.2SO.sub.4, and evaporated. The residue was chromatographed
on silica gel eluting hexane and ethyl acetate (5:1) to give 72 mg
(35%) of 786 as a white solid. .delta.(CDCl.sub.3): 1.23-1.33 (15H,
m), 1.48-1.71 (21H, m), 1.90-1.96 (8H, m), 2.04-2.06 (3H, m), 2.31
(2H, t, J=6.9 Hz), 3.05-3.12 (2H, m), 3.67 (2H, s), 4.00 (1H, s),
4.05 (1H, s), [M+H].sup.+ 541.33, mp 68.degree. C.
[0204] Compound 792, 793 and 787 were prepared in this manner using
ethylamine, isopropylamine, and 1-naphthalenemethanol,
respectively, instead of adamantanemethanol.
[0205] 1-(1-Adamantyl)-3-(11-ethylaminocarbonylundecyl)urea
(792)
[0206] .delta.(CDCl.sub.3): 1.14 (3H, t, J=6.9 Hz), 1.24-1.31 (12H,
m), 1.43-1.46 (2H, m), 1.58-1.66 (10H, m), 1.94-1.98 (6H, m),
2.05-2.07 (3H, m), 2.15 (2H, t, J=6.9 Hz), 3.06-3.12 (2H, m),
3.25-3.13 (2H, m), 4.05 (1H, s), 4.12 (1H, s), 5.43 (1H, s),
[M+H].sup.+ 420.48, mp 119.degree. C.
[0207] 1-(1-Adamantyl)-3-(11-isopropylaminocarbonylundecyl)urea
(793)
[0208] .delta.(CDCl.sub.3): 1.14 (6H, d, J=6.9 Hz), 1.24-1.31 (12H,
m), 1.43-1.46 (2H, m), 1.61-1.69 (10H, m), 1.94-1.98 (6H, m),
2.07-2.18 (5H, m), 3.07-3.13 (2H, m), 4.03-4.10 (2H, m), 4.14 (1H,
s), 5.26 (1H, s), [M+H].sup.+ 434.50, mp 115.degree. C.
[0209] 1-(1-Adamantyl)-3-(11-(1-naphthlyl)meth
oxycarbonylundecyl)urea (787)
[0210] .delta.(CDCl.sub.3): 1.20-1.27 (12H, m), 1.43-1.46 (2H, m),
1.61-1.67 (10H, m), 1.96-2.06 (6H, m), 2.14-2.16 (2H, m), 2.35 (2H,
t, J=6.9 Hz), 3.06-3.10 (2H, m), 4.02(1H, s), 4.08 (1H, s), 5.57
(2H, s), 7.43-7.56 (4H, m), 7.84-7.87 (2H, m), 7.90 (8.02 (1H, m),
[M+H].sup.+ 533.59
Example 9
[0211] Synthesis of
1-(1-Adamantyl)-3-(11-t-butoxycarbonylundecyl)urea (801)
[0212] To a solution of compound 687 (0.10 g, 0.25 mmol),
N,N-dimethylaminopyridine (DMAP, 10 mg, 0.13 mmol), and t-butanol
(23 mg, 0.31 mmol) in methylene chloride (20 mL) was added
1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride
(EDCI, 50 mg, 0.25 mmol) at room temperature. The mixture was
stirred for 20 hr. The solvent was evaporated, and the residue was
partitioned between ether (30 mL) and water (30 mL). The ether
layer was dried over Na.sub.2SO.sub.4 and evaporated. Purification
of the residue by silica gel column chromatography eluting hexane
and ethyl acetate (3:1) provided 21 mg (18%) oft-butyl ester as a
white solid.
[0213] .delta.(CDCl.sub.3): 1.23-1.35 (12H, m), 1.44-1.50 (2H, m),
1.57-1.61 (13H, m), 1.66-1.72 (6H, m), 1.96-2.00 (6H, m), 2.07-2.09
(3H, m), 2.27 (2H, t, J=6.9 Hz), 3.09-3.13 (2H, m), 3.96 (1H, s),
4.01 (1H, s), [M+H].sup.+ 449.36, mp 150.degree. C.
Example 10
[0214] Synthesis of 4-(3-Cyclohexyl-ureido)-butyric acid (632).
[0215] To a cold solution of 4-aminobutyric acid (2.16 g, 21 mmol)
and catalytic amount of DBU in 22 mL of 1.0 N NaOH, 2.5 g (20 mmol)
of cyclohexyl isocyanate were added in one time. The mixture was
strongly mixed at room temperature overnight. The reaction was then
acidified with concentrated HCl. The formed white solid was
collected by filtration. The mixture was purified by chromatography
on a silica column (8.times.3 cm). Elution with a mixture 50:50:1
of hexane:ethyl acetate: acetic acid gave the pure targeted
product. The resulting white crystal (3.46 g; yield: 76%) had a mp
of 153.0-154.0.degree. C. [M+H].sup.+ 281.18
Example 11
[0216] Synthesis of
2-[4-(3-Cyclohexyl-ureido)-butyrylamino]-3-(4-hydroxy--
phenyl)-propionic acid (632-Tyr).
[0217] To a solution of 632 (0.45 g, 2.0 mmol) and
1-ethyl-3-(3-(dimethyla- mino)-propyl) carbodiimide (0.5 g, 2.2
mmol) in 15 mL of DMF, 0.53 g (2.3 mmol) of tyrosine methyl ester
and 2.4 mmol of diisopropylethylamine were added. The mixture was
heated at 60.degree. C. for 6 h. Then, 50 mL of 0.1 N NaOH were
added and the mixture was left at room temperature overnight. The
reaction mixture was then acidified with concentrated HCl and
extracted twice with a 2:1 mixture of chloroform:methanol. The
organic phases were pooled, dried and evaporated. The residue was
purified by chromatography on a silica column (5.times.4 cm).
Elution with a 75:25:1 mixture of ethyl acetate:methanol:acetic
acid yielded 140 mg (yield: 18%) of the target product as a brown
oily liquid. LC-MS-ES negative mode: 390.3 (100%, [M-H]-), 290.9
(10%, (M-C.sub.6H.sub.10N].sup- .-), 264.9 (5%,
[M-C.sub.7H.sub.12NO].sup.-); positive mode: 392.5 (40%,
[M+H].sup.+), 264.95 (100%, [M-C.sub.7H.sub.10NO].sup.+).
Example 12
[0218] This example provides assays and illustrates the inhibition
of mouse and human soluble epoxide hydrolases by compounds of the
invention having a secondary pharmacophore that is a carboxylic
acid or carboxylic methyl ester functional group.
[0219] Enzyme Preparation
[0220] Recombinant mouse sEH and human sEH were produced in a
baculovirus expression system and purified by affinity
chromatography..sup.34,35,36 The preparations were at least 97%
pure as judged by SDS-PAGE and scanning densitometry. No detectable
esterase or glutathione transferase activity, which can interfere
with this sEH assay, was observed..sup.37 Protein concentration was
quantified by using the Pierce BCA assay using Fraction V bovine
serum albumin as the calibrating standard.
[0221] IC.sub.50 Assay Conditions
[0222] IC.sub.50 values were determined as described by using
racemic 4-nitrophenyl-trans-2,3-epoxy-3-phenylpropyl carbonate as
substrate..sup.37 Enzymes (0.12 .mu.M mouse sEH or 0.24 .mu.M human
sEH) were incubated with inhibitors for 5 min in sodium phosphate
buffer, 0.1 M pH 7.4, at 30.degree. C. before substrate
introduction ([S] 40 .mu.M). Activity was assessed by measuring the
appearance of the 4-nitrophenolate anion at 405 nm at 30.degree. C.
during 1 min (Spectramax 200; Molecular Devices). Assays were
performed in triplicate. IC.sub.50 is a concentration of inhibitor,
which reduces enzyme activity by 50%, and was determined by
regression of at least five datum points with a minimum of two
points in the linear region of the curve on either side of the
IC.sub.50. The curve was generated from at least three separate
runs, each in triplicate, to obtain the standard deviation (SD)
given in Table 1 thru Table 4.
[0223] Assays were conducted with the compounds indicated in Table
1, as described above.
2TABLE 1 Inhibition of mouse and human sEH by
1-cyclohexyl-3-n-(substituted)al- kylureas.sup.a 7 IC.sub.50
(.mu.M) No. n Z Mouse sEH Human sEH 625 1 H >500 >500 549 1
CH.sub.3 33 .+-. 2 70 .+-. 6 109 2 H 122 .+-. 2 358 .+-. 2 635 2
CH.sub.3 2.5 .+-. 0.1 78 .+-. 4 632 3 H >500 >500 774 3
CH.sub.3 0.33 .+-. 0.03 6.2 .+-. 0.5 884 4 H 0.25 .+-. 0.02 2.4
.+-. 0.1 854 4 CH.sub.3 0.13 .+-. 0.03 5.0 .+-. 0.6 56 5 H 90 .+-.
3 253 .+-. 8 .sup.aEnzymes (0.12 .mu.M mouse sEH and 0.24 .mu.M
human sEH) were incubated with inhibitors for 5 min in sodium
phosphate buffer (pH 7.4) at 30.degree. C. before substrate
introduction ([S] = 40 .mu.M). Results are means .+-. SD of three
separate experiments.
[0224] As can be seen from the above table, the conversion of a
carboxylic acid function to its methyl ester (549, 635, and 774)
increased inhibition potency for both mouse and human sEHs.
Moreover, the methyl ester of butanoic acid (774) showed 8-100 fold
higher activity than the esters of acetic and propanoic acids (549
and 635) for both enzymes, indicating that a polar functional group
located three carbon units (carbonyl on the fourth carbon, about
7.5 angstroms from the urea carbonyl) from the carbonyl of the
primary urea pharmacophore can be effective for making potent sEH
inhibitors of improved water solubility. In addition, the distance
from the carbonyl of the primary urea pharmacophore to the
secondary ester pharmacophore in compound 854 is about 8.9 .ANG.
showing that the secondary pharmacophore may be located about 7
.ANG. to about 9 .ANG. from the carbonyl of the primary urea
pharmacophore group.
Example 13
[0225] This example illustrates the inhibition of mouse and human
soluble epoxide hydrolases by compounds of the invention having a
secondary pharmacophore, with comparison to compounds having only a
primary pharmacophore. As can be seen from the results in Table 2,
the activity is relatively consistent.
[0226] Assays were conducted with the compounds indicated in Table
2, according to established protocols (see, above).
3TABLE 2 Inhibition of mouse and human sEH by
1-cycloalkyl-3-alkylureas.sup.a IC.sub.50 (.mu.M) No. Structure
Mouse sEH Human sEH 772 8 0.05 .+-. 0.01 1.02 .+-. 0.05 789 9 0.05
.+-. 0.01 0.17 .+-. 0.01 791 10 0.05 .+-. 0.01 0.14 .+-. 0.01 790
11 0.05 .+-. 0.01 0.10 .+-. 0.01 297 12 0.05 .+-. 0.01 0.14 .+-.
0.01 686 13 0.05 .+-. 0.01 0.10 .+-. 0.01 .sup.aEnzymes (0.12 .mu.M
mouse sEH and 0.24 .mu.M human sEH) were incubated with inhibitors
for 5 min in sodium phosphate buffer (pH 7.4) at 30.degree. C.
before substrate introduction ([S] = 40 .mu.M). Results are means
.+-. SD of three separate experiments.
[0227] As shown in the above table, the substitution at R.sup.1
with a cyclohexyl (772) or adamantyl (789) increased inhibitor
potency 10-fold over the 3-chlorophenyl analog (767, see Table 3
below). Furthermore, these compounds functionalized with a polar
group were as active and potent as non-functionalized lipophilic
inhibitors (for example, 791, 790, 297, and 686) for both murine
and human enzymes. Adding polar groups to compounds generally
increases their water solubility, and this was the case when one
compares compounds 772 or 789 to 791 and 790. In addition,
stripping water of hydration out of the enzyme catalytic site
requires about the same amount of energy that is gained by forming
a new hydrogen bond between the inhibitor and the enzyme. Thus
addition of polar groups which hydrogen bond to a target enzyme
does not dramatically increase potency if the inhibitor is already
potent. However, the presence of an additional polar group can be
expected to dramatically increase specificity by decreasing
hydrophobic binding to biological molecules other than the primary
target (sEH). In this way combining several active pharmacophores
into a single molecule often has a massive increase in specificity
and biological activity in complex biological systems.
Example 14
[0228] This example illustrates the inhibition of mouse and human
soluble epoxide hydrolases by compounds of the invention having a
secondary pharmacophore that is a ketone, amide, alcohol,
carbonate, carbamate, urea, carboxylate ester functional group.
[0229] Based on the initial activity shown in Table 1, urea
compounds were prepared having a polar carbonyl group located
approximately 7.5 angstroms from the carbonyl of the primary urea
pharmacophore to improve water solubility of lipophilic sEH
inhibitors (192 and 686). The table below shows various
functionalities such as ketone, ester, amide, carbonate, carbamate,
and urea which contribute a carbonyl group, and are termed as the
secondary pharmacophores. To determine the effect for each of the
secondary pharmacophores, a 3-chlorophenyl group was held constant
as one of substituents of the urea pharmacophore. The
3-chlorophenyl group is also particularly useful for monitoring
chemical reactions quickly via chromatography. After optimizing the
secondary pharmacophore, the aryl substituent can be replaced by a
cyclohexyl, adamantyl or other group leading to more potent
inhibitors.
[0230] Assays were conducted with the compounds indicated in Table
3, according to established protocols (see, above).
4TABLE 3 Inhibition of mouse and human sEH by
1-(3-chlorophenyl)-3-(2-alkylated ethyl)ureas.sup.a 14 IC.sub.50
(.mu.M) No. X Y Mouse sEH Human sEH 794 CH.sub.2 CH.sub.2 0.41 .+-.
0.05 2.1 .+-. 0.2 767 CH.sub.2 O 0.37 .+-. 0.04 2.1 .+-. 0.07 768
CH.sub.2 NH 7.2 .+-. 0.9 32 .+-. 0.8 761 O CH.sub.2 7.7 .+-. 0.6 26
.+-. 1 760 O O 7.6 .+-. 0.3 22 .+-. 1 762 O NH 5.3 .+-. 0.1 18 .+-.
0.9 765 NH CH.sub.2 100 .+-. 10 >100 777 NH O 78 .+-. 6 >100
766 NH NH 110 .+-. 20 >100 .sup.aEnzymes (0.12 .mu.M mouse sEH
and 0.24 .mu.M human sEH) were incubated with inhibitors for 5 min
in sodium phosphate buffer (pH 7.4) at 30.degree. C. before
substrate introduction ([S] = 40 .mu.M). Results are means .+-. SD
of three separate experiments.
[0231] When the left of the carbonyl (X) is a methylene carbon, the
best inhibition was obtained if a methylene carbon (ketone, 794) or
oxygen (ester, 767) is present in the right position (Y). The ester
bond can be stabilized by stearic hindrance of the alcohol or acid
moiety or both (805). The presence of nitrogen (amide, 768) reduced
the activity. In compounds with an oxygen in the left of the
carbonyl group, a >10-fold drop in activity was observed and
there was not any change in the activity even if the right
position, Y, was modified with a methylene carbon (ester, 761),
oxygen (carbonate, 760), or nitrogen (carbamate, 762),
respectively. All compounds (765, 777, and 766) with nitrogen in
the left position had lower activities than 794 or 767. Comparing
compounds 767 and 761, the presence of a methylene carbon around
the carbonyl showed a very different effect on the inhibition
activity. The compound with a methylene carbon in the left of the
carbonyl (767) showed a 20-fold better inhibition than that in the
right (761). While the rank-order potency of this inhibitor series
was equivalent with mouse and human sEH, a 3-5-fold higher
inhibition potency was observed for the murine enzyme.
Example 15
[0232] This example illustrates the inhibition of mouse and human
soluble epoxide hydrolases by compounds of the invention having no
secondary pharmacophore, but having a tertiary pharmacophore that
is an amide or a carboxylate ester functional group (with alkyl,
alkenyl, alkynyl, cycloalkyl and arylalkyl ester groups).
[0233] Compound 687, having a carboxylic acid group at the end of
twelve carbon chain, was found to be an excellent inhibitor of both
the mouse and human enzymes. Additionally, an ester found to be a
suitable secondary pharmacophore. As a result, a variety of ester
derivatives having a carbonyl group located eleven carbon units
from the urea pharmacophore were synthesized and evaluated to
examine contributions of a tertiary pharmacophore.
[0234] Assays were conducted with the compounds indicated in Table
4, according to established protocols (see, above).
5TABLE 4 Inhibition of mouse and human sEH by
1-(1-adamantyl)-3-(11-alkylated undecyl)-ureas.sup.a 15 IC.sub.50
(.mu.M) No. X R Mouse sEH Human sEH 687 O H 0.05 .+-. 0.01 0.10
.+-. 0.01 780 O 16 0.05 .+-. 0.01 0.10 .+-. 0.01 784 O 17 0.05 .+-.
0.01 0.10 .+-. 0.01 792 NH 18 0.05 .+-. 0.01 0.10 .+-. 0.01 783 O
19 0.05 .+-. 0.01 0.10 .+-. 0.01 781 O 20 0.05 .+-. 0.01 0.10 .+-.
0.01 788 O 21 0.05 .+-. 0.01 0.10 .+-. 0.01 800 O 22 0.05 .+-. 0.01
0.10 .+-. 0.01 785 O 23 0.05 .+-. 0.01 0.10 .+-. 0.01 793 NH 24
0.05 .+-. 0.01 0.10 .+-. 0.01 801 O 25 0.05 .+-. 0.01 0.10 .+-.
0.01 802 O 26 0.05 .+-. 0.01 0.10 .+-. 0.01 803 O 27 0.05 .+-. 0.01
0.10 .+-. 0.01 786 O 28 0.07 .+-. 0.01 0.23 .+-. 0.02 804 O 29 0.07
.+-. 0.01 0.13 .+-. 0.01 782 O 30 0.10 .+-. 0.01 0.29 .+-. 0.01 787
O 31 0.09 .+-. 0.01 0.21 .+-. 0.01 .sup.aEnzymes (0.12 .mu.M mouse
sEH and 0.24 .mu.M human sEH) were incubated with inhibitors for 5
min in sodium phosphate buffer (pH 7.4) at 30.degree. C. before
substrate introduction ([S] = 40 .mu.M). Results are means .+-. SD
of three separate experiments.
[0235] While the presence of a polar group at the end of a shorter
chain reduced inhibition potency for both enzymes (see Table 1),
when the carboxylic acid was modified to esters with various
aliphatic groups (780, 784, 783, 781, 788, 800, 785, 801, 802, and
803) inhibition potencies were as high as that of the acid (687)
for both enzymes. Ethyl (792) and isopropyl (793) amide derivatives
were also potent inhibitors. Compounds with methyl-branched
aliphatic chains were also potent (785, 801, 802, 803, and 793).
Still further, larger bulky group such as 1-adamantylmethyl (786),
benzyl (804), 2-chlorobenzyl (782) or 2-naphthylmethyl (787)
provided good levels of activity, although slightly reduced
(1.5-3-fold) for both enzymes. These results identified an
additional site within the sEH inhibitor structure which allows the
inclusion of a third polar function, i.e. a tertiary
pharmacophore.
Example 16
[0236] This example provides assays and illustrates the inhibition
of mouse and human soluble epoxide hydrolases by compounds of the
invention having a both a secondary and tertiary pharmacophore that
is a carboxylic ester functional group.
[0237] Assays were conducted with the compounds indicated in Table
5, according to established protocols (see, above).
6TABLE 5 Inhibition of mouse and human sEH by
4-(3-adamantan-1-yl-ureido)butyryloxy compounds 32 Mouse sEH.sup.b
Human sEH.sup.b MP No. n T.sub.A.sup.a IC.sub.50 (.mu.M) IC.sub.50
(.mu.M) IC.sub.50 (.mu.M) IC.sub.50 (.mu.M) (.degree. C.) cLog
P.sup.c 857 1 8 0.05 .+-. 0.01 0.11 .+-. 0.01 0.39 .+-. 0.01 9 .+-.
2 123 0.98 .+-. 0.47 876 2 9 0.05 .+-. 0.01 0.63 .+-. 0.02 0.54
.+-. 0.05 9 .+-. 2 95-97 1.27 .+-. 0.47 858 3 10 0.05 .+-. 0.01
0.16 .+-. 0.01 0.12 .+-. 0.01 5.0 .+-. 0.1 89-91 1.55 .+-. 0.47 877
4 11 0.05 .+-. 0.01 0.10 .+-. 0.01 0.13 .+-. 0.01 1.5 .+-. 0.1
84-86 1.97 .+-. 0.47 878 6 13 0.05 .+-. 0.01 0.13 .+-. 0.01 0.12
.+-. 0.01 0.81 .+-. 0.01 65-67 2.81 .+-. 0.47 879 7 14 0.05 .+-.
0.01 0.16 .+-. 0.02 0.11 .+-. 0.01 0.72 .+-. 0.01 58-59 3.22 .+-.
.47 880 9 16 0.05 .+-. 0.01 0.26 .+-. 0.03 0.10 .+-. 0.01 0.68 .+-.
0.01 60-61 4.06 .+-. 0.47 881 10 17 0.05 .+-. 0.01 0.35 .+-. 0.05
0.10 .+-. 0.01 1.2 .+-. 0.1 54-55 4.48 .+-. 0.47 882 11 18 0.05
.+-. 0.01 0.63 .+-. 0.04 0.10 .+-. 0.01 1.8 .+-. 0.2 64-65 4.89
.+-. 0.47 .sup.aThe total number of atoms extending from the
carbonyl group of the primary urea pharmacophore, T.sub.A = n + 7
.sup.bEnzymes (0.12 .mu.M mouse sEH and 0.24 .mu.M human sEH) were
incubated with inhibitors for 5 min in sodium phosphate buffer (pH
7.4) at 30.degree. C. before substrate introduction ([S] = 40
.mu.M). Results are means .+-. SD of three separate experiments.
.sup.cLog P: calculated log P by Crippen's method by using CS
ChemDraw 6.0 version
[0238] As can be seen from the above table, in increasing the
distance between the secondary ester pharmacphore and the tertiary
ester pharmacaphore (549, 635, and 774) increased inhibition
potency for human sEHs but mouse EH activity remained relatively
consistent.
Example 17
[0239] This example illustrates the inhibition of mouse and human
soluble epoxide hydrolases by compounds of the invention (formula
(I)) having a secondary ether pharmacophore.
[0240] Adamantyl-urea compounds were prepared having a polar ether
group located various distances from the carbonyl of the primary
urea pharmacophore. These compounds were prepared to improve water
solubility of lipophilic sEH inhibitors (192 and 686). As can be
seen from the results in Table 6, the activity is relatively
consistent.
[0241] Assays were conducted with the compounds indicated in Table
6, according to established protocols (see, above).
7TABLE 6 Inhibition of mouse and human sEH by alkyl ether
derivatives IC.sub.50 (.mu.M).sup.a No. Structure Mouse sEH Human
sEH 866 33 0.06 .+-. 0.01 1.5 .+-. 0.2 867 34 0.05 .+-. 0.01 0.22
.+-. 0.02 868 35 0.05 .+-. 0.01 0.17 .+-. 0.01 869 36 0.05 .+-.
0.01 0.12 .+-. 0.01 870 37 0.05 .+-. 0.01 0.10 .+-. 0.01
[0242] As shown in the above table, these compounds functionalized
with a single ether group could be as active and potent as
non-functionalized lipophilic inhibitors (790, see Table 2 above)
for both murine and human enzymes. Adding a polar ether group to
these compounds increased their water solubility (compare compound
866-870 with 790). The distance from the carbonyl of the primary
urea pharmacophore to the secondary ether pharmacophore in compound
869 is about 8.9 .ANG. showing that the secondary pharmacophore may
be located about 7 .ANG. to about 9 .ANG. from the carbonyl of the
primary urea pharmacophore group.
Example 18
[0243] This example illustrates the inhibition of mouse and human
soluble epoxide hydrolases by compounds of the invention (formula
(I)) having a secondary ether or polyether pharmacophore, with
comparison to compounds further including a tertiary
pharmacophore.
[0244] Because compounds having a ether secondary pharmacophore
were found to be suitable inhibitors of both the mouse and human
enzymes, a variety of polyether derivatives were synthesized and
evaluated along with contributions of a tertiary pharmacophore. As
can be seen from the results in Table 7, the activity is relatively
consistent.
[0245] Assays were conducted with the compounds indicated in Table
7, according to established protocols (see, above).
8TABLE 7 Inhibition of mouse and human sEH by substituted ether
derivatives IC.sub.50 (.mu.M).sup.a No. Structure Mouse sEH Human
sEH 908 38 0.05 .+-. 0.01 0.16 .+-. 0.01 913 39 0.05 .+-. 0.01 0.10
.+-. 0.01 940 40 0.05 .+-. 0.01 0.10 .+-. 0.01 941 41 0.05 .+-.
0.01 0.10 .+-. 0.01 950 42 0.05 .+-. 0.01 0.10 .+-. 0.01 951 43
0.05 .+-. 0.01 0.10 .+-. 0.01 952 44 0.05 .+-. 0.01 0.10 .+-. 0.01
950-1 45 R = isopropyl, trifluoromethyl, imidazole, phenyl
[0246] Compounds with from two to four ether groups (908, 950, and
952) had inhibition potencies that were as high as
non-functionalized lipophilic inhibitors (790, see Table 2 above)
for both murine and human enzymes, as well as increased water
solubility and improved pharmacokinetics. Including a tertiary
pharmacophore were also potent inhibitors but did not further
increase their activity (compare compounds 913 and 940 with 908 and
compound 951 with 950).
Example 19
[0247] This example illustrates the inhibition of mouse and human
soluble epoxide hydrolases by compounds of the invention (formula
(I)) having an arylene or cycloalkylene linker.
[0248] Because compounds having an alkylene linker between the
primary and secondary pharmacophore were found to be excellent
inhibitors of both the mouse and human enzymes, a variety of
admantyl-urea derivatives having a phenyl or cyclohexyl spacer
between a primary urea and secondary pharmacophore were synthesized
and evaluated to examine the contributions of the linker.
[0249] Assays were conducted with the compounds indicated in Table
8, according to established protocols (see, above).
9TABLE 8 Inhibition of mouse and human sEH by substituted phenyl
and cyclohexyl derivatives IC.sub.50 (.mu.M).sup.a No. Structure
Mouse sEH Human sEH 859 46 0.05 .+-. 0.01 0.10 .+-. 0.01 860 47
0.05 .+-. 0.01 0.10 .+-. 0.01 861 48 0.05 .+-. 0.01 0.10 .+-. 0.01
863 49 0.05 .+-. 0.01 0.12 .+-. 0.01 904 50 0.05 .+-. 0.01 0.10
.+-. 0.01 909 51 0.05 .+-. 0.01 0.11 .+-. 0.01 909-1 52 n = 1, 2,
3, 4 909-2 53 n = 1-10
[0250] Compounds with alkylene and arylene linker groups (859 and
861) had inhibition potencies that were higher than compounds with
alkylene linkers (789, see Table 2 above, and 868, see Table 6
above) for both murine and human enzymes, independent of the
topography (compare compound 859 with 860 and compound 861 with
863) or type of the secondary pharmacophore (compare compounds 860
and 863 with 909).
Example 20
[0251] This example illustrates the inhibition of mouse soluble
epoxide hydrolases by compounds of the invention (formula (II))
having a secondary pharmacophore, and further including a mono
amino acid moiety. This example further illustrates the use of a
combinatorial approach toward compound preparation and
evaluation.
[0252] The utility of a combinatorial approach is illustrated by
using the butanoic acid derivatives from Table 9 and Table 10 to
form amide bonds with one or more natural or synthetic amino acids.
This approach rapidly leads to a large number of compounds that are
highly active and can be recognized by the intestinal peptide
uptake system. As shown above, polar groups could be incorporated
into one of the alkyl groups of the dialkyl-urea sEH inhibitors
without loss of activity, when placed at an appropriate distance
from the urea function. These modifications give the new inhibitors
better solubility and availability. To expand this assessment of
inhibitor structure refinement a semi-combinatorial approach was
used with amino acids. Because amino acids are simple bifunctional
synthons with a wide variety of side chains, mono and di-peptidic
derivatives of 4-(3-cyclohexyl-ureido)-butyric acid 625 were
synthesized. This parent compound (acid 625) was selected due to
its low inhibition of sEH. Furthermore, to make the peptidic bond,
reactants were used, such as 1-ethyl-3-(3-(dimethylamino)-propyl)
carbodiimide, that themselves or their reaction product, such as
1-ethyl-3-(3-dimethylamino)- -propyl urea, are not inhibitors of
sEH. Therefore, any inhibition observed was derived from the
targeted peptidic derivatives. This approach allows the preparation
of compounds on an analytical scale (10 .mu.mol) without
purification of the products. The presence of the desired products
was confirmed by LC-MS and the ratio of the LC-MS peak of the
desire compounds with the starting material was used to estimate
the reaction yield. Because each inhibitor presents a single
carboxyl group for negative mode ionization, the estimation of
yield is reasonably quantitative.
[0253] Syntheses of amino acid derivatives of
4-(3-cyclohexyl-ureido)-buty- ric acid (632) were performed at
analytical scale. Reactions were performed in 2 mL glass vials for
each amino acid. To 100 mL of a solution of 632 in DMF at 100 mM
(10 .mu.mol), 200 .mu.L of a solution of
1-ethyl-3-(3-(dimethylamino)-propyl) carbodiimide in DMF at 100 mM
(20 .mu.mol) was added. After 15 minutes reaction at room
temperature, 400 .mu.L of amino acid methyl ester solution at 100
mM (40 .mu.mol) in 90:10 DMF:1 N NaOH was added. The reaction was
strongly mixed at 40.degree. C. overnight. Three hundred
microliters of 1 N NaOH was then added and allowed to react
overnight at 40.degree. C. Product formation was confirmed for each
amino acid using electrospray-ionization mass spectrometry
(ESI-MS). Reaction solutions were used directly for inhibitor
potency measurement with a theoretical concentration of 10 mM.
[0254] Assays were conducted with the compounds indicated in Table
9, according to established protocols (see, above).
10TABLE 9 Inhibition of mouse sEH by mono-amino acid derivatives of
4-(3-cyclo- hexyl-ureido)-butyric acid (632). 54 Mouse sEH MS m/z
(Da) IC.sub.50 R: M.sub.th (M .+-. H).sup.+- (.mu.M) OH 228.1
Control >50 Alanine 299.2 229.5 >50 Arginine 384.3 385.8
>50 Aspartate 344.2 344.7 >50 Cysteine 331.2 332.8 >50
Glutamate 357.2 358.7 >50 Glycine 285.2 286.6 >50 Histidine
365.2 366.6 1.9 .+-. 0.2 Isoleucine 341.2 342.7 18 .+-. 3 Leucine
341.2 342.7 >50 Lysine 356.3 357.7 2.2 .+-. 0.5 Methionine 359.2
360.7 >50 Phenylalanine 375.2 376.7 5.6 .+-. 0.4 Proline 325.2
326.7 >50 Serine 315.2 316.7 >50 Threonine 329.2 330.7 >50
Tryptophane 414.2 415.8 1.6 .+-. 0.2 Tyrosine 391.2 392.8 0.59 .+-.
0.03 Valine 327.2 328.7 >50 Results are means .+-. SD of three
separate experiments.
[0255] Significant improvement of the inhibition potency was
observed for the aromatic derivatives (phenylalanine, tryptophane
and tyrosine), histidine and lysine. Again, without intending to be
bound by theory, it is believed that the specificity of the
interaction of the enzyme with the five peptidic inhibitors listed
results from specific pi-pi stacking between tryptophane 334
(Trp.sup.334) located in close proximity to the secondary
pharmacophore, and the aromatic moieties with four of the five
amino acids above. This interaction should alter the fluorescence
spectrum of the enzyme. For the lysine derivative, because reaction
can occur with the side chain amino group, the resulting product
could resemble the alkyl derivatives synthesized above with the
acid function playing the role of the third pharmacophore.
Example 21
[0256] This example illustrates the inhibition of mouse soluble
epoxide hydrolases by compounds of the invention (formula (II))
having a secondary pharmacophore, and further including a dipeptide
moiety.
[0257] Compounds in the amino acid derivative series, 625-Tyr,
showed an inhibition potency in the hundreds of nanomolar range,
prompting the evaluation of the effect of adding a second amino
acid.
[0258] In a manner similar to that described above, syntheses of
amino acid derivatives of
2-[4-(3-Cyclohexyl-ureido)-butyrylamino]-3-(4-hydroxy-
-phenyl)-propionic acid (632-Tyr) that are examples of dipetide
derivatives of 632 were done on an analytical scale. Synthesis was
performed as described above for the derivatives of 632, simply
substituting this compound by 632-Tyr. Product formation was
confirmed by ESI-MS.
[0259] Assays were conducted with the compounds indicated in Table
10, according to established protocols (see, above).
11TABLE 10 Inhibition of mouse sEH by mono-amino acid derivatives
of 4-(3-cyclo- hexyl-ureido)-butyryl-tyrosine. 55 MS m/z (Da) Mouse
sEH (M - H).sup.-: IC.sub.50 IC.sub.90 R: M.sub.th (M - H).sup.-
m/z.sub.390.2 (.mu.M) OH 391.5 390.2 Control 0.50 30 Alanine 462.6
461.4 3 0.22 25 Arginine 547.7 546.2 1 0.05 4.0 Aspartate 506.6
505.3 1 0.05 1.6 Glycine 448.5 447.3 1 0.06 6.5 Isoleucine 504.6
503.2 3 0.07 12.5 Leucine 504.6 503.5 6 0.07 16.0 Lysine 519.7
518.4 0.5 0.05 6.3 Methionine 522.8 521.2 2 0.05 2.0 Phenylalanine
538.7 537.5 1 0.05 1.6 Proline 488.6 487.4 1 0.06 6.3 Serine 478.6
477.3 1 0.07 3.3 Threonine 492.6 491.3 4 0.12 12.5 Tryptophane
577.7 576.4 1 0.05 1.0 Tyrosine 554.7 553.4 5 0.05 2.5 Valine 490.6
489.4 2 0.05 3.1 Results are means .+-. SD of three separate
experiments.
[0260] Significant improvement of inhibition potency was observed
for almost all the derivatives tested except for alanine,
isoleucine, leucine and threonine. These results indicate that the
enzyme has a narrower specificity close to the catalytic center
than toward the end of the active site tunnel. The inhibition
potency found for the best dipeptidic derivatives are similar to
those found for the corresponding alkyl inhibitors (see, C.
Morisseau, et al., Biochem. Pharm. 63: 1599-1608 (2002)),
indicating that such peptide-mimics are excellent inhibitors of
sEH. Because of the presence of the amino acid derivatives in their
structure, these compounds have excellent water solubility.
Furthermore, because of the presence of active small peptide
transport system in the gut, the dipeptidic urea derivatives will
be absorbed in the gut by such systems as observed for several
peptide derivative drugs (see, E. Walter, et al., Pharm. Res. 12:
360-365 (1995) and K. Watanabe, et al., Biol. Pharm. Bull. 25:
1345-1350 (2002)), giving these compounds excellent
bioavailability.
Example 22
[0261] This example provides studies directed to the metabolic
stability of certain inhibitors of sEH.
[0262] To evaluate the metabolic stability of these inhibitors, the
microsomal and NADPH dependent metabolism of a number of potent sEH
inhibitors was evaluated. The rates of metabolism among the
compounds varied dramatically, however the appearance of an
omega-terminal acid was observed for all inhibitors containing
n-alkane substitutions. When tested, the potent alkyl derivatives
(e.g. 686) are rapidly metabolized in microsomal preparations by
P450 dependents processes (see FIG. 6), while the omega acid
analogs (e.g. 687) were stable (see FIG. 7). The first step in the
metabolic transformation of the n-alkyl to n-alkanoic acid
derivatives is an NAPDH dependent process carried out by cytochrome
P450 dependent omega hydroxylation in rodent and human hepatic
tissue preparations (see FIG. 8). The metabolites identified along
this metabolic route are provided in Table 11. When in vivo
metabolism was evaluated, evidence for the beta-oxidation of the
alkanoic acid derivatives was also found (see FIG. 9). Together,
these data indicate that P450 omega hydroxylation can result in the
rapid iii vivo metabolic inactivation and excretion of these
inhibitors.
12TABLE 11 Structure of metabolites formed from compound 686. 56 No
X Y 686 H CH.sub.3 686-M1 H CH.sub.2OH 686-M2 H CHO 687 H COOH
686-M3 OH CH.sub.2OH
Example 23
[0263] This example provides the structures of compounds of the
invention designed to slow esterase dependent inactivation, block
beta-oxidation, block cytochrome P450 dependent omega
hydroxylation, or inhibit cytochrome P450 omega hydrolase.
[0264] Beta-oxidation can be blocked in a variety of ways, for
example with an alpha halogen or alpha branched alkyl group (806),
cyclopropane (807) or aromatic groups (808), or by replacing the
acid or ester functional groups with alternate functionalities,
such as sulfonamides (809 and 810), which mimic ester and acid
functional groups yet provide metabolic stability in vivo.
Similarly in pharmacology heterocyclic groups are used for hydrogen
bond donors and acceptors to mimic carboxylic acids and esters
(811). In addition, P450 omega hydroxylation can be blocked by
including acetylene (812), trifluoromethyl (813), or aryl (814)
groups at the terminus of the alkyl chain. This series of
inhibitors also illustrates that with both the secondary and
tertiary pharmacophore, replacement can be made for the carbonyl
with other functionalities as hydrogen bond donors and
acceptors.
13TABLE 12 Structures of sEH inhibitors designed to prevent
beta-oxidation and P450 omega hydroxylation. No. Structure Action
805 57 Retard esterase dependent inactivation 806 58 Block
beta-oxidation 807 59 Block beta-oxidation 808 60 Block
beta-oxidation 809 61 Block beta-oxidation 810 62 Block
beta-oxidation 811 63 Block beta-oxidation Block P450 dependent
omega hydroxylation 812 64 Block beta-oxidation Inhibit P450 omega
hydroxylase 813 65 Block P450 dependent omega hydroxylation 814 66
Block P450 dependent omega hydroxylation R.sub.1 and R.sub.2 =
alkyl or aryl group, R.sub.3 = alkyl group (ethyl or butyl).
Example 24
[0265] This example illustrates a comparison of cyclohexyl and
adamantyl groups in stability and solubility.
[0266] Another consistent observation during the metabolism studies
was that the adamantyl substituent (both 192 and 686 substituted)
provided compounds having improved stability (see FIG. 6).
Surprisingly the adamantyl compounds were approximately 2.times.
more soluble than the corresponding cyclohexyl derivatives (772 vs.
789, 791 vs. 790, and 297 vs. 686 see Table 2 for structures).
Surprisingly, the LC-MS/MS analyses producing collision induced
dissociation of compounds containing the adamantyl substituent
provided extremely high abundance ions, which dramatically enhanced
the analytical sensitivity for these inhibitors (see Table 13
below). This enhanced sensitivity is a distinct advantage for drug
metabolism studies using either in vivo or in vitro systems.
Moreover, adamantane represents the smallest diamond nucleus and
the adamantyl substituents not only yield compounds of improved
metabolic stability and pharmacokinetic parameters, but also
compounds that are very easy to detect.
14TABLE 13 Calibration curves and detections limit (DL) of
inhibitors analyzed by HPLC-MS/MS. No. Structure Calibration curve
r.sup.2 DL (ng/mL) 686 67 y = 0.067x - 0.003 0.999 0.05 687 68 y =
0.099x - 0.274 0.999 0.05 297 69 y = 0.024x + 0.091 0.999 0.50 425
70 y = 0.009x - 0.003 0.999 0.50
Example 25
[0267] This example provides the pharmacokinetic studies carried
out using compounds of the present invention.
[0268] The pharmacokinetic properties of some of the most potent
sEH inhibitors was evaluated following oral gavage in mice. As
noted above, the use of 1-adamantyl urea inhibitors afforded
exquisite sensitivity, allowing the determination of the determined
pharmacokinetic parameters from serial blood samples collected from
individual mice (see Table 14).
[0269] Animals. Male Swiss Webster mice, 6 weeks-old, were obtained
from Charles River (CA, USA). After 1-2 week acclimation period,
healthy animals were assigned to study groups based on body-weight
stratified randomization procedure. The body weight of animals used
in all the experiments ranged from 28 g to 38 g. Mice were
maintained on a 12 h light/12 h dark cycle under controlled
temperature and humidity conditions, and food and water available
ad libid um.
[0270] Administration and measurement. Pharmacokinetic studies in
mice used a 5 mg/kg dose of sEH inhibitors dissolved in corn oil
and 4% DMSO administered orally. Serial tail bled blood samples
(5-10 .mu.L) were collected in heparinized 1.5 mL tubes at various
time points (0.5, 1, 2, 3, 4, 5, 6, and 24 hr) after the
administration for measuring parent compounds and their metabolites
by using LC-MS/MS: a Waters 2790 liquid chromatograph equipped with
a 30.times.2.1 mm 3 .mu.m C18 Xterra.TM. column (Waters) and a
Micromass Quattro Ultima triple quadrupole tandem mass spectrometer
(Micromass, Manchester, UK). To the collected samples were added
100 .mu.L of distilled water, 25 .mu.L of internal standard (500
ng/mL; 1-cyclohexyl-3-tetradecylurea, CTU), and 500 .mu.L of ethyl
acetate. Then the samples were centrifuged at 6000 rpm for 5 min,
and the ethyl acetate layer was dried under nitrogen. The residue
was reconstituted in 25 mL of methanol, and aliquots (5 .mu.L) were
injected onto the LC-MS/MS system.
[0271] Pharmacokinetic studies using a human subject employed doses
of 0.1-1.0 mg/kg of sEH inhibitors (800) or a 0.3 mg/kg dose of 687
dissolved in olive oil administered orally. Serial bled blood
samples (3-50 .mu.L) were collected from finger tips into 50 .mu.L
heparinized capillary tube at various time points (0.5, 1, 2, 4, 6,
12 and 24 hr) after administration. These samples were used to
measure parent compounds and their metabolites using LC-MS/MS as
described above for experiments with mice. Blood samples were added
400 .mu.L of distilled water and 25 .mu.L of internal standard (500
ng/mL CTU), and vortexed. The blood samples were then extracted
with 500 .mu.L of ethyl acetate twice and the ethyl acetate layer
was dried under nitrogen. The residue was reconstituted in 25 .mu.L
of methanol, and aliquots (10 .mu.L) were injected onto the
LC-MS/MS system as described above. Biological end points came from
clinical chemistry samples run at The University of California
Davis Clinical Laboratory and a series of 6 inflammatory markers
including C reactive protein were run blind at the University of
California Davis Department of Nephrology.
[0272] Analysis. Pharmacokinetics analysis was performed using
SigmaPlot software system (SPSS science, Chicago, Ill.). A
one-compartment model was used for blood concentration-time
profiles for the oral gavage dosing and fits to the following
equation (see, Gibson, G. G. and Skett, P.: INTRODUCTION TO DRUG
METABOLISM, SECOND ED., Chapman and Hall, New York 1994,
199-210):
C=ae.sup.-bt
[0273] The half-life (t.sub.1/2) for the elimination phase was
calculated by the following equation:
t.sub.1/2=0.693/b
[0274] The area under the concentration (AUC) was calculated by the
following equation:
AUC=a/b
[0275] Where:
[0276] C=the total blood concentration at time t
[0277] a=the extrapolated zero intercept
[0278] b=the apparent first-order elimination rate constant
15TABLE 14 Pharmacokinetic parameters of
1-(1-adamantyl)-3-(11-alkylated undecyl)ureas.sup.a 71
C.sub.max.sup.b tC.sub.max.sup.c AUC.sup.d t.sub.1/2.sup.e No. R
(ng/mL) (hr) (ng .multidot. hr/mL) (hr) 686 CH.sub.3 19.8 1 47 2.3
687 72 26.9 0.5 87 2.3 780 73 144.3 0.5 168 1.3 784 74 101.7 1 198
1.5 783 75 62.6 1 137 1.6 781 76 45.3 1 111 2 788 77 39.6 1 130 2.9
800 78 39.5 1 96 1.5 785 79 29.6 2 84 1.9 801 80 5.3 2 10 2.1 802
81 13.1 2 47 3.8 803 82 42.9 2 110 2.9 804 83 42.3 1 141 3 .sup.a5
mg/kg dosing of compounds were administered orally to male Swill
Webster mice, .sup.bmaximum concentration, .sup.ctime of maximum
concentration, .sup.darea under concentration, .sup.ehalf-life.
[0279] The ester compounds were generally hydrolyzed to the acid
compound (687) when administered orally. As a result, the maximum
concentration described in Table 14 represents the maximum
concentration of 687 in the blood. An example of the time course of
free acid appearance is shown in FIG. 10. When compound 687 was
administered orally, it reached the maximum concentration (2-fold
higher than 686) in 30 min, while compound 686 reached its maximum
concentration in 2 hr (see Table 14). Furthermore, the area under
the curve (AUC) for 687 was 2-fold higher, indicating an
improvement in oral bioavailability. The maximum concentrations of
primary esters (780, 784, 783, 781, 788, 800, 803 and 804) esters
were 1.5-5-fold higher than 687, and the AUC increased 1.2-2.3-fold
for the ester compounds indicating higher bioavailabilities. On the
other hand, secondary esters (785 and 802) showed similar maximum
concentrations and bioavailabilities to those of 687 in mice, while
the tertiary ester (801) displayed a 4-8-fold decrease in maximum
concentration and bioavailability. Accordingly, the alkylation of a
potent acid inhibitor (687) to form primary esters improves the
oral availability of these inhibitors. Following these results, a
preliminary investigation of the pharmacokinetics of compounds 687
and 800 in a human male was performed (see FIG. 11). The findings
suggest that in general rodents provide a good model for pre-human
trials.
Example 26
[0280] This example provides a table of structures for compounds of
the invention having all three pharmacophores present.
16TABLE 15 Structures of sEH inhibitors containing the primary,
secondary, and tertiary pharmacophores. No. STRUCTURE 1100 84 1110
85 1120 86 1130 87 1140 88 1150 89 1160 90 1170 91 1180 92 1190 93
1200 94 1210 95 Z = O or NH, R = alkyl group (ethyl or butyl)
[0281] The primary urea pharmacophore can be varied (compound #)
with amide or carbamate functionality to improve physical
properties of sEH inhibitors as well: A and B=CH.sub.2, O, or NH,
R.sub.2 and R.sub.3=H or methyl group, Y=CH.sub.2, O, or NH. The
carbonyls can be replaced by heterocyclic or acyclic hydrogen bond
acceptors and donators as shown in Table 12.
Example 27
[0282] This example shows the effect of sEH inhibitors on serum and
urinary oxylipin profiles in rodents.
[0283] The described soluble epoxide inhibitors have been shown to
modulate the relative abundance and amounts of epoxy and dihydroxy
fatty acids formed in treated animals. One such example of this
alteration is provided in FIG. 14. In this example, hypertension
was induced in one group of Sprague-Dawley rats by the infusion of
angiotensin II (ANGII). A second group of rats received both ANGII
and a subcutaneous injection of the model sEH inhibitor
1-adamantyl-3-(dodecanoic acid) urea (i.e. compound 687). Urine
samples were collected for 24 hr post exposure to compound 687 and
analyzed for linoleate (Panel A) and arachidonate (Panel B) derived
epoxides and diols using LC/MS/MS. As shown in FIG. 14, ANGII
exposure decreased the concentration of both linoleate (EpOMEs) and
arachidonate (EETs) derived epoxides and increased arachidonate
derived diols (DHETs) but not linoleate derived diols (DHOMEs). In
the case of both lipid classes, treating animals with compound 687
resulted in an increase in urinary epoxides, as well as a decrease
in diol concentrations.
Example 28
[0284] This example shows the effect of AUDA butyl ester (800) on
blood urea nitrogen and C reactive protein in a patient with
ESRD.
17TABLE 16 Effect of AUDA butyl ester (800) on blood urea nitrogen
and C reactive protein in patient with end stage renal disease
(ESRD).* ESRD PARAMETER NORMAL RANGE ESRD +AUDA Sodium 135-145
mEq/L 135 137 Potassium 3.3-5.0 mEq/L 5.8 4.9 Urea nitrogen 8-22
mg/dL 53 40 Creatinine 0.5-1.3 mg/dL 5.0 4.9 Glucose 70-110 mg/dL
84 89 Calcium 8.6-10.5 mg/dL 8.3 8.0 Albumin 3.4-4.8 g/dL 4.0 4.1
C-Reactive Protein mg/dL 0.59-0.62 <0.01 (CRP){circumflex over (
)} Systolic <130 126+/-4.9 114+/14.9 Diastolic <80 81+/-2.0
76+/-3.9 *ESRD defined as 14 mL/min surface corrected creatinine
clearance. Normal is 70-130. #The total dose of AUDA butyl ester is
0.5 mg/Kg-day taken in 3 equal doses of 2 ml olive oil at 8 hour
intervals for 6 days prior to blood test. Normal values for C
Reactive Protein are debated. Data indicated range of two samples
for both trials. Limit of detection is 0.01. @The BUN averaged
47.2+/-3.8 (n = 13) for 30 months prior to the text and increased
steadily over the 30 month period. +Resting blood pressure taken
multiple times 2 weeks before (n = 6) and during the drug trial (n
= 10).
Example 29
[0285] This example illustrates the effect of certain compounds of
the invention on members of the arachidonic acid cascade.
[0286] For epoxy fatty acid hydrolysis, the soluble epoxide
hydrolase prefers substrates with epoxide moieties that are more
distant from the carboxyl terminal. Specifically the substrate
preference decreases in the order of
14,15-EET>11,12-EET>8,9-EET>>>5,6-EET for the
epoxides of arachidonic acid. Independently, the relative substrate
turnover of the epoxy arachidonates were calculated at 0.1:8.1:14.3
when a 1:1:2 mixture of 8,9-, 11,12-, and 14,15-EET fatty acid was
hydrolyzed to 30% by rat renal cortex cytosol. By considering the
primary pharmacophore of the urea to be a transition-state analog
of epoxide hydrolysis, preferred inhibitors have now been developed
which incorporate long aliphatic acids. These compounds are better
substrate and transition state mimics than those incorporating
shorter aliphatic acids. Accordingly, optimal soluble epoxide
hydrolase inhibitors can be obtained by producing compounds with
aliphatic acid substituents (i.e. a tertiary pharmacophore) which
are separated from the primary pharmacophore by an equivalent
distance as the terminal acid is separated from the epoxide in
optimal substrates. Within the enzyme active site, epoxy fatty
acids have been predicted to exist in an extended or pseudo-linear
confirmation. Therefore, both the epoxy fatty acids and the
aliphatic acid containing urea structures were approximated as two
dimensional linear representations and measurements were made on
each species. The critical measurements taken were distances (in
angstroms) from the carboxylate hydroxyl to the urea carbonyl and
the urea nitrogens.
[0287] The distance of the carboxylate to the urea function of
1-cyclohexyl-3-octanoic acid is similar to the distance of the
epoxide to the carboxylate in 8,9-EET. Therefore, the calculated
inhibitor potencies were normalized to this compound, resulting in
a ranked inhibitor potency. We then correlated epoxide to carbonyl
distance with respect to relative substrate turnover rate to
establish a correlative regression. By plotting the relative
inhibitor potency on this graph we find that the distances of the
carboxyl to the N'-nitrogen correlate best with the carboxyl to
epoxide oxygen distance. These data further highlight the
similarity between inhibitor and substrate interaction with the
soluble epoxide hydrolase.
[0288] Programs:
[0289] All structures were drawn and exported as MDL MOL files
using ACD/ChemSketch v 4.55 (May 6, 2000) Advanced Chemistry
Development Inc., Toronto, Ontario, Canada). Distance measurements
were made on the corresponding MOL file image using ACD/3D v 4.52
(Apr. 10, 2000). Structural optimizations were not used.
[0290] Table 17 provides results for this analysis (see also, FIG.
13).
18TABLE 17 Linear distances between the primary and secondary
pharmacophores of a series of sEH inhibitors and their rank order
potencies with the mouse (MsEH) and human sEHs (HsEH) are shown in
comparison with the epoxide to free acid distances and relative
turnover rate of the four arachidonic acid epoxides with the rat
sEH. sEH Inhibitors Endogenous sEH Substrates 96 N'to COOH (.ANG.)
MsEH HsEH Substrates O.sub.Ep to COOH (.ANG.) Relative EET Turnover
--(CH.sub.2).sub.5COOH 9.6 0.01 0.01 5,6-EET 8 0.1
--(CH.sub.2).sub.6COOH 10.9 0.1 0.1 --(CH.sub.2).sub.8COOH 12.4 1 1
8,9-EET 12.1 1 --(CH.sub.2).sub.11COOH 16.5 11 4.8 11,12-EET 16.4
8.1 --(CH.sub.2).sub.12COOH 17.8 10 10 14,15-EET 20.7 14.3
Example 30
[0291] The examples illustrates the effectiveness of selected
compounds for the treatment of Raynaud syndrome.
[0292] The experimental design involved preparing the Vanicream
solutions with ethanol with or without active compound, then
covering the syringe barrels with aluminum foil. The compounds were
applied in a bind fashion approximately 20 minutes before exposure
and then the hands were exposed to cold for approximately 30
minutes and the results recorded. The following day the results
were decoded. Treatments (left or right index finger) were random.
Controls included prescription nitroglycerine cream (had a major
effect in turning treated finger pink) and commercial lanoline
based L-arginine hand warming cream (probably contains
capsaicin)(had no effect on parameters listed below). The test
compounds were dissolved in ethanol at a concentration of 10 mg/mL
and this in turn mixed with commercial Vanicream at a 10:1
concentration to give 1 mg/mL final concentration of active
ingredient in the Vanicream/ethanol mixture. Approximately 100
.mu.L of cream (+/-sEH inhibitor) were applied to a single finger.
The first two columns indicate that over a range of exposure
conditions the results from the left and right hind were similar.
The third and fourth columns indicate that the sEH inhibitor CDU
reduces severity of Raynaud's symptoms and the fifth and sixth
columns indicate the same conclusion for ADU. Since the experiment
was run blind, the left and right index fingers were treated in a
random fashion. For convenience the treatments are shown on the
right in each case.
[0293] The scale used for the study is shown below:
[0294] 0--Finger feels warm when touched to neck
[0295] 1--Finger feels neutral when touched to neck
[0296] 2--Finger feels cool when touched to neck, red under
fingernail, bleaches and turns back red when one presses on the
nail
[0297] 2.5--Same as above but remains bleached under nail under
pressure and reperfusion
[0298] 3--Finger white to first joint, when warmed it turns pink
without going through blue phase
[0299] 4--Finger white to second joint
[0300] 5--Finger turns blue (note finger turns white, then blue and
with longer exposure turns white again, giving an almost china
plate appearance)
[0301] 6--Finger white to base. Turns blue before turning red with
warming.
19TABLE 18 Effect of CDU & ADU on patient with Raynaud
syndrome. No No CDU ADU treatment treatment Control (297) Control
(686) 2 2 6 2 6 3 2 2.5 5 2 4 3 0 1 3 2 4 2 0 0 1 1 5 5 1 1 4 2 3 3
1 1 3 2 3 2 1 1 6 2 3 3 1 1 5 3 3 2.5 1 1 6 2 4 2 0 1 5 2 0 1 6 2 1
1 6 2 2 2 6 2 0 0 5 2 4 2 6 2 4 4 5 2 4 4 5 2 4 4 5 2 2 2 6 6 4 4 4
4 3 3 4 4 1 1 4 4 1 1 3 3 4 4 4 4 4 3 2 2 4 4 4 3 2 2 4 4 2 2 2 2 4
4 6 6 6 5 6 5
[0302]
Sequence CWU 1
1
4 1 555 PRT Homo sapiens human soluble epoxide hydrolase (sEH) 1
Met Thr Leu Arg Ala Ala Val Phe Asp Leu Asp Gly Val Leu Ala Leu 1 5
10 15 Pro Ala Val Phe Gly Val Leu Gly Arg Thr Glu Glu Ala Leu Ala
Leu 20 25 30 Pro Arg Gly Leu Leu Asn Asp Ala Phe Gln Lys Gly Gly
Pro Glu Gly 35 40 45 Ala Thr Thr Arg Leu Met Lys Gly Glu Ile Thr
Leu Ser Gln Trp Ile 50 55 60 Pro Leu Met Glu Glu Asn Cys Arg Lys
Cys Ser Glu Thr Ala Lys Val 65 70 75 80 Cys Leu Pro Lys Asn Phe Ser
Ile Lys Glu Ile Phe Asp Lys Ala Ile 85 90 95 Ser Ala Arg Lys Ile
Asn Arg Pro Met Leu Gln Ala Ala Leu Met Leu 100 105 110 Arg Lys Lys
Gly Phe Thr Thr Ala Ile Leu Thr Asn Thr Trp Leu Asp 115 120 125 Asp
Arg Ala Glu Arg Asp Gly Leu Ala Gln Leu Met Cys Glu Leu Lys 130 135
140 Met His Phe Asp Phe Leu Ile Glu Ser Cys Gln Val Gly Met Val Lys
145 150 155 160 Pro Glu Pro Gln Ile Tyr Lys Phe Leu Leu Asp Thr Leu
Lys Ala Ser 165 170 175 Pro Ser Glu Val Val Phe Leu Asp Asp Ile Gly
Ala Asn Leu Lys Pro 180 185 190 Ala Arg Asp Leu Gly Met Val Thr Ile
Leu Val Gln Asp Thr Asp Thr 195 200 205 Ala Leu Lys Glu Leu Glu Lys
Val Thr Gly Ile Gln Leu Leu Asn Thr 210 215 220 Pro Ala Pro Leu Pro
Thr Ser Cys Asn Pro Ser Asp Met Ser His Gly 225 230 235 240 Tyr Val
Thr Val Lys Pro Arg Val Arg Leu His Phe Val Glu Leu Gly 245 250 255
Ser Gly Pro Ala Val Cys Leu Cys His Gly Phe Pro Glu Ser Trp Tyr 260
265 270 Ser Trp Arg Tyr Gln Ile Pro Ala Leu Ala Gln Ala Gly Tyr Arg
Val 275 280 285 Leu Ala Met Asp Met Lys Gly Tyr Gly Glu Ser Ser Ala
Pro Pro Glu 290 295 300 Ile Glu Glu Tyr Cys Met Glu Val Leu Cys Lys
Glu Met Val Thr Phe 305 310 315 320 Leu Asp Lys Leu Gly Leu Ser Gln
Ala Val Phe Ile Gly His Asp Trp 325 330 335 Gly Gly Met Leu Val Trp
Tyr Met Ala Leu Phe Tyr Pro Glu Arg Val 340 345 350 Arg Ala Val Ala
Ser Leu Asn Thr Pro Phe Ile Pro Ala Asn Pro Asn 355 360 365 Met Ser
Pro Leu Glu Ser Ile Lys Ala Asn Pro Val Phe Asp Tyr Gln 370 375 380
Leu Tyr Phe Gln Glu Pro Gly Val Ala Glu Ala Glu Leu Glu Gln Asn 385
390 395 400 Leu Ser Arg Thr Phe Lys Ser Leu Phe Arg Ala Ser Asp Glu
Ser Val 405 410 415 Leu Ser Met His Lys Val Cys Glu Ala Gly Gly Leu
Phe Val Asn Ser 420 425 430 Pro Glu Glu Pro Ser Leu Ser Arg Met Val
Thr Glu Glu Glu Ile Gln 435 440 445 Phe Tyr Val Gln Gln Phe Lys Lys
Ser Gly Phe Arg Gly Pro Leu Asn 450 455 460 Trp Tyr Arg Asn Met Glu
Arg Asn Trp Lys Trp Ala Cys Lys Ser Leu 465 470 475 480 Gly Arg Lys
Ile Leu Ile Pro Ala Leu Met Val Thr Ala Glu Lys Asp 485 490 495 Phe
Val Leu Val Pro Gln Met Ser Gln His Met Glu Asp Trp Ile Pro 500 505
510 His Leu Lys Arg Gly His Ile Glu Asp Cys Gly His Trp Thr Gln Met
515 520 525 Asp Lys Pro Thr Glu Val Asn Gln Ile Leu Ile Lys Trp Leu
Asp Ser 530 535 540 Asp Ala Arg Asn Pro Pro Val Val Ser Lys Met 545
550 555 2 554 PRT Rattus norvegicus rat soluble epoxide hydrolase
(sEH) 2 Met Ala Leu Arg Val Ala Ala Phe Asp Leu Asp Gly Val Leu Ala
Leu 1 5 10 15 Pro Ser Ile Ala Gly Val Leu Arg His Thr Glu Glu Ala
Leu Ala Leu 20 25 30 Pro Arg Asp Phe Leu Leu Gly Ala Phe Gln Met
Lys Phe Pro Glu Gly 35 40 45 Pro Thr Glu Gln Leu Met Lys Gly Lys
Ile Thr Phe Ser Gln Trp Val 50 55 60 Pro Leu Met Asp Glu Ser Cys
Arg Lys Ser Ser Lys Ala Cys Gly Ala 65 70 75 80 Ser Leu Pro Glu Asn
Phe Ser Ile Ser Glu Ile Phe Ser Gln Ala Met 85 90 95 Ala Ala Arg
Ser Ile Asn Arg Pro Met Leu Gln Ala Ala Ala Ala Leu 100 105 110 Lys
Lys Lys Gly Phe Thr Thr Cys Ile Val Thr Asn Asn Trp Leu Asp 115 120
125 Asp Ser Asp Lys Arg Asp Ile Leu Ala Gln Met Met Cys Glu Leu Ser
130 135 140 Gln His Phe Asp Phe Leu Ile Glu Ser Cys Gln Val Gly Met
Ile Lys 145 150 155 160 Pro Glu Pro Gln Ile Tyr Lys Phe Val Leu Asp
Thr Leu Lys Ala Lys 165 170 175 Pro Asn Glu Val Val Phe Leu Asp Asp
Phe Gly Ser Asn Leu Lys Pro 180 185 190 Ala Arg Asp Met Gly Met Val
Thr Ile Leu Val Arg Asp Thr Ala Ser 195 200 205 Ala Leu Arg Glu Leu
Glu Lys Val Thr Gly Thr Gln Phe Pro Glu Ala 210 215 220 Pro Leu Pro
Val Pro Cys Ser Pro Asn Asp Val Ser His Gly Tyr Val 225 230 235 240
Thr Val Lys Pro Gly Ile Arg Leu His Phe Val Glu Met Gly Ser Gly 245
250 255 Pro Ala Ile Cys Leu Cys His Gly Phe Pro Glu Ser Trp Phe Ser
Trp 260 265 270 Arg Tyr Gln Ile Pro Ala Leu Ala Gln Ala Gly Phe Arg
Val Leu Ala 275 280 285 Ile Asp Met Lys Gly Tyr Gly Asp Ser Ser Ser
Pro Pro Glu Ile Glu 290 295 300 Glu Tyr Ala Met Glu Leu Leu Cys Glu
Glu Met Val Thr Phe Leu Asn 305 310 315 320 Lys Leu Gly Ile Pro Gln
Ala Val Phe Ile Gly His Asp Trp Ala Gly 325 330 335 Val Leu Val Trp
Asn Met Ala Leu Phe His Pro Glu Arg Val Arg Ala 340 345 350 Val Ala
Ser Leu Asn Thr Pro Leu Met Pro Pro Asn Pro Glu Val Ser 355 360 365
Pro Met Glu Val Ile Arg Ser Ile Pro Val Phe Asn Tyr Gln Leu Tyr 370
375 380 Phe Gln Glu Pro Gly Val Ala Glu Ala Glu Leu Glu Lys Asn Met
Ser 385 390 395 400 Arg Thr Phe Lys Ser Phe Phe Arg Thr Ser Asp Asp
Met Gly Leu Leu 405 410 415 Thr Val Asn Lys Ala Thr Glu Met Gly Gly
Ile Leu Val Gly Thr Pro 420 425 430 Glu Asp Pro Lys Val Ser Lys Ile
Thr Thr Glu Glu Glu Ile Glu Tyr 435 440 445 Tyr Ile Gln Gln Phe Lys
Lys Ser Gly Phe Arg Gly Pro Leu Asn Trp 450 455 460 Tyr Arg Asn Thr
Glu Arg Asn Trp Lys Trp Ser Cys Lys Ala Leu Gly 465 470 475 480 Arg
Lys Ile Leu Val Pro Ala Leu Met Val Thr Ala Glu Lys Asp Ile 485 490
495 Val Leu Arg Pro Glu Met Ser Lys Asn Met Glu Asn Trp Ile Pro Phe
500 505 510 Leu Lys Arg Gly His Ile Glu Asp Cys Gly His Trp Thr Gln
Ile Glu 515 520 525 Lys Pro Ala Glu Val Asn Gln Ile Leu Ile Lys Trp
Leu Lys Thr Glu 530 535 540 Ile Gln Asn Pro Ser Val Thr Ser Lys Ile
545 550 3 554 PRT Mus musculus mouse liver soluble epoxide
hydrolase (sEH) 3 Met Ala Leu Arg Val Ala Ala Phe Asp Leu Asp Gly
Val Leu Ala Leu 1 5 10 15 Pro Ser Ile Ala Gly Ala Phe Arg Arg Ser
Glu Glu Ala Leu Ala Leu 20 25 30 Pro Arg Asp Phe Leu Leu Gly Ala
Tyr Gln Thr Glu Phe Pro Glu Gly 35 40 45 Pro Thr Glu Gln Leu Met
Lys Gly Lys Ile Thr Phe Ser Gln Trp Val 50 55 60 Pro Leu Met Asp
Glu Ser Tyr Arg Lys Ser Ser Lys Ala Cys Gly Ala 65 70 75 80 Asn Leu
Pro Glu Asn Phe Ser Ile Ser Gln Ile Phe Ser Gln Ala Met 85 90 95
Ala Ala Arg Ser Ile Asn Arg Pro Met Leu Gln Ala Ala Ile Ala Leu 100
105 110 Lys Lys Lys Gly Phe Thr Thr Cys Ile Val Thr Asn Asn Trp Leu
Asp 115 120 125 Asp Gly Asp Lys Arg Asp Ser Leu Ala Gln Met Met Cys
Glu Leu Ser 130 135 140 Gln His Phe Asp Phe Leu Ile Glu Ser Cys Gln
Val Gly Met Ile Lys 145 150 155 160 Pro Glu Pro Gln Ile Tyr Asn Phe
Leu Leu Asp Thr Leu Lys Ala Lys 165 170 175 Pro Asn Glu Val Val Phe
Leu Asp Asp Phe Gly Ser Asn Leu Lys Pro 180 185 190 Ala Arg Asp Met
Gly Met Val Thr Ile Leu Val His Asn Thr Ala Ser 195 200 205 Ala Leu
Arg Glu Leu Glu Lys Val Thr Gly Thr Gln Phe Pro Glu Ala 210 215 220
Pro Leu Pro Val Pro Cys Asn Pro Asn Asp Val Ser His Gly Tyr Val 225
230 235 240 Thr Val Lys Pro Gly Ile Arg Leu His Phe Val Glu Met Gly
Ser Gly 245 250 255 Pro Ala Leu Cys Leu Cys His Gly Phe Pro Glu Ser
Trp Phe Ser Trp 260 265 270 Arg Tyr Gln Ile Pro Ala Leu Ala Gln Ala
Gly Phe Arg Val Leu Ala 275 280 285 Ile Asp Met Lys Gly Tyr Gly Asp
Ser Ser Ser Pro Pro Glu Ile Glu 290 295 300 Glu Tyr Ala Met Glu Leu
Leu Cys Lys Glu Met Val Thr Phe Leu Asp 305 310 315 320 Lys Leu Gly
Ile Pro Gln Ala Val Phe Ile Gly His Asp Trp Ala Gly 325 330 335 Val
Met Val Trp Asn Met Ala Leu Phe Tyr Pro Glu Arg Val Arg Ala 340 345
350 Val Ala Ser Leu Asn Thr Pro Phe Met Pro Pro Asp Pro Asp Val Ser
355 360 365 Pro Met Lys Val Ile Arg Ser Ile Pro Val Phe Asn Tyr Gln
Leu Tyr 370 375 380 Phe Gln Glu Pro Gly Val Ala Glu Ala Glu Leu Glu
Lys Asn Met Ser 385 390 395 400 Arg Thr Phe Lys Ser Phe Phe Arg Ala
Ser Asp Glu Thr Gly Phe Ile 405 410 415 Ala Val His Lys Ala Thr Glu
Ile Gly Gly Ile Leu Val Asn Thr Pro 420 425 430 Glu Asp Pro Asn Leu
Ser Lys Ile Thr Thr Glu Glu Glu Ile Glu Phe 435 440 445 Tyr Ile Gln
Gln Phe Lys Lys Thr Gly Phe Arg Gly Pro Leu Asn Trp 450 455 460 Tyr
Arg Asn Thr Glu Arg Asn Trp Lys Trp Ser Cys Lys Gly Leu Gly 465 470
475 480 Arg Lys Ile Leu Val Pro Ala Leu Met Val Thr Ala Glu Lys Asp
Ile 485 490 495 Val Leu Arg Pro Glu Met Ser Lys Asn Met Glu Lys Trp
Ile Pro Phe 500 505 510 Leu Lys Arg Gly His Ile Glu Asp Cys Gly His
Trp Thr Gln Ile Glu 515 520 525 Lys Pro Thr Glu Val Asn Gln Ile Leu
Ile Lys Trp Leu Gln Thr Glu 530 535 540 Val Gln Asn Pro Ser Val Thr
Ser Lys Ile 545 550 4 536 PRT Mus musculus mouse ovary soluble
epoxide hydrolase (sEH) 4 Met Arg Phe Ala Ala Met Ala Ala Phe Ser
Val Phe Phe Val Ser Lys 1 5 10 15 Gly Leu Leu Met Asn Ser Asn Ile
Trp Cys Val Gly Gln Glu Gly Pro 20 25 30 Ser Gln Glu Asp Thr Asp
Thr Ile His Thr Ser Glu Trp Val Pro Leu 35 40 45 Met Asp Glu Ser
Tyr Arg Lys Ser Ser Lys Ala Cys Gly Ala Asn Leu 50 55 60 Pro Glu
Asn Phe Ser Ile Ser Gln Ile Phe Ser Gln Ala Met Ala Ala 65 70 75 80
Arg Ser Ile Asn Arg Pro Met Leu Gln Ala Ala Ile Ala Leu Lys Lys 85
90 95 Lys Gly Phe Thr Thr Cys Ile Val Thr Asn Asn Trp Leu Asp Asp
Gly 100 105 110 Asp Lys Arg Asp Ser Leu Ala Gln Met Met Cys Glu Leu
Ser Gln His 115 120 125 Phe Asp Phe Leu Ile Glu Ser Cys Gln Val Gly
Met Ile Lys Pro Glu 130 135 140 Pro Gln Ile Tyr Asn Phe Leu Leu Asp
Thr Leu Lys Ala Lys Pro Asn 145 150 155 160 Glu Val Val Phe Leu Asp
Asp Phe Gly Ser Asn Leu Lys Pro Ala Arg 165 170 175 Asp Met Gly Met
Val Thr Ile Leu Val His Asn Thr Ala Ser Ala Leu 180 185 190 Arg Glu
Leu Glu Lys Val Thr Gly Thr Gln Phe Pro Glu Ala Pro Leu 195 200 205
Pro Val Pro Cys Asn Pro Asn Asp Val Ser His Gly Tyr Val Thr Val 210
215 220 Lys Pro Gly Ile Arg Leu His Phe Val Glu Met Gly Ser Gly Pro
Ala 225 230 235 240 Leu Cys Leu Cys His Gly Phe Pro Glu Ser Trp Phe
Ser Trp Arg Tyr 245 250 255 Gln Ile Pro Ala Leu Ala Gln Ala Gly Phe
Arg Val Leu Ala Ile Asp 260 265 270 Met Lys Gly Tyr Gly Asp Ser Ser
Ser Pro Pro Glu Ile Glu Glu Tyr 275 280 285 Ala Met Glu Leu Leu Cys
Lys Glu Met Val Thr Phe Leu Asp Lys Leu 290 295 300 Gly Ile Pro Gln
Ala Val Phe Ile Gly His Asp Trp Ala Gly Val Met 305 310 315 320 Val
Trp Asn Met Ala Leu Phe Tyr Pro Glu Arg Val Arg Ala Val Ala 325 330
335 Ser Leu Asn Thr Pro Phe Met Pro Pro Asp Pro Asp Val Ser Pro Met
340 345 350 Lys Val Ile Arg Ser Ile Pro Val Phe Asn Tyr Gln Leu Tyr
Phe Gln 355 360 365 Glu Pro Gly Val Ala Glu Ala Glu Leu Glu Lys Asn
Met Ser Arg Thr 370 375 380 Phe Lys Ser Phe Phe Arg Ala Ser Asp Glu
Thr Gly Phe Ile Ala Val 385 390 395 400 His Lys Ala Thr Glu Ile Gly
Gly Ile Leu Val Asn Thr Pro Glu Asp 405 410 415 Pro Asn Leu Ser Lys
Ile Thr Thr Glu Glu Glu Ile Glu Phe Tyr Ile 420 425 430 Gln Gln Phe
Lys Lys Thr Gly Phe Arg Gly Pro Leu Asn Trp Tyr Arg 435 440 445 Asn
Thr Glu Arg Asn Trp Lys Trp Ser Cys Lys Gly Leu Gly Arg Lys 450 455
460 Ile Leu Val Pro Ala Leu Met Val Thr Ala Glu Lys Asp Ile Val Leu
465 470 475 480 Arg Pro Glu Met Ser Lys Asn Met Glu Lys Trp Ile Pro
Phe Leu Lys 485 490 495 Arg Gly His Ile Glu Asp Cys Gly His Trp Thr
Gln Ile Glu Lys Pro 500 505 510 Thr Glu Val Asn Gln Ile Leu Ile Lys
Trp Leu Gln Thr Glu Val Gln 515 520 525 Asn Pro Ser Val Thr Ser Lys
Ile 530 535
* * * * *